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Abstract 
The entry stage of the HIV-1 viral life cycle has become a prime target for preventing 
HIV-1 infection. This has led to the development of a new class of anti-retroviral agents 
termed entry inhibitors, which have proven effective in vitro and in the clinic. These new 
agents target three different stages of entry, namely CD4 binding, coreceptor interaction 
with either CCR5 or CXCR4 and the fusion process. Here we studied isolates from 
patients with HIV-1 subtype C infection and the effectiveness of different coreceptor and 
fusion inhibitors in vitro. Further we examined resistance profiles to the first licensed 
entry inhibitor, T-20. 
 
In Chapter 2 we examined coreceptor usage of HIV-1 subtype C isolates and their 
sensitivity to CCR5 and CXCR4 inhibitors. Twenty-nine viral isolates with different 
coreceptor usage profiles were isolated from patients with advanced AIDS. The CCR5-
specific agents, PRO140 an anti-CCR5 monoclonal antibody and RANTES, the natural 
ligand for CCR5 inhibited all 24 R5 isolates, while the two X4 and the three R5X4 
viruses were sensitive to the CXCR4-specific inhibitor, AMD3100. The five X4 or R5X4 
viruses were all able to replicate in peripheral blood mononuclear cells (PBMC) that did 
not express CCR5 confirming their ability to use CXCR4 on primary cells. When tested 
using coreceptor-transfected cell lines, one R5 virus was also able to use CXCR6, and 
another R5X4 virus could use CCR3, Bob/GPR15 and CXCR6. The R5X4 and X4 
viruses contained more diverse V3 loop sequences with a higher overall positive charge, 
compared to the R5 viruses. Hence, HIV-1 subtype C viruses are able to use CCR5, 
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CXCR4 or both for entry, and they are sensitive to specific inhibitors of entry via these 
coreceptors.  
 
In Chapter 3 we analyzed isolates from 10 acutely infected individuals, who were 
followed longitudinally for up to three years. Two of these individuals (Du151 and 
Du179) underwent a coreceptor switch and were studied more intensively. The other 
eight individuals retained CCR5 usage throughout the duration of the study. The initial 4 
isolates from Du151 were able to utilize CCR5 but the later isolates were able to use both 
CCR5 and CXCR4 (R5X4). Du179 used both CCR5 and CXCR4 (R5X4) initially, but 
the later isolate was found to be monotropic and used CXCR4 (X4) exclusively. Viral 
isolates were tested for their sensitivity to small molecule inhibitors of CCR5, CXCR4 
and the fusion process in a PBMC assay. All of the R5 isolates were sensitive to 
RANTES and PRO140 and insensitive to the two CXCR4 coreceptor inhibitors 
AMD3100 and T-140. There was a tendency for later isolates to become slightly less 
sensitive to the CCR5 inhibitors and more sensitive to the CXCR4 entry inhibitors. None 
of the R5X4 Du179 isolates were effectively inhibited by PRO140 and RANTES, but the 
X4 isolate of Du179 became sensitive to CXCR4 entry inhibitors. Both Du151 and 
Du179 underwent amino acid changes in their V3 sequences that included an increased 
charge associated with CXCR4 usage. This indicates that coreceptor switching can occur 
in subtype C infections and is associated with changes in the V3 loop. However, both 
Du151 and Du179 were subsequently found to be dually infected with another subtype C 
strain, which may account for some of the phenotypic and genotypic changes seen in 
these individuals including the appearance of CXCR4-virus variants. 
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In Chapter 4 we explored two HIV-1 isolates (CM4 and CM9) able to use 
alternate HIV-1 coreceptors for entry (i.e. coreceptors other than CCR5 or CXCR4) on 
transfected cell lines. These isolates were tested for their sensitivity to inhibitors of HIV-
1 entry on primary cells. Both isolates were from patients with cryptococcal meningitis, a 
severe AIDS defining condition. CM4 was able to use CCR5 and Bob/GPR15 efficiently 
in transfected cells. This isolate grew in D32/D32 CCR5 PBMC in the presence of 
AMD3100, indicating that it used a receptor other than CCR5 or CXCR4 on primary 
cells. It was insensitive to the CCR5 entry inhibitors RANTES and PRO140, but was 
partially inhibited by vMIP-1, a chemokine that binds CCR3, CCR8, Bob/GPR15 and 
CXCR6. The coreceptor used by this isolate on primary cells is thus currently unknown. 
CM9 used CCR5, CXCR4, Bob/GPR15, CXCR6 and CCR3 on transfected cells and was 
able to replicate in the presence of AMD3100 in D32/D32 CCR5 PBMC. It was 
insensitive to vMIP-1, eotaxin and I309 used individually, but was inhibited completely 
when vMIP-1 or I309, the ligand for CCR8, were combined with AMD3100. These 
results strongly suggest that this isolate can use CCR8 on primary cells. Collectively 
these data suggest that some HIV-1 isolates can use alternate coreceptors on primary 
cells, which may have implications for strategies that aim to block viral entry using 
coreceptor inhibitors. 
 
In Chapter 5 we examined the effectiveness of T-20 to inhibit HIV-1 subtype C 
isolates. T-20 blocks the fusion stage of the viral entry cycle and it is the first entry 
inhibitor to be licensed for clinical use. T-20 consists of 36 amino acids and was designed 
  v 
based on the HR-2 region of HIV-1 subtype B. A total of 23 HIV-1 subtype C isolates 
were tested for their ability to replicate in the presence and absence of T-20. This 
included five isolates with multiple genotypic drug resistance mutations to reverse 
transcriptase and protease inhibitors. Among the 23 subtype C isolates there were 10-16 
amino acid changes in the 36 amino acid region corresponding to T-20. However, all 
isolates were effectively inhibited by T-20 at 1 mg/ml, including the 5 isolates resistant to 
other anti-retroviral drugs. The gp41 region was sequenced and the HR-1 and HR-2 
amino acids analyzed. All isolates had the amino acids GIV at positions 36-38 in gp41, 
which are associated with sensitivity to T-20. One X4 had a GVV motif but this did not 
affect its sensitivity. Thus, T-20 inhibited subtype C viruses despite significant genetic 
differences in the HR-2 regions of subtypes B and C. These data suggest that T-20 would 
be highly effective in patients with HIV-1 subtype C infection including those failing 
existing anti-retroviral drug regimens. 
 
In Chapter 6 we examined the in vitro resistance patterns of HIV-1 subtype C to 
T-20. Resistance to T-20 is a consequence of persistent exposure to the antiretroviral 
peptide. To establish if patterns of resitance to T-20 were similar to resistance mutations 
occurring in subtype B viruses, 11 subtype C and 4 subtype B viruses were passaged in 
the presence of increasing concentrations of T-20. The subtype C isolates showed varying 
levels of replication at 1 mg/ml T-20 by day 18, but by day 29 all replicated efficiciently 
at 10 mg/ml T-20. All isolates showed evidence of genotypic changes in gp41 HR-1 
following exposure to T-20 that included G36S/E/D, I37T, V38M/A/L/E, N42D, 
N43K/S, L45R/M and A50T/V. Five viruses had compensatory changes in the HR-2 
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region, which corresponds to the T-20 sequence, and two isolates had changes in the V3 
region. Mutational patterns among the 4 subtype B viruses were similar to those for 
subtype C and those previously published in the literature. These data indicate that in 
vitro resistance to T-20 develops rapidly among HIV-1 subtype C isolates. In general, 
mutational patterns for subtype C were similar to those described for subtype B, 
suggesting that the mechanism of action for T-20 is similar for HIV-1 subtype B and C 
isolates.  
 
Observations from these studies indicate that HIV-1 subtype C predominantly use 
the CCR5 coreceptor to enter cells. CXCR4 usage is rare compared to other subtypes, 
although such isolates are found in patients with advanced AIDS. The two cases of 
coreceptor switching reported here were dually infected. Subtype C isolates were 
sensitive to coreceptor and fusion inhibitors except for two isolates able to utilize 
alternate coreceptors. However, alternate coreceptor usage is very rare and unlikely to 
impact on the utility of coreceptor inhibitors. Given the propensity for CCR5 usage this 
may imply that CCR5 coreceptor inhibitors may be more effective in countries where 
HIV-1 subtype C predominate. Entry inhibitors may be useful for prevention and 
treatment strategies and have the potential to provide sterilizing immunity. These agents 
could be used as microbicides and as an adjunct to existing antiretroviral therapies for use 
in HIV-1 subtype C infected individuals. However resistance to entry inhibitors can 
emerge and should be used in combination with other antiretrovirals to minimize this 
outcome. While entry inhibitors provide a new line of defence against HIV-1, their cost 
may prevent their use in developing countries in the immediate future. Nevertheless, this 
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is the first comprehensive study of the sensitivity of HIV-1 subtype C isolates to entry 
inhibitors providing a data-driven rationale for their use in individuals infected with HIV-
1 subtype C. 
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CHAPTER ONE 
 
1.  INTRODUCTION 
The South African HIV-1 epidemic has reached explosive proportions. The total number 
of HIV-1 infected individuals is estimated to be 5.3 million [4.5million –6.2 million] 
(www.unaids.org). Over the next five years AIDS deaths will increase dramatically and 
urgent intervention is required (www.unaids.org). In April 2004 the antiretroviral rollout 
was initiated and 50,000 individuals are expected to be treated in the first year. It is 
foreseen that 500,000 people will be treated over the next 7 years. The criteria for 
treatment include patients with a CD4 count lower than 200 or a diagnosis of clinical 
AIDS. The provision of anti-retroviral therapy (ARV) in South Africa is expected to 
reduce morbidity and mortality as seen in other countries where treatment is available. 
 
The predominant strain of HIV-1 circulating in South Africa is subtype C, which is the 
fastest spreading HIV-1 subtype worldwide (www.unaids.org). Subtype A/+CRF02_AG 
was estimated to be the second fastest spreading subtype followed by subtype B strains. 
Subtype A/+CRF02_AG is predominant in Africa together with subtype A and D and 
other circulating recombinant forms (CRF). Subtype B is most predominant in the 
developed world such as North America, Europe and Australia. Subtype C predominates 
in India, China, Ethiopia and other regions in southern Africa. Some evidence exists that 
subtype C is different from other subtypes in both phenotypic and genotypic 
characteristics. It was shown that subtype C was almost exclusively non-syncytium 
inducing (NSI) and did not switch to the syncytium inducing (SI) phenotype (Abebe et 
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al., 1999; Ping et al., 1999; Tien et al., 1999). Only recently have SI variants been 
identified but the frequency thereof is still low (Cilliers et al., 2003; Janse Van Rensburg 
et al., 2002; Johnston et al., 2003; Pollakis et al., 2004). More studies are needed on 
patient cohorts followed longitudinally to determine the frequency of a coreceptor switch 
in this subtype. 
 
1.1 Natural history of HIV-1 infection in adults and children 
HIV-1 is mainly transmitted through bodily fluids during sexual transmission (Haseltine, 
1998). HIV-1 can also be transmitted through infected blood products as well as needle 
sharing amongst intravenous drug users. Sexual transmission of the virus occurs when it 
crosses the mucosal barrier and attaches to cells that express the necessary receptors to 
allow HIV-1 infection. After attachment the virus is transported to the local lymph nodes 
where it replicates and is later detected in the blood. An acute clinical syndrome occurs 2-
4 weeks after the initial exposure to the virus. This syndrome presents as flu- like 
symptoms and it can also affect the central nervous system (Vanhems et al., 2000). 
During the acute phase viral replication is very high and can be determined using a viral 
load assay (Mellors et al., 1996). In the initial phases of HIV-1 infection there is a 
window period when patients are HIV-1 positive, but antibody negative. Antibodies can 
take up to 3 months to develop and are used to detect HIV-1 infection in an ELISA assay. 
HIV-1 is accompanied by a cellular as well as a humoral immune response (Fauci, 1996). 
The rate at which the initial infection is controlled is normally a good indicator of how 
quickly a patient will progress to develop AIDS (Fauci, 1996). The higher the viral load 
set point the higher the chances are the person will progress faster to develop AIDS. A 
  3 
cytotoxic T-cell response in combination with an antibody response helps control the 
initial phase of infection and to reach a set point, which can remain relatively constant 
over a long time (Koup et al., 1994) (Figure 1.1). The acute phase is followed by the 
asymptomatic phase where the patient remains disease free. AIDS is the end stage of the 
disease and is associated with CD4 counts below 200 cells/ml, and the onset of 
opportunistic infections especially tuberculosis and meningitis. 
 
 
Figure 1.1: Schematic diagram showing the natural history of viral load and CD4 count. 
Three stages associated with disease progression are shown. HIV replicates and steadily 
depletes the immune system until the culmination of AIDS. The viral load increases 
dramatically in the acute phase and CD4 numbers decline. After a few weeks the immune 
system responds to HIV infection, which reduces the viral load and the CD4 number 
returns to near normal levels. The CTL response is responsible for control of viremia and 
to lesser extent the neutralizing antibody response. Neutralizing antibodies take much 
longer to develop and only play a role later in infection. In the AIDS phase viral load 
increases and CD4 counts drop. These events allow individuals to remain clinically well 
for many years. (Courtesy of Natasha Taylor) 
Neutralizing antibodies
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Binding antibodies
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In general, children progress at a faster rate than adults in developing AIDS (Powderly, 
1997). This might be attributed to the timing of infection, as these infants could be 
infected in utero or as a result of their immature immune system. The highest incidence 
of AIDS occurs within the first year of life and accounts for over a third of all pediatric 
cases and are referred to as rapid progressors (RP) (Bobat et al., 1999; Powderly, 1997; 
Scarlatti et al., 1996). Some children do live longer and even into their adolescent years. 
These children are referred to as slow progressors (SP) (Powderly, 1997). Factors 
influencing this are mostly unexplained, but in some cases attenuation of the virus or 
defective genes or host genetic defects have been shown to be associated with slow 
disease progression (Greenough, Sullivan, and Desrosiers, 1999; Papathanasopoulos et 
al., 2003; Pilgrim et al., 1997).  
 
1.2. HIV-1 life cycle 
HIV-1 requires infection of a host cell to enable it to survive and to multiply. It enters the 
host cells by binding to CD4 and a cellular coreceptor. This enables the viral envelope 
glycoprotein to undergo conformational changes and for cell fusion to occur. Once it 
enters the cell the viral RNA is released into the host cell cytoplasm. The reverse 
transcriptase enzyme transcribes single stranded RNA into double stranded DNA, which 
then establishes itself via the enzyme integrase into the host DNA. This enables the virus 
to make use of the host cell machinery to produce more viral particles. Firstly strands of 
protein are synthesized which then assembles at the host cell membrane. These are 
cleaved into functional proteins by the viral protease enzyme. Once all the proteins are 
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cleaved viral particles bud out of the host cell membrane using parts of the host cell 
membrane to construct viral particles (Pope and Haase, 2003). Approximately 109 viral 
particles are produced daily (Zhang et al., 1999). Knowing how the virus enters and 
reproduces itself has presented novel approaches to inhibit parts of the viral life cycle. 
These opportunities to inhibit virus replication can be divided into distinct different 
phases. Entry inhibitors inhibit the first phase of the viral life cycle by preventing entry of 
HIV-1. The reverse transcriptase enzyme was one of the first therapeutic targets in 
preventing virus replication (Kilby and Eron, 2003). Targeting the integrase enzyme is 
another approach and agents preventing its function have entered clinical trials (Kilby 
and Eron, 2003). Protease inhibitors are already in use and play a major role in the 
clinical treatment of patients. Viral budding offers another potential target for inhibiting 
viral replication but no agent yet has been identified to inhibit this phase of replication.  
 
1.3 Use of highly active antiretroviral therapy 
Highly active antiretroviral therapy (HAART) is one of the major factors influencing 
morbidity and mortality among HIV-infected patients in industrialized countries (Gallant, 
2000). The effectiveness of these drugs has been shown by the rapid decline in AIDS 
deaths in the USA since their introduction (Palella et al., 1998). Reverse transcriptase 
inhibitors can be grouped as nucleoside antagonists, which consist of zidovudine, 
didanosine, zalcitabine, lamivudine, stavudine, abacavir and tenofovir (Kilby and Eron, 
2003). The non-nucleoside reverse transcriptase inhibitors consist of nevirapine, 
delavirdine, and efavirenz (Kilby and Eron, 2003). The protease inhibitors consist of 
ritonavir, indinavir, nelfinavir, amprenavir, lopinavir-ritonavir and two combinations of 
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saquinavir (Kilby and Eron, 2003). These drugs are usually used in combinations as triple 
drug therapies and prolong the asymptomatic phase of infection and can partially restore 
immune function. However, drug resistance and poor tolerability in some individuals has 
focused attention on the need for additional drug therapies (Hirschel and Opravil, 1999).  
 
1.4. HIV-1 entry 
In 1986, the CD4 molecule was shown to serve as the primary receptor used by HIV to 
enter cells (Maddon et al., 1986). However, it was soon realized that CD4 was not 
sufficient for entry. The discovery that chemokines secreted by CD8 cytotoxic T cells 
inhibit HIV-1 infection, as well as the existence of persons exposed to HIV who 
remained uninfected, provided clues to this second receptor (Cocchi et al., 1995; Paxton 
et al., 1996). Fusin was first identified as the receptor for viruses that caused syncytia (SI) 
in T-cells and was later renamed CXCR4 (Berger, 1997; Feng et al., 1996). A second 
coreceptor, termed CCR5 was shown to serve as the coreceptor for macrophage tropic or 
non-syncytium inducing (NSI) HIV-1 isolates (Deng et al., 1996; Dragic et al., 1996). 
Together, CD4 and CCR5 and/or CXCR4 serve as the major entry molecules for all 
subtypes of HIV-1 and the expression of these molecules on CD4  cells determines the 
cellular host range. 
 
1.4.1 The envelope glycoprotein 
The entry of HIV-1 into cells is a multi-step process that is mediated by the viral 
envelope (Env) glycoprotein (Wyatt and Sodroski, 1998). Env originates as a single chain 
glycoprotein precursor, gp160, which dissociates to yield the functional glycoproteins 
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gp120 and gp41. These two subunits assemble non-covalently on the virion surface as 
trimers (Chan et al., 1997; Wyatt and Sodroski, 1998). The envelope region comprises of 
five variable domains (V1-V5), in which nucleotide substitutions, duplications and 
deletions produce extensive amino acid diversity and five constant regions (C1-C5), 
which is responsible for the more conserved functions of the envelope (Lamers et al., 
1993). The third variale loop (V3 loop) is associated with coreceptor binding and cellular 
tropism (Shimizu et al., 1999; Chan et al., 1999). The V3 loop is located between amino 
acids 296 and 331 of gp120 and has a type 2ß-turn conserved secondary structure and 
usually consists of 35 amino acids (De Jong et al., 1992; Jansson et al., 1994). The V3 
loop shows a high degree of genetic diversity including substitutions, deletions and 
insertions (Lamers et al., 1993). A minimum of three amino acid substitutions in V3 can 
confer macrophage tropism and alter T-cell line tropism (De Jong et al., 1992). The tip of 
the V3 loop is very conserved in HIV-1 subtype C isolates with a GPGQ motif in almost 
all cases whereas for subtype B it is GPGR (Milich et al., 1993). Subtype E isolates in 
Asia also has the GPGQ motif for non-syncytium inducing (NSI) isolates, whereas for 
syncytium inducing (SI) isolates it is GPGR or GPGH (Menu et al., 1999). 
A high net charge of V3, due to additional basic amino acids substituting 
negatively charged amino acids, is correlated with the SI phenotype. SI and NSI variants 
can be predicted by studying positively charged, or neutral charged amino acid changes at 
positions 11, 25, 13, 19, 23, 24 and 32 (De Wolf et al., 1994; Hwang et al., 1991; Milich, 
Margolin, and Swanstrom, 1997; Shioda, Levy, and Cheng-Mayer, 1991; Yoshimura et 
al., 1996). Determination of the total number of positively charged amino acids in the V3 
loop revealed that SI variants have the highest positive charge compared to the NSI 
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variants (De Wolf et al., 1994; Fauci et al., 1996). 
The crystal structure of the gp120 subtype B strain HXBc2 was elucidated in 
1998 in complex with a two-domain fragment of the CD4 receptor and a neutralizing 
human antibody that blocks chemokine receptor binding (Kwong et al., 1998). From this 
data it was shown that the CD4 binding site on gp120 is fairly well conserved and is 
located within a cavity at the interface of the outer domain, inner domain and the bridging 
sheet. A total of 22 CD4 and 26 gp120 amino-acid residues are required for the gp120-
CD4 structure to interact (Kwong et al., 1998). As a result of the binding to CD4 the Env 
molecule undergoes conformational changes enabling the virus to bind to the coreceptor. 
The gp120 molecule requires approximately three CD4 molecules to enable this 
conformational change to occur (Doms, 2000). An approximately ninety degree angle is 
formed between the chemokine receptor-binding site and the CD4 binding site and 
consists of the bridging sheet and the base of the V1/V2 loop (Kwong et al., 1998; Parren 
et al., 1999; Wyatt and Sodroski, 1998). Experimental data has shown that the V1/V2 
loops partially cover the CD4 and chemokine receptor binding sites (Wyatt and Sodroski, 
1998). When gp120 binds CD4 further displacement of the V1/V2 and V3 loop occurs, 
which allows chemokine receptor binding (Parren et al., 1999; Rizutto and Sodroski, 
2000). About four to six CCR5 coreceptors are required for viral fusion to occur 
(Kuhmann et al., 2000). Binding to CCR5 induces further conformational changes that 
activate the fusion machinery of gp41. These changes include the formation of a coiled 
coil structure domain of gp41 (Chan et al., 1997; Weissenhorn et al., 1997). Fusion with 
the cell membrane takes place by insertion of the gp41 subunit into the lipid bilayer of the 
target cell, thus rendering Env an integral component of the viral and the target cell 
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membranes (Chan et al., 1997; Sattentau, Zolla-Pazner, and Poignard, 1995).  
 
 
Figure 1.2: A schematic diagram of HIV-1 envelope. The variable loops are shown in 
boxes (V1-V5). Glycosylations sites containing mannose-type or hybrid-type 
oligosaccharide structures are indicated by branched structures and glycosylation sites 
containing complex-type oligosaccharides structures are indicated by the U-shaped 
branches. Epitopes able to induce neutralizing antibodies are highlighted in color.  
      Taken from (Zolla-Pazner, 2004) 
 
1.4.2 Coreceptor usage 
The discovery of the chemokine receptors CCR5 and CXCR4 as HIV-1 entry coreceptors 
allowed for a more precise understanding of biological phenotypes (Doms and Peiper, 
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1997). The MT-2 cell line, which traditionally is used to classify viruses as SI or NSI, 
express high levels of CXCR4, but do not express CCR5. Thus the ability to grow in MT-
2 cells is a function of the ability of SI isolates to use CXCR4. HIV-1 strains that use 
CXCR4 are designated X4 and those that use CCR5 are called R5 viruses (Berger et al., 
1998). Viral strains often show preferential use of a coreceptor, although some dual 
tropic strains have the ability to use both CCR5 and CXCR4 equivalently and are termed 
R5X4 variants (Berger et al., 1998; Glushakova et al., 1999). CCR5 and CXCR4 are used 
by most, if not all HIV-1 strains regardless of genetic subtype (Bjorndal et al., 1997; 
Vodicka et al., 1997). CCR5 is expressed on activated lymphocytes, macrophages, 
dendritic cells and brain cells while CXCR4 is expressed on resting T cells and 
monocytes (He et al., 1997; Lusso, 2000). Viruses isolated from recently infected 
individuals are almost exclusively CCR5-using indicating that R5 viruses are selectively 
transmitted. It is thought that macrophages and dendritic cells, which are abundant in 
mucosal tissues, transport the virions to the lymphoid tissues and are responsible for 
dissemination of the virus throughout the body.  
 
1.4.3 Structure of CCR5 and CXCR4 
The chemokine receptors CCR5 and CXCR4 are seven-transmembrane molecules of the 
G-protein coupled receptor family (Berger, 1997) (Figure 1.3 and 1.4). They share 
approximately 32% amino acid identity, although this is reduced to 20% when only the 
amino acids on the extracellular surface are compared (Doms and Peiper, 1997). Both 
CCR5 and CXCR4 contain 352 amino acids and have three extracellular loops on the 
surface of the cell. The extracellular domain contains four cysteine residues (indicated in 
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red) (Figures 1.3 and 1.4), which form disulfide bonds between the amino terminus and 
the third extracellular loop and between the first and second extracellular loops (Berson 
et al., 1996). It is likely that mutations in one extracellular domain may indirectly affect 
the function of neighboring regions and that residues in all four extracellular regions can 
influence coreceptor usage (Horuk et al., 1994). Alanine scanning mutagenesis and the 
use of monoclonal antibodies has identified important regions in the coreceptor for gp120 
binding (Blanpain et al., 2003; Dragic, 2001; Dragic et al., 1998; Rabut et al., 1998; Wu 
et al., 1997a). For both CCR5 and CXCR4, specific amino acids within the amino-
terminal domain including negatively charged and tyrosine residues are essential for 
binding and entry of viral isolates. The second extracellular loop of CXCR4 has also been 
implicated in entry of X4 and R5X4 strains (Brelot et al., 1997; Kajumo et al., 2000; Lu 
et al., 1997). Despite the low amino acid homology between CCR5 and CXCR4, HIV–1 
isolates have been identified that are able to use both coreceptors very efficiently (Doranz 
et al., 1996; Simmons et al., 1996). This might be explained by the fact that coreceptors 
have common structural features or that a single gp120 molecule engages different 
determinants for each coreceptor. HIV can evolve to use CXCR4 during disease 
progression suggesting that the ability of gp120 to interact with specific amino acids 
within the coreceptor may change over time (Doranz et al., 1997; Picard et al., 1997). 
The surface of CXCR4 is negatively charged whereas CCR5 has an almost neutral charge 
(Moore and Stevenson, 2000). This is an indication that the interaction between CCR5, 
CXCR4 and the HIV envelope might be charge related and the higher the charge of the 
gp120 the more likely a viral isolate is to use CXCR4 (Edinger et al., 1998). 
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Figure 1.3: Two-dimensional structure of CCR5. The receptor transcends the membrane 
7 times. The amino terminus is on the outside and the carboxy terminus on the inside of 
the cell. The three extracellular domains are indicated. The cysteine residues are shown in 
red. 
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Figure 1.4: Two-dimensional structure of CXCR4. The receptor transcends the 
membrane 7 times. The amino terminus (NH2) is on the outside and the carboxy terminus 
(COOH) on the inside of the cell. The three extracellular domains are indicated. The 
cysteine residues are shown in red. ECL refers to the extracellular loops 1-3. 
 
1.4.4 Alternate coreceptors  
In addition to CCR5 and CXCR4, some HIV-1 isolates are able to utilize other 
coreceptors, namely CCR1, CCR2b, CCR3, CCR8, CXCR6 (Bonzo/STRL33), 
Bob/GPR15, and GPR1 (Edinger et al., 1998; Zhang et al., 1998) (Table 1.1). The use of 
alternate coreceptors is rare and is normally associated with viral isolates from late-stage 
disease (Pohlmann, Krumbiegel, and Kirchhoff, 1999). In some cases this may provide a 
selective advantage, for example, the ability of some isolates from cerebrospinal fluid to 
use CCR3 may allow them to infect microglia, which express both CD4 and CCR3 (He et 
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al., 1997). HIV-1 isolates able to infect thymocytes and utilizing CCR8 was reported 
indicating use of alternate coreceptors on primary cells (Lee et al., 2000). Of all the 
alternate coreceptors proposed to be utilized by HIV-1, CCR3 and CCR8 appear to be the 
most commonly used (Table 1.1). Hoffman and co-workers have shown that the V1 and 
V2 loops play an important part in the utilization of minor coreceptors in vitro (Hoffman 
et al., 1998). However, the role of these minor coreceptors in vivo still remains uncertain 
(Zhang and Moore, 1999). 
 
Use of known and unknown alternate coreceptors has been more commonly reported 
amongst HIV-2 isolates (Guillon et al., 1998; McKnight et al., 1998; Reeves et al., 1998; 
Reeves et al., 1997). Two HIV-2 isolates were able to use an unidentified coreceptor as 
they were able to productively infect PBMC but were unable to replicate in cell lines 
expressing CCR5, CXCR4, CCR1, CCR2, CCR3, CXCR6 and Bob/GPR15 (Azevedo-
Pereira et al., 2003). Similar results were found by Willey et al., in that HIV-2, SIV and 
HIV isolates were able to infect CCR5 defective PBMC and brain microvascular 
endothelial cells (BMVEC’s) which lack both CCR5 and CXCR4 (Willey et al., 2003). 
Most of these HIV-2 isolates tested had an R5X4 phenotype except one, which used 
CXCR4 exclusively (Willey et al., 2003). These viruses were inhibited by vMIP-1, a 
chemokine secreted by human herpes virus-8 (HHV-8), which is able to bind to a wide 
range of chemokine receptors including CCR8, GPR1 and CXCR6 thus indicating an 
unknown route of entry into cells relevant to in vivo infection (Willey et al., 2003).  
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Table 1.1: In vitro use of coreceptors by HIV-1.  
* Rarely or never used as a coreceptor (-); occasional use by a few isolates (+); used by 5-20% of isolates 
(++); frequent use by many isolates or by major subgroup (+++) (for example CXCR4 used by X4 and 
R5X4 isolates in bold); major coreceptor used by predominant virus in vivo (++++) (for example CCR5 
usage by HIV-1 R5 isolates).  
 Taken from (Clapham and McKnight, 2002) 
 
1.5 Resistance to HIV-1 infection 
HIV-1 variants transmitted sexually are associated with CCR5 as the coreceptor of 
preference (Rana et al., 1997; Samson et al., 1996a). This coreceptor was first discovered 
by analyzing cells from people who engaged in high-risk sexual behavior, but who 
remained HIV-uninfected (Connor et al., 1996; Paxton et al., 1996; Samson et al., 
1996a). Subsequently a 32-base pair deletion (D32) in the CCR5 gene in the region 
encoding the second extra-cellular loop was discovered which results in a frame shift and 
premature truncation of the protein (Liu et al., 1996; Samson et al., 1996b). This 
truncated polypeptide is expressed, but does not appear on the cell surface and lacks 
coreceptor activity (Liu et al., 1996; Rana et al., 1997; Samson et al., 1996a). Individuals 
Coreceptor Ligand HIV-1 Reference for coreceptor use
CCR1 MIP-1a, MPIF-1, MCP-3, RANTES  -* Bron et al., 1997; McKnight et al., 1998
CCR2b MCP-1, MCP-2, MCP-3  + Doranz et al., 1996
CCR3 Eotaxin, eotaxin-2, MCP-3, MCP-4, RANTES  ++ Choe et al., 1996; Doranz et al., 1996
CCR4 MDC, TARC, RANTES, MIP-1  - McKnight et al., 1998
CCR5 MIP-1a, MIP-1ß, RANTES, MCP-2  ++++ Alkhatib et al., 1996; Deng et al., 1996; Dragic et al., 1996
CCR8 I-309  ++ Rucker et al., 1997
CCR9 TECK  + Choe et al., 1998
CXCR4 SDF-1  +++ Feng et al., 1996
CX3CR1/V28 Fractalkine  + Reeves et al., 1997
CXCR6/Bonzo CXCL16  + Alkhatib et al., 1997; Deng et al., 1997
GPR1 ?  + Farzan et al., 1997
Bob/GPR15 ?  + Farzan et al., 1997
Apj Apelin  + Choe et al., 1998; Edinger et al., 1998
Chem R23 ?  + Samson et al., 1998
RDC1 ?  + Shimizu et al., 2000
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who are homozygous for D32 CCR5 are highly resistant, but not immune to HIV-1 
infection as they can be infected by viruses that use CXCR4 (Biti et al., 1997; O'Brien et 
al., 1997; Theodorou et al., 1997). Individuals who are heterozygous for D32 CCR5 
progress to disease more slowly and have a much lower viral load, probably as a result of 
reduced expression of CCR5 (Dean et al., 1996; Huang et al., 1996; Michael et al., 
1997). The allele frequency of D32 CCR5 in the Caucasian population is approximately 
10%, with 1% being homozygous and approximately 18% being heterozygous (Dean et 
al., 1996; Samson et al., 1996b). This mutation is very rare among African populations 
(Williamson et al., 2000). The surprisingly high allelic frequency in the western 
European population suggests some selective pressure in the past, which gave individuals 
with this allele a survival advantage. The D32 CCR5 polymorphism was proposed to have 
a protective advantage against bubonic plague but no difference in protection or survival 
rate were noted when BALB/c and SCID mice were challenged with Yersinia pestis or Y. 
pseudotuberculosis (Mecsas et al., 2004). This indicates that some other pathogen or 
natural selection is responsible for the occurrence of this mutation. While the D32 CCR5 
polymorphism explains why some individuals remain uninfected by HIV, despite 
multiple exposures to the virus, only a minority of highly exposed persistent seronegative 
individuals are homozygous for the D32 CCR5, indicating that there are other naturally 
occurring mechanisms for HIV resistance. 
 
1.6 Entry inhibitors  
HIV-1 entry into a cell is a multi-step process and involves the envelope region of HIV-1 
and two molecules on the cell surface (Wyatt and Sodroski, 1998). This entry step occurs 
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in three distinct phases, allowing multiple opportunities for intervention. Entry inhibitors 
can act at all three stages during this process: the attachment of gp120 to CD4, the 
interaction of the gp120-CD4 complex with a coreceptor and the gp41 mediated 
membrane fusion process. Agents that target these 3 steps are broadly referred to as entry 
inhibitors (Figure 1.5). Novel compounds targeting each one of these three stages are in 
development and one, T-20, has already been registered by the Food and Drug 
Administration and is in use as a therapeutic agent in combination with other 
antiretroviral agents. 
 
Figure 1.5: Three stages of HIV-1 entry and specific inhibition of each stage. The 
sequential interactions of HIV-1 gp120 with the host cell membrane are depicted. The 
first interaction is gp120-CD4 followed by coreceptor binding which then allows fusion 
of the host and virus cell membranes. Compounds able to prevent CD4 binding and 
coreceptor binding are indicated using arrows to show binding sites and which 
interactions are interrupted. The mechanism of action for T-20 and T1249 is shown. 
CCR5
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SCH-D
TAK779
PRO140
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AMD3100
T140
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1.6.1 Preventing CD4-gp120 interactions  
1.6.1.1 PRO542 
PRO542 is a tetravalent CD4-immunoglobin fusion protein that comprises the D1 and D2 
domains of human CD4 genetically fused to the heavy and light constant regions of 
human IgG2. This agent is also known as CD4-IgG2 (Allaway et al., 1995). It consists of 
two heavy chains from a human-CD4-IgG2 heavy chain fusion protein and two chains of 
a CD4-human kappa light-chain fusion protein (Figure 1.6) (Allaway et al., 1995). 
PRO542 has four gp120 binding sites, which make it more stable and far more effective 
than soluble CD4 (Allaway et al., 1995). Phase-I clinical trials have shown that PRO542 
is safe and has satisfactory pharmacological properties (Jacobson et al., 2000). The 
antiviral effect of PRO542 was very effective and a reduction of up to 2-log10 copies/ml 
was observed one to two weeks post administration (Jacobson et al., 2004; Jacobson et 
al., 2000). Similar results were seen for HIV-infected children who took part in a Phase-I 
clinical trial (Shearer et al., 2000). No free virus was detected up to 72 hours after 
treatment, which demonstrate long lasting effects of PRO542. PRO542 has the ability to 
selectively eliminate X4 and R5X4 viruses from treated patients rendering R5 viruses 
post-treatment, which is consistent with other antiretroviral agents when treating patients. 
(Jacobson et al., 2004). PRO542 may be particularly useful as a salvage therapy as the 
most notable effects were seen in patients with high viral loads and low CD4 counts 
(Jacobson et al., 2004).  
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Figure 1.6: The structure of PRO542 (Taken from Allaway et al., 1995) 
 
1.6.1.2 BMS-378806 
BMS-378806 is a small molecule compound and has inhibitory activity by binding to or 
close to the CD4 binding site on gp120 (Guo et al., 2003; Lin et al., 2003). It has been 
shown to have high potency with an effective concentration of 40 nM against HIV-1 but 
is ineffective against HIV-2 and Simian Immunodeficiency Virus (SIV) (Lin et al., 
2003). Its inhibitory activity is independent of coreceptor usage, which makes it a useful 
agent to treat HIV (Guo et al., 2003; Lin et al., 2003). It has significant pharmacological 
advantages such as low protein binding, minimal human sera effect on anti-HIV potency. 
It has good oral bioavailablity and low toxicity in animal studies (Lin et al., 2003). 
Although it was shown to be very potent against most HIV-1 subtype B strains resistance 
to this compound developed by amino acid substitutions in the CD4 binding region 
S-S
S-S
S-S
S-S
S-S
S -S
V1
V1
V2
V2
CL
CH 1
S S
V1
V1
V2
S-S
CL
CH1
S-S
S-S
S-S
S-S
S-S
S S
S-S S-S
S-S S-S
CH2 CH3
CH2 CH3
Hinge
S
S
S
S
S
S
S
S
CD4-IgG2
CD4 IgG2 Constant Region
V2
  20 
within 20 days or more (Lin et al., 2003). Three amino acid differences were prominent 
with an M426L, M434I/V/T and M475I being able to render these isolates resistant to the 
compound (Guo et al., 2003; Lin et al., 2003). Mutations in other regions were also noted 
and had a complementary role in developing resistance (Lin et al., 2003). Analysis of 
sequences from non-B subtypes show a high frequency of naturally occurring resistance 
mutations, suggesting that it may be less useful in other subtypes (Moore et al., 2004). 
 
 
 
 
 
 
 
Figure 1.7: The structure of BMS-378806 (Taken from Guo et al., 2003) 
 
1.6.1.3 Cyanovirin-N 
Cyanovirin–N (CV-N) is a protein compound consisting of 101 amino acids (11-kDa) 
and was extracted from the cyanobacterium Nostoc ellisporum (Boyd et al., 1997). It has 
been produced in recombinant form in Escherichia coli and has identical properties to 
natural CV-N (Boyd et al., 1997). It is extremely stable and able to withstand 
denaturation by heat, denaturants, detergents, organic solvents and can withstand multiple 
freeze thaw cycles (Boyd et al., 1997). CV-N targets the virion attachment to the host cell 
and blocks the CD4-gp120 interaction. CV-N recognizes Man (alpha) 1à 2Man-linked 
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mannose residues. CV-N thus also is able to block 2G12 binding to the viral envelope 
since this antibody recognizes an epitope that includes complex and hybrid carbohydrate 
residues. CV-N targets the same epitope as the 2G12 monoclonal antibody and prevents 
CD4 binding to HIV envelope possibly through steric hindrance, importantly the binding 
patterns of CV-N overlap but are not identical (Esser et al., 1999; Wyatt and Sodroski, 
1998). CV-N has shown antiviral activity against a broad range of viruses such as HIV-1, 
HIV-2, SIV, human herpes virus 6 (HHV-6), Ebola and influenza virus (Barrientos et al., 
2003; Boyd et al., 1997; O'Keefe et al., 2003). This compound might be especially useful 
as a therapeutic agent as well as a topical microbicide as a result of its broad activity 
(Dey et al., 2000; O'Keefe et al., 2003). 
 
1.6.2 CCR5 Inhibitors  
1.6.2.1 RANTES 
RANTES (regulated upon activation, normal T cell expressed and secreted) is a ß-
chemokine secreted by cytotoxic CD8 T-cells and binds to CCR5 and other chemokine 
receptors. It plays an important role during the inflammatory response and is responsible 
for leukocyte migration (Fernandez and Lolis, 2001; Wu et al., 1997a). It is the natural 
ligand for CCR5 and prevents HIV from entering the cell by binding to CCR5 (Cocchi et 
al., 1995; Trkola et al., 1996; Trkola et al., 2001). RANTES has been speculated to play 
a major role during disease progression in that high RANTES concentrations might 
inhibit R5 strains and thus prolong the asymptomatic phase or predict the switch to X4 
variants (Saha et al., 1998). It was shown by Trkola and coworkers that very high 
concentration of RANTES (>500 ng/ml) might enhance HIV infection (Trkola et al., 
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1999). A proposed mechanism might be that RANTES bind free virions and enhances 
virus cell interactions (Trkola et al., 1999). Escape of R5 variants from RANTES has 
been shown in rapid progressors but not in long-term survivors predicting a role for 
RANTES in controlling HIV-1 viral load as well as progression to disease (Koning et al., 
2003). 
RANTES has proven to be a useful agent to screen for other small molecule 
inhibitors of CCR5 as they compete for the same binding site on CCR5 (Strizki et al., 
2001). Examples of compounds identified in this way include SCH-C and SCH-D, which 
are potent inhibitors of R5 isolates (Strizki et al., 2001) (see below). 
A derivative of RANTES called AOP-RANTES was generated by adding an 
aldehyde- like group to the amino terminal and then adding amino-oxy-pentane (Simmons 
et al., 1997). Met-RANTES was developed by adding a methionine at the amino terminus 
and has potent antagonistic effects to RANTES (Simmons et al., 1997). Met-RANTES 
and AOP-RANTES have similar abilities at inhibiting R5 isolates compared to natural 
RANTES (Gordon et al., 1999; Simmons et al., 1997). In contrast, excess concentrations 
of AOP-RANTES can enhance HIV infectivity possibly via crosslinking with 
glycosaminoglycans (Gordon et al., 1999; Marozsan et al., 2001). Both Met-RANTES 
and AOP-RANTES are only effective against R5 isolates and are not effective against X4 
isolates (Simmons et al., 1997).  
 
1.6.2.2 TAK779 
TAK779 prevents HIV-1 infection by binding a pocket formed by the trans-membrane 
helices 1, 2, 3 and 7 of CCR5 and does not induce down-modulation or signaling of the 
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receptor (Baba et al., 1999; Dragic et al., 2000). It has high specificity for CCR5 and 
CCR2 (Baba et al., 1999; Dragic et al., 2000). It has an IC50 ranging between 2-4 nM 
(Dragic et al., 2000). TAK779 is not being considered for clinical application but is a 
useful inhibitor of R5 isolates in vitro (Trkola et al., 2001). 
 
 
 
Figure 1.8: Structure of TAK779 (Taken from Baba et al., 1999) 
 
1.6.2.3 PRO140 
PRO140 is an anti-CCR5 monoclonal antibody and has high specificity for the cellular 
coreceptor CCR5 (Olson et al., 1999). It does not induce down-modulation or signaling 
of the receptor (Olson et al., 1999). It is very potent and prevents R5 strains from binding 
to the coreceptor and has no ability to block X4 isolates and has an IC90 of 2 µg/ml 
(Trkola et al., 2001). PRO140 binds amino acids in the amino terminus and second 
extracellular loop of CCR5 preventing both gp120 and chemokine binding (Olson et al., 
1999). PRO140 is effective against most R5 HIV-1 strains including HIV-1 subtype C 
isolates (Cilliers et al., 2003; Trkola et al., 2001). No resistance mutants have thus far 
been shown for PRO140, which makes it very useful as a possible drug therapy 
(LaBranche et al., 2001). It is still in pre-clinical testing. 
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1.6.2.4 SCH-C (SCH-351125) and SCH-D 
SCH-C is a small non-peptide molecule called oxime-piperidine and has a molecular 
weight of 557.5 KDa (Strizki et al., 2001). It is very specific for CCR5 with no cross 
reactivity to other chemokine receptors and prevents R5 viruses from binding to CCR5 
(Strizki et al., 2001). It has a mean IC50 concentration ranging between 0.4 and 0.9 nM 
for primary R5 HIV-1 isolates (Strizki et al., 2001). SCH-C binds to a part of the second 
extracellular loop of CCR5 and binding is dependent on a cavity formed in helices 1, 2, 3, 
5 and 7 (Tsamis et al., 2003). Binding of SCH-C to CCR5 disrupts the structure and thus 
prevents chemokine and HIV-1 interacting with the coreceptor (Tsamis et al., 2003). The 
residues that play a role in SCH-C binding to CCR5 were found to be L33 and Y37 in the 
first transmembrane region (TM1), D76 and W86 in TM2, F113 in TM3, I198 in TM5 
and E283 in TM7 (Tsamis et al., 2003). It was found to be inactive against one HIV-1 
subtype G isolate and it might be due to this virus’ ability to use another coreceptor or 
use CCR5 in the presence of SCH-C (Strizki et al., 2001). It has good pharmacokinetic 
profile in rats and monkeys and has a serum half- life of 5-6 hours (Strizki et al., 2001). 
However human clinical trials have been less favorable due to cardiac irregularities 
(Reyes, 2001). 
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Figure 1.9: Chemical structure of SCH-C (Taken from Tremblay et al., 2002) 
 
SCH-D is a follow-up compound of SCH-C. It has a different structure compared to 
SCH-C but the mechanism of action is more or less the same. It is reported to be more 
potent than SCH-C in vitro (Schurmann et al., 2004). SCH-D has a longer half- life, better 
absorption and higher bioavailability in rat and monkey studies (Schurmann et al., 2004). 
It has entered clinical trials and shown to be more effective at the higher dose range. It 
had a longer lag phase before viral rebound compared to patients in the lower dose trial 
group. This might be due to saturation of the CCR5 receptors giving prolonged inhibition 
of viral rebound (Schurmann et al., 2004).  
 
1.6.3 CXCR4 Inhibitors  
Inhibitors targeting CXCR4 are highly cationic compounds and specific for CXCR4 
(Fujii, Nakashima, and Tamamura, 2003). Targeting CXCR4 as a potential therapy may 
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prove to be very difficult as CXCR4 is important for embryogenesis and both CXCR4 
and its natural ligand stromal cell derived factor-1 (SDF-1) play important 
immunological roles (Fernandez and Lolis, 2001). Nevertheless a number of compounds 
have been developed. 
 
1.6.3.1 SDF-1a  
SDF-1 consists of 67 amino acids and is the natural ligand for CXCR4 (Bleul et al., 1996; 
Oberlin et al., 1996). It is highly specific for CXCR4 as no other chemokine receptor has 
been shown to be able to interact with SDF-1 (Bleul et al., 1996; Oberlin et al., 1996). 
SDF-1 is highly efficient at attracting lymphocytes (Bleuel et al 1996). Maximal 
lymphocyte chemotaxis was induced at 1µg/ml of SDF-1 (Bleuel et al., 1996). 
 
1.6.3.2 AMD3100 
AMD3100 is a bicyclam and is a cationic compound that binds to the extracellular loops 
of CXCR4 (Labrosse et al., 1998; Schols et al., 1997) (Figure 1.9). It has an effective 
concentration in the nanomolar range and it prevents X4 and R5X4 isolates from binding 
to CXCR4 and has no activity against R5 viruses (Donzella et al., 1998; Labrosse et al., 
1998; Schols et al., 1997). Resistance to AMD3100 takes a long time to develop in vitro 
and occurs after 50-60 serial passages, which is likely to give it a favorable resistance 
profile (Hendrix et al., 2000). It is not orally available and is administered intravenously 
or sub-cutaneously. It has an in vivo half- life of approximately 0.9 hours (Hendrix et al., 
2000). AMD3100 was the first known chemokine receptor blocker to enter Phase I 
clinical trials (Hendrix et al., 2000). However AMD3100 caused an elevated white blood 
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cell count and due to this side effect no further clinical trials were undertaken (Hendrix et 
al., 2000). 
 
 
 
Figure 1.10: Structure of AMD3100. (Taken from Hendrix et al., 2000) 
 
1.6.3.3 T-140 and T22 
T22 is the precursor peptide compound of T-140 and is a synthetic polyphemusin 
analogue consisting of 18 amino acids and two disulfide bridges forming an anti-parallel 
ß-sheet structure (Figure 1.10) (Tamamura et al., 1996; Tamamura et al., 1998b). It has a 
half maximal effective concentration at 290 nM in vitro and has specificity for X4 viruses 
(Tamamura et al., 1996). T-140 is a smaller peptide and consists of 14 amino acid 
residues with a single disulfide bond (Tamamura et al., 1998a; Tamamura et al., 1998b). 
It has higher anti-HIV activity at a lower IC50 of 12 nM. 
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Figure 1.11: The peptide structure of T-140 taken from (Tamamura et al., 2003) 
 
1.6.3.4 ALX40-4C 
ALX40-4C is a peptide consisting of nine-D-Arginine residues (Doranz et al., 1997; 
Nakashima et al., 1992; O'Brien et al., 1996). It has specificity against X4 viruses but is 
ineffective against R5 viruses. It has an approximate IC50 of 3 nM for X4 strains (O'Brien 
et al., 1996). Due to displacement studies with both 12G5 (a monoclonal antibody to 
CXCR4) it is postulated that ALX40-4C binds to the first and second extracellular loops 
of CXCR4 (Doranz et al., 2001; Doranz et al., 1997). ALX40-4c proved to be safe and 
well tolerated in Phase-I/II clinical trials. It was tested on 40 patients, 12 of whom 
harbored X4 viruses (Doranz et al., 2001). Due to low efficiency of this compound to 
broadly inhibit HIV-1 clinical development of this compound was halted (Doranz et al., 
2001). Even though this clinical trial did not result in the desired outcome it proved that 
X4 inhibitors could be safely administered without severe adverse side effects even 
though the effects on white blood cell counts were not investigated (Doranz et al., 2001). 
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1.6.4 Inhibiting gp41 
The fusion process is another useful target for entry inhibitors. The gp41 consists of a 
fusion peptide and 2-terminal heptad repeat regions (HR-1 and HR-2), which are coiled 
coils and fold into each other to enable fusion to take place (Chan et al., 1997). These two 
heptad regions contain conserved areas that can serve as target areas for development of 
entry inhibitors. 
 
 
Figure 1.12: A schematic map of gp41 is shown from the amino terminus to the carboxy 
terminus. The fusion peptide (FP) is situated at the amino terminus and acts as a spike 
that inserts into the host cell membrane. The HR-1 region is the first heptad-repeat region 
and forms part of the coiled coil structure. The CC is the linker between HR-1 and HR-2 
and acts as a hinge during fusion. The second heptad-repeat region (HR-2) is shown in 
blue and is situated near the transmembrane region (TM) of the virus. The region from 
which T-20 was derived is indicated (Taken from (Kilby and Eron, 2003). 
 
1.6.4.1 T-20 
T-20 is a 36 amino acid peptide derived from the HR-2 sequence of the HIV-1LAI subtype 
B gp41 envelope glycoprotein (Wild et al., 1994) (Figure 1.11 and Figure 1.12). It 
interferes with the formation of the six-helical bundle by binding to the HR-1 region of 
gp41, thereby preventing fusion between the viral and host cell membranes (Kilby et al., 
1998; Wild et al., 1994). T-20 is the first in a new class of anti-retroviral drugs termed 
entry inhibitors licensed for use in humans and is known by the name Enfuvirtide or 
Fuzeon. In Phase III human clinical trials this drug has been shown to be effective for 
patients in deep salvage therapy including those with viruses resistant to reverse 
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transcriptase and protease inhibitors (Lalezari et al., 2003b). Phase III clinical trials 
involving T-20 were referred to as T-20 versus Optimized Regimen Only (TORO). 
TORO I trials enrolled 491 patients from North America and Brazil and the TORO II trial 
enrolled 504 patients in Europe and Australia (Clotet et al., 2004; Lalezari et al., 2003a). 
Results from these clinical trials showed that patients who received T-20 as part of their 
combination regimen achieved a mean reduction in HIV levels of 1.43 log10 copies/ml 
compared to a mean of 0.65 log10 copies/ml in a control group at 24 week analysis (Clotet 
et al., 2004; Lalezari et al., 2003a). Serum antibodies to T-20 and preexisting antibodies 
to gp41 had no effect on T-20 efficacy (Walmsley et al., 2003). Adverse effects included 
reactions at the site of injection and other minor side effects, which could not be linked to 
T-20 (Clotet et al., 2004; Lalezari et al., 2003a). Bacterial pneumonia was more frequent 
among patients taking T-20 than in patients on the optimized regimen alone (Lalezari et 
al., 2003a). T-20 was effective for children at lower dosages but the same target plasma 
viral loads were achieved (Soy et al., 2003). Thus T-20 is an effective therapeutic agent 
with application for both adults and children with good tolerability combined with good 
pharmacokinetics profiles and efficacy. T-20 needs to be injected, as it is not orally 
available. It is very expensive to produce and was initially used as a salvage therapy but 
has become more freely available (www.fuzeon.com). The use of the drug is likely to be 
restricted in developing countries due to high cost. 
 
Coreceptor interactions have been reported to play a role in T-20 efficiency with CCR5-
using isolates requiring higher concentrations of T-20 to inhibit replication compared to 
CXCR4-using viruses (Derdeyn et al., 2000; Derdeyn et al., 2001; Reeves et al., 2002). It 
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was found that expression levels of CCR5 on the host cell could influence the 
effectiveness of T-20 (Reeves et al., 2002). Reduced coreceptor affinity can also affect 
fusion levels and viral infectivity although there is no correlation between coreceptor 
affinity and entry inhibitor sensitivity (Reeves et al., 2004). A point mutation outside the 
ß-21 sheet did affect coreceptor and TAK779 affinity but had no impact on the fusion 
kinetics or sensitivity to T-20 (Reeves et al., 2004). 
 
Resistance to T-20 is associated with changes in the HR-1 region, particularly the GIV 
motif at positions 36 and 38 in gp41 (Hanna et al., 2002; Kilby et al., 2002; Villahermosa 
et al., 2003; Wei et al., 2002). The changes occur mostly in G36D/S/V/A and V38M and 
G37V (Poveda et al., 2002; Rimsky, Shugars, and Matthews, 1998; Roman et al., 2003; 
Wei et al., 2002). A V38 mutation has an approximately 20-fold increase in resistance 
(Lu et al., 2004). The N42T and N42D mutants confer two and fourfold resistance and 
the N43S and N43K confer five-and six-fold resistance. Combinations of these resistance 
mutations confer much higher levels of resistance with N42T/N43K approximately 32-
fold resistance and V38A/N42T approximately 149-fold higher resistance (Lu et al., 
2004). An order of fitness was determined and shown to be 
WT>N42T>V38A>N42T/N43K~N42T/N43S>V38A/N42D~V38AN42T>V38E/N42S 
(Lu et al., 2004). These orders of fitness were determined on X4 envelopes, which may 
be different for R5 envelopes (Lu et al., 2004). Changes in the V3 loop as well as 
sensitivity to T-20 are determined in the V3 loop based on coreceptor usage (Derdeyn et 
al., 2000; Derdeyn et al., 2001; Reeves et al., 2002). Changes in the HR-2 region from 
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which T-20 was derived have also been reported to undergo changes to facilitate 
resistance (Poveda et al., 2002). 
 
 
Figure 1.13: The structure of T-20 consists of 36 amino acids and targets the HR-1 
region of gp41. (www.trimeris.com) 
 
1.6.4.2 T-1249 
T-1249 is the follow-up compound to T-20. It is a designer peptide consisting of 39 
amino acids and was developed to be effective against T-20 resistant isolates and was 
derived from sequences of HIV-1, HIV-2 and SIV (Eron et al., 2004). The inclusion of 
HIV-2 and SIV sequences gives it a broader range of activity. It is currently in Phase I 
clinical trials and was used for patients failing phase II/III clinical trials with T-20 due to 
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resistance. Among these patients a drop of HIV plasma RNA of 1.1-log10 copies/ml was 
seen (Eron et al., 2004). T-1249 was well tolerated over a 14-day treatment period (Eron 
et al., 2004). Most patients had injection site reactions and these increased as the dose of 
T-1249 was increased. Cross serum antibody responses were noted for some patients 
receiving T-1249 and for some patients the response was accompanied with rash or fever 
(Eron et al., 2004). The response was specific for T-1249 and some patients had 
preexisting antibodies to T-1249 most probably because T-1249 share some homology 
with HIV-1 gp41 (Eron et al., 2004). Evidence of T-1249 resistance was seen in some 
patients with reduced sensitivity to T-1249 when the HR-1 region had V38E and Q40K 
mutations (Eron et al., 2004). Preliminary results appear to be promising for T-1249 to be 
used as a substitute or follow-up treatment for T-20 as a salvage regimen. The clinical 
development of T1249 is no longer being pursued (www.trimeris.com). 
 
1.6.4.3 5-Helix 
5-Helix is a recombinant C-peptide derived from the carboxy terminal of gp41 (Root, 
Kay, and Kim, 2001). It was designed to consist of five of the six helix bundles when the 
trimer of hairpins form and is connected by small peptide linkers. This peptide has one 
linker missing, which enables it to bind to the carboxy terminus of gp41 (Root, Kay, and 
Kim, 2001). It was derived from the region directly adjacent to the 2F5 epitope 
suggesting its action would be antagonistic with other C-peptides. Its efficacy is in the 
nanomolar range (Root, Kay, and Kim, 2001). 
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1.7 Combinations of entry inhibitors  
A promising approach is to use a combination of entry inhibitors and existing anti-
retrovirals. This approach will target different stages of viral entry and replication cycle 
and might give a better prognosis in delaying drug resistance (Tremblay et al., 2003). 
Combination of antiretroviral drugs has already been shown to be synergistic or 
antagonistic and these can only be established during clinical trials (Havlir et al., 2000; 
Merril et al., 1996; Tremblay et al., 2003). Pre-clinical studies showed a marked synergy 
in drug combination therapies between the CCR5 inhibitor SCH-C and reverse 
transcriptase inhibitors (zidovudine and lamivudine) and non-nucleoside reverse 
transcriptase inhibitors (efavirenz) and protease inhibitors (Indinavir). All these 
combinations with SCH-C were shown to be synergistic (Tremblay et al., 2002). SCH-C 
worked synergistically with T-20 and AOP-RANTES (Tremblay et al., 2002). Synergy 
between AMD3100 and T-20 was observed and is a useful combination to inhibit 
CXCR4 using viruses (Tremblay et al., 2002). Synergy was detected between 1-B-D-2.6-
diaminopurinedioxolane (DAPD) a nucleoside reverse transcriptase inhibitor effective 
against both R5 and X4 isolates (Tremblay et al., 2003). T-20 and PRO542 proved to be 
a good combination as both CD4 binding and fusion was targeted to prevent virus entry 
(Nagashima et al., 2001). All these drug combinations targeting different stages of the 
virus life cycle provide good proof of concept that drug combinations will be effective in 
combating drug resistance and gives ample opportunity to switch drug combinations. 
Clinical tria ls are necessary to establish which combinations will be most favorable and 
to establish first line and follow-up drug regimens. 
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1.8 Monoclonal antibodies to CCR5 and CXCR4 
Various monoclonal antibodies to CCR5 and CXCR4 have been identified. Of these 2D7  
and PRO140 seem to be the most effective at inhibiting HIV entry via the CCR5 
coreceptor. Both 2D7 and PRO140 are mouse monoclonal antibodies. However PRO140 
was subsequently transformed into a humanized version (Olson et al., 1999; Wu et al., 
1997b). Antibodies that bind to other regions especially the amino terminus of CCR5 
have been developed but their efficacy at inhibiting HIV-1 replication was poor (Olson et 
al., 1999; Wu et al., 1997b). PRO140 was described earlier in section 1.6.2.3. Naturally 
occurring antibodies to CCR5 has been found in individuals who were exposed to HIV 
but remained uninfected (Lopalco et al., 2000). This suggests that the effectiveness of 
CCR5 antibodies may play a role in preventing HIV-1 replication. 
 
1.8.1 2D7 
2D7 was generated from a mouse and binds to the second extracellular loop of CCR5. It 
was shown to prevent the natural ligands RANTES, macrophage inflammatory protein-  
1a and 1ß from binding which make 2D7 a very potent CCR5 antagonist (Wu et al., 
1997b). The monoclonal antibody has proven that the second extracellular loop of CCR5 
plays an important role in binding gp120 (Wu et al., 1997b). Resistance to 2D7 has been 
shown for isolates able to replicate in the presence of 2D7 without the use of other 
coreceptors (Aarons et al., 2001).  
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1.8.2 12G5 
12G5 targets CXCR4 and binds to the second extracellular loop of CXCR4 and has the 
ability to prevent X4 viruses from binding to this coreceptor (McKnight et al., 1998). Full 
inhibition of X4 isolates was obtained at between 10-20 µg/ml (Strizki et al., 1997). It 
was found that not all X4 viruses were inhibited by this monoclonal antibody suggesting 
that other regions of CXCR4 can be used to bind CXCR4 and enter cells (McKnight et 
al., 1998; Strizki et al., 1997). This monoclonal antibody is useful in screening for other 
agents able to bind to CXCR4. 
 
1.9 Monoclonal antibodies targeting HIV envelope  
Monoclonal antibodies (Mabs) targeting the virus have been identified to play an 
important role in neutralization of HIV-1 and have assisted in identifying epitopes 
sensitive to antibodies. Several monoclonal antibodies have been described and some of 
their binding epitopes are known. These Mabs are IgG1b12 (b12), 2G12, 2F5 and 4E10 
(Burton and Montefiori, 1997; Burton et al., 1994; Moulard et al., 2002; Trkola et al., 
1995).  
 
1.9.1 IgG1b12 
One of the most effective cross-clade neutralizing antibodies is IgG1b12. It has a 
conformational epitope overlapping the CD4 binding site and thus prevents CD4 gp120 
interactions (Burton and Montefiori, 1997; Burton et al., 1994; Roben et al., 1994). It has 
an IC50 of between 3 and 7 ng/ml for laboratory adapted HIV strains and was higher for 
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primary isolates at less or equal to 1 µg/ml (Burton and Barbas, 1994). Trials with 
macaques proved that IgG1b12 could prevent HIV-1 infection at 25 mg/ml making it a 
possible therapeutic agent (Parren et al., 2001). Its efficacy has been demonstrated in an 
animal model where cocktails of monoclonal antibodies, which included IgG1b12, were 
able to protect macaques from infection (Ferrantelli et al., 2003). It is effective against 
most but not all HIV-1 subtype C strains, which accounts for most infections worldwide 
(Binley et al., 2004; Bures et al., 2002).  
 
1.9.2 2G12 
The monoclonal 2G12 binds to gp120 and has broad cross-clade neutralization and its 
mannose rich glycosylation sites at positions N295, N332, N339, N386 and N392 play a 
major role in binding 2G12 (Moulard et al., 2002). 2G12 binding is ineffective if changes 
in these regions occur (Sanders et al., 2002; Scanlan et al., 2002). 2G12 has been proven 
not to be able to neutralize most HIV-1 subtype C probably due to the absence of the 
glycosylation site at position 295 (Bures et al., 2002; Binley et al., 2004). 
 
1.9.3 2F5 
2F5 is an antibody targeting a linear epitope ELDKWA on the C-terminal region of gp41 
(Purtscher et al., 1994; Muster et al., 1994; Zwick et al., 2005). It is very potent against 
viruses harboring this epitope especially subtype B with an IC50 ranging between 0.7 
µg/ml and 9.7 µg/ml (Purtscher et al., 1994). Most HIV-1 subtype C does not have the 
ELDKWA epitope and have natural polymorphisms in this region thus rendering 2F5 
largely ineffective against this subtype (Bures et al., 2002; Binley et al., 2004).  
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1.9.4 4E10 
4E10 is an IgG1 monoclonal antibody targeting the gp41 region near the 2F5 epitope 
(Stiegler et al., 2001). 4E10 recognizes the sequence NWFDIT and binding to this 
epitope is dose related (Stiegler et al., 2001; Zwick et al., 2005). The NWFDIT epitope is 
adjacent to the ELDKWA epitope and is very conserved for most subtypes (Stiegler et 
al., 2001; Zwick et al., 2001). The IC50 of 4E10 ranged from 0.3 to 12.5 µg/ml and was 
effective against a variety of HIV-1 subtypes and was also effective against subtype C 
viruses (Stiegler et al., 2001; Xu et al., 2001; Binley et al., 2004).  
 
1.9.5 sCD4-17b 
A novel approach to inhibit HIV-1 was to link soluble CD4 (sCD4) with 17b, which is an 
antibody able to bind to a region after gp120 bound to CD4 (CD4 induced epitope) and it 
is able to prevent coreceptor binding. The sCD4 was linked to 17b via a polypeptide 
linker (Dey, Del Castillo, and Berger, 2003). sCD4-17b was found to be a very potent 
inhibitor of HIV-1 and was reactive against a broad range of subtypes. It was effective at 
an IC50 of 3.2 nM and more than 99% neutralization was obtained at 32 nM (Dey, Del 
Castillo, and Berger, 2003). sCD4-17b was more potent than other monoclonal antibodies 
such as 2G12, 2F5 and IgG1b12 and it was effective against both R5 and X4 isolates 
(Dey, Del Castillo, and Berger, 2003).  
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1.10 Combinations of monoclonal antibodies 
Monoclonal antibodies with an effective cross-clade neutralizing ability can be used as a 
possible therapeutic intervention. Combinations of monoclonal antibodies can be used 
against subtype A, B, C and D if one antibody fails to neutralize, another monoclonal 
antibody might do so. Combinations of monoclonal antibodies can work synergistically 
in lowering the concentration needed to neutralize virus (Ferrantelli et al., 2004; 
Kitabwalla et al., 2003; Xu et al., 2001). The effectiveness of combinations of 
monoclonal antibodies has been demonstrated in a macaque model where neonate 
macaques were protected from SHIV89.6P infection by a cocktail of monoclonal 
antibodies while control macaques were infected (Veazey et al., 2003b). This suggests 
that monoclonal antibodies might be useful in preventing mother-to-child transmission 
via breastfeeding (Veazey et al., 2003b). Further immunogens able to induce such 
antibodies may be useful in the prevention of infection by vaccination. Thus neutralizing 
antibodies can either be used as a prophylactic or can have therapeutic applications. 
 
1.11 Entry inhibitors as microbicides 
An effective microbicide is urgently needed to help stem the spread of HIV. Entry 
inhibitors present an attractive option as they can prevent HIV from entering the cell. The 
first microbicide in human clinical trials was Nonoxynol-9. It was unable to prevent HIV 
and may have increased infection (Van Damme et al., 2002). Other potential agents are 
PRO2000 and CV-N (Dey et al., 2000; Mayer et al., 2003; O'Keefe et al., 2003). 
PRO2000 is a synthetic naphthalene sulfonate polymer and is contained in a gel 
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formulation with a pH of 4.5 (Mayer et al., 2003). PRO2000 efficacy has been proven to 
be at 100 µg/ml or less and is effective at blocking HIV-1 infection (Mayer et al., 2003). 
PRO2000 binds to gp120 and prevents CD4 binding as well as V3 loop interactions with 
the coreceptor (Mayer et al., 2003). As with CV-N it is also effective against other 
viruses such as herpes viruses and sexually transmitted pathogens such as Chlamydia 
trachomatis and Neisseria gonorrhea (Mayer et al., 2003). Phase I trials demonstrated 
that PRO2000 was safe and well tolerated by women and men (Mayer et al., 2003; Tabet 
et al., 2003). Only minor side effects were reported which makes PRO2000 a potential 
candidate to prevent sexual transmission of HIV-1 (Mayer et al., 2003). 
 
A study using monoclonal antibodies in macaques has demonstrated the efficacy of a 
microbicide containing monoclonal antibodies targeting the virus (Veazey et al., 2003b). 
Monoclonal antibodies are very expensive and would not be a financially viable option 
for use in a microbicide but demonstrate proof of concept that agents targeting the virus 
will be effective (Veazey et al., 2003b). Microbicides using non-nucleoside reverse 
transcriptase inhibitors such as TMC120 and entry inhibitors may also be very effective 
as they target both the virus as well as the host cell receptors and further studies needs to 
be done to prove their usefulness in preventing sexual transmission of HIV-1 (Di Fabio et 
al., 2003; Veazey et al., 2003a). 
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1.12 OBJECTIVES 
 
1.12.1 Primary objective 
To determine the sensitivity of HIV-1 subtype C viruses to inhibitors of viral entry. 
 
1.12.2 Secondary objectives 
 
1. To determine the effectiveness of coreceptor inhibitors against HIV-1 subtype 
C isolates from adult AIDS patients with different coreceptor usage patterns. 
 
2. To determine coreceptor usage of isolates from an acutely infected cohort and 
to establish if isolates from two individuals who showed a coreceptor switch 
become less sensitive to entry inhibitors over time. 
 
3. To determine alternate coreceptor use on primary cells of two unusual HIV-1 
isolates using chemokines and entry inhibitors with defined receptor-binding 
profiles. 
 
4. To assess the effectiveness of T-20 against HIV-1 subtype C isolates and to 
compare the sensitivity of HIV-1 subtype C isolates to subtype B isolates. 
 
5. To determine T-20 resistance patterns of HIV-1 subtype C and to compare 
these to HIV-1 subtype B. 
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CHAPTER 2 
 
SENSITIVITY OF SUBTYPE C ISOLATES FROM AIDS PATIENTS TO CCR5 
AND CXCR4 INHIBITORS IN PBMC 
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2.1 INTRODUCTION 
 
Transmission of HIV-1 is almost always associated with viruses that utilize CCR5 (R5 
viruses) which predominate during the acute and asymptomatic phases of infection 
(Michael et al., 1997; Rana et al., 1997). Disease progression is often associated with the 
emergence of viruses that have acquired the ability to use CXCR4 (X4 viruses), instead 
of, or as well as, CCR5 (R5X4 viruses) (Connor et al., 1997; Scarlatti et al., 1997). These 
patterns of coreceptor usage correspond to the phenotypes previously defined by the MT-
2 assay; here, syncytium-inducing (SI) viruses use CXCR4 while non-syncytium-
inducing (NSI) viruses use CCR5 (Bjorndal et al., 1997). Some isolates from AIDS 
patients can also use other chemokine receptors as coreceptors in receptor-transfected 
cell- lines, including CCR1, CCR2b, CCR3, B0b/GPR15 and CXCR6 (Bonzo/STRL33) 
(Deng et al., 1996; Edinger et al., 1998; Pohlmann, Krumbiegel, and Kirchhoff, 1999; 
Sharron et al., 2000; Xiao et al., 1998; Zhang et al., 1998). Rarely, however, are such 
alternative coreceptors used in primary cells (Sharron et al., 2000; Zhang and Moore, 
1999). 
 
HIV-1 cellular tropism and coreceptor specificity is largely determined by the sequence 
of the third hypervariable loop (V3) of the viral gp120 glycoprotein, and distinct changes 
in this region have been associated with the NSI/SI phenotype among subtype B viruses 
(Chan et al., 1999; De Jong et al., 1992; Ivanoff et al., 1992; Shimizu et al., 1999). 
Compared to other subtypes, the V3 regions of the subtype C viruses studied to date tend 
to be highly conserved and have a low overall positive charge, which is consistent with 
  44 
the NSI phenotypes and restricted coreceptor usage of subtype C viruses (Gaschen, 
Korber, and Foley, 1999).  
 
The reported low frequency of SI HIV-1 subtype C isolates might be that in most cases 
isolates were studied, from asymptomatic patients or from poorly defined disease stages 
(Abebe et al., 1999; Bjorndal et al., 1999; Cecilia et al., 2000; Morris  et al., 2001; Ping et 
al., 1999; Tien et al., 1999). We have therefore isolated viruses from patients with 
subtype C infection and advanced AIDS, to determine whether SI viruses are identified 
more frequently under these conditions than previously reported. We have also explored 
whether subtype C isolates able to use either or both CCR5 and CXCR4 are sensitive to 
coreceptor-specific entry inhibitors. 
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2.2 Materials and Methods  
2.2.1 Isolation of NSI and SI HIV-1 subtype C viruses 
Patients admitted to the Sizwe Infectious Diseases Hospital in Johannesburg, South 
Africa between August and December 1999 with HIV-1-related opportunistic infections 
and CD4 T cell counts less than 100 cells/ml were selected for this study. Ethical 
clearance was obtained from the University of the Witwatersrand Committee for 
Research on Human Subjects (Medical) and informed consent was obtained from all 
patients prior to drawing 5 ml of blood in EDTA (Appendix E). Plasma viral levels were 
measured using the Versant HIV-1 RNA 3.0 assay (bDNA assay from Bayer Nucleic 
Acid Diagnostics), previously shown to amplify HIV-1 RNA from all HIV-1 group M 
genetic subtypes (Elbeik et al., 2002; Swanson et al., 2001). The median plasma viral 
load for this cohort was high at 321,070 HIV-1 RNA copies/ml consistent with advanced 
HIV-1 disease. Twenty-two patients had tuberculosis (TB), 4 had cryptococcal meningitis 
(CM), 2 had Pneumocystis carinii pneumonia (PCP) and one had mycobacterium other 
than tuberculosis (MOTT). HIV-1 was isolated from 22 patients when their peripheral 
blood mononuclear cells (PBMC) were co-cultured with phytohemagglutinin (PHA)-
activated donor PBMC as previously described (Morris et al., 2001). Isolates from the 
remaining 7 patients were obtained by culturing 100 ml of plasma overnight with PHA-
activated PBMC. Culture supernatants were tested weekly using a commercial p24 
antigen kit (Beckman Coulter Ltd., Buckinghamshire, UK) and expanded when high 
levels of p24 antigen were present. Cultures were replenished with fresh interleukin –2 
(IL-2) medium every 3-4 days and with PHA-stimulated donor PBMC every 7 days for 
up to 3 weeks. Virus-containing supernatants were spun to remove cellular debris and 
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frozen at –70°C until use. Some isolates were re-expanded using PBMC stimulated with 
both PHA and surface- immobilized anti-CD3 Mab plus IL-2 as previously described 
(Trkola et al., 1999), to generate high titer stocks for further experiments. These isolates 
had limited expansion in PBMC in vitro and are likely to reflect the viral swarm present 
in vivo, although we cannot exclude that some selection, albeit limited, occurred during in 
vitro passage.   
 
2.2.2 Determination of biological phenotype  
The MT-2 cell line was used to determine virus phenotype. MT-2 cells were grown in 
RPMI 1640 media containing 10% fetal calf serum (FCS) and seeded at 0.5x106 cells/ml 
in 12 well plates. The MT-2 cells were infected with 500µl of virus and monitored daily 
for the appearance of syncytia (Morris et al., 2001).  
 
2.2.3 Coreceptor usage in transfected cell lines 
Viral isolates were tested for their abilities to replicate in U87.CD4 cells transfected with 
CCR5, CXCR4, CCR1, CCR2b or CCR3. Cells were plated in 12-well plates at 105 
cells/well in 2 ml of selection medium (Dulbecco’s modified eagle’s medium (DMEM) 
containing 10% FCS, antibiotics plus 500 mg/ml G418 (Boehringer Mannheim GmbH) 
and 1 mg/ml puromycin (ICN Biomedicals Inc., Ohio, USA). The following day, 1,000 
TCID50 (50% tissue culture infectious doses) of virus was added. After incubation 
overnight, the cultures were washed three times with DMEM plus 10% FCS to remove 
unbound virus, then monitored for syncytium formation and p24 antigen production on 
days 4, 8 and 12. The in-house p24 antigen ELISA has a detection limit of 250 pg/ml 
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(Trkola et al., 2001). Isolates that induced syncytia formation and generated increasing 
concentrations of p24 antigen were considered to be replication positive.  
 
GHOST.3 cell lines expressing Bob/GPR15 or CXCR6 were used to determine alternate 
coreceptor use. The assays were performed essentially as described for the U87.CD4 cell 
assays except that cells were grown in the presence of 100 mg/ml hygromycin (Sigma-
Aldrich, South Africa) in addition to the other two antibiotics mentioned above. Because 
GHOST.3 cell lines express endogenous CXCR4 it was necessary to add 1.3 mM of 
AMD3100 to prevent entry via this coreceptor (Zhang et al., 2000; Zhang and Moore, 
1999). Viral replication in the presence of AMD3100 therefore indicated use of the 
transfected coreceptor (either Bob/GPR15 or CXCR6). 
 
2.2.4 Viral replication in wild type and D32/D32-CCR5 PBMC 
PBMC from a CCR5 D32/D32 donor and CCR5 +/+ control donors were isolated and 
stimulated using PHA and surface- immobilized anti-CD3 Mab, as described above. On 
the following day, the cultures were washed 3 times and incubated in IL-2 containing 
medium. Supernatants were assayed for p24 antigen levels using a commercial assay with 
a kinetic readout (Dupont/NEN Life Sciences, Boston, MA) on days 4, 8 and 11.  
 
2.2.5 Inhibitor assays in PBMC 
Entry inhibitor assays were performed using CD8+ T cell depleted PBMC utilizing 
RosetteSep CD8 antibody cocktail (StemCell Technologies, Vancouver, Canada) and 
stimulated with phytohemagglutinin (PHA). CD8 depletion was confirmed using flow 
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cytometry (Becton Dickinson, San Jose, CA). The PBMC were incubated with the 
specific inhibitor for 1 hour before adding 1,000 TCID50 (50% tissue culture infectious 
dose per ml) of virus. Assays were performed on 96 well plates using RPMI 1640, 10% 
fetal calf serum and IL-2. Inhibitors tested included the anti-CCR5 Mab PRO140 
(Progenics Pharmaceuticals, New York), chemokines RANTES (PeproTech Inc., Rocky 
Hill, N.J) and the small molecule CXCR4 antagonist, AMD3100. Viral replication was 
measured by p24 antigen (ag) production. The reduction in p24 ag levels was calculated 
relative to cultures without inhibitors and the percentage inhibition at a high and low 
concentration of each inhibitor is reported. Results shown are from duplicate cultures and 
each experiment was repeated twice as previously described (Trkola et al., 2001). 
 
2.2.6 Sequencing of V3 region 
The V3 region was amplified using primers BF (5'-TAACACAAGCCTGTCCAAAGG-
3') and BR (5'-AATTCTAGGTCCCCTCCTGA-3'). RNA was reverse transcribed with 
AMV Reverse Transcriptase (Roche Molecular Biochemicals) and amplified with Super-
Therm Polymerase (Southern Cross Biotechnologies); the PCR product was cleaned with 
a High Pure PCR Product Purification kit (Roche Applied Science). Sequencing was 
performed in both directions with the BF and BR primers. 
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2.3 RESULTS 
2.3.1 Characteristics of AIDS patients with NSI or SI isolates 
Twenty-nine isolates were generated from 13 men and 16 women with a median age of 
34 years and a median CD4 count of 40 cells/ml. Among the 29 isolates, 5 (17%) were 
able to grow in MT-2 cells, leading to syncytia formation (SI isolates) (Table 2.1). The 
subset of patients with SI viruses had significantly reduced CD4 T cell counts, which is 
similar to observations made on patients infected with subtype B strains (Richman and 
Bozzette, 1994). Viral loads among the patients with SI viruses were not particularly 
high, compared to levels in the cohort as a whole, perhaps because too few memory CD4 
T cells remain to support high- level viral replication. However, viral load measurements 
were available from only 3 patients with SI viruses, so no conclusions can be drawn from 
the statistical perspective. SI viruses were isolated from 3 of 22 (14%) TB patients and 2 
of 4 (50%) cryptococcal meningitis (CM) patients (Table 2.1). However, overall, there 
were no significant differences in the age, gender or opportunistic infections of patients 
with SI isolates compared to those that harbored NSI isolates. A cohort containing larger 
numbers of patients with SI isolates will be needed to fully address such issues.   
 
2.3.2 Sub-typing of HIV-1 isolates 
The HIV-1 isolates were subtyped in the C2-V5 region of env gene by heteroduplex 
mobility assay (HMA) and all shown to belong to HIV-1 subtype C, the predominant 
subtype in South Africa (Bredell et al., 1998; Van Harmelen et al., 1999). Thirteen 
isolates were also subtyped in gag by HMA and shown to belong to subtype C (data not 
shown) suggesting that these isolates were unlikely to be inter-subtype recombinants, 
  50 
although this cannot be excluded. Two viruses, CM9 and SW7, have been confirmed as 
being subtype C throughout its genome (Papathanasopolous et al., 2002).  
 
2.3.3 Coreceptor use of HIV-1 subtype C isolates from AIDS patients 
There was an absolute correlation between the NSI and SI phenotype and the ability of an 
isolate to use CCR5 or CXCR4, respectively (Table 2.2). Thus, all 24 NSI isolates were 
able to replicate in CCR5-expressing cells, but not in the CXCR4-expressing cells (hence 
they are conventionally designated as R5 viruses). The 5 SI isolates all replicated in 
CXCR4-expressing cells. Among them, 3 could replicate in CCR5-expressing cells 
(designated as R5X4 viruses) while 2 did not (designated as X4 viruses). Although PCP1 
was classified as an R5 virus it did show low-level usage of CXCR4 that was below the 
cut-off for the p24 antigen assay (data not shown). The ability of this virus to use CXCR6 
(see below) very efficiently may account for these low levels of replication as U87.CD4 
cells express this receptor, and also GPR1, endogenously (Farzan et al., 1997; Unutmaz 
et al., 2000). CM9 could use CXCR6, Bob/GPR15 and CCR3 (Table 2.2). In each case, 
entry via the alternate coreceptor was at a comparable level of efficiency but less than 
CCR5 or CXCR4 (Table 2.2). 
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Table 2.1: Characteristics of 29 South African AIDS patients with NSI or SI isolates 
 
2.3.4 Sensitivity of HIV-1 subtype C isolates to coreceptor inhibitors in PBMC 
To confirm the use of CCR5 or CXCR4 in PBMC, viral isolates were cultured in the 
presence of CCR5-specific (RANTES and PRO140) or CXCR4-specific (AMD3100) 
entry inhibitors. A subset of 13 subtype C viruses able to use different coreceptors was 
selected for analysis, in comparison with a panel of 7 isolates from subtypes A, B and E 
(from National Institute for Health, Reference and Reagents Repository). The replication 
of 7 of the 8 R5 subtype C viruses was effectively inhibited (>90%) by the highest 
concentrations of RANTES and PRO140 that were tested (Table 2.3). One such isolate 
(CM1) was marginally less sensitive to RANTES (87% inhibition) and PRO140 (78% 
inhibition). In contrast, the CCR5 inhibitors were ineffective against R5X4 and X4  
viruses, suggesting that these viruses can all use CXCR4 to enter PBMC efficiently. 
AMD3100 effectively inhibited all the R5X4 and X4 viruses, although two isolates 
(SW30 and SW12) were slightly less sensitive (85% and 86% inhibition, respectively) 
than the others. The ability of AMD3100 to restrict the replication of all 3 R5X4 viruses 
suggests that they use CXCR4 in preference to CCR5 to enter PBMC in vitro as 
Total NSI isolates SI isolates
Number (% of total) 30 25 (83%) 5 (17%)
Female (% of total) 16 13 (81%) 3 (19%)
Male (% of total) 14 12 (86%) 2 (14%)
Median age 34 34 29
Median viral load (copies/ml) 26 776100* 68410*
Median CD4 count (cells/ul) 42 48** 10**
Diagnosis
Tuberculosis (TB) (% of NSI/SI) 22 19 (76%) 3 (60%)
Cryptococcal meningitis (% of NSI/SI) 5 3 (12%) 2 (40%)
Pneumocystic Carinii pneumonia (PCP) (% of NSI/SI) 2 2 (8%) 0
MOTT/Mac (% of NSI/SI) 1 1 (4%) 0
* significantly different (p=0.0134) by Mann Whitney test, data from only 3 of 5 ppatients available
** significantly different (p=0.0033) by Mann Whitney test 
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previously described (Yi et al., 1999). As expected, AMD3100 was ineffective against all 
the R5 isolates, because it is known not to interfere with CCR5-mediated entry (Donzella 
et al., 1998; Schols et al., 1997). The ability of an isolate to use alternate coreceptors in 
transfected cell lines did not influence whether it was sensitive to any of the entry 
inhibitors in PBMC cultures. Thus, both PCP1 and CM9 were fully sensitive to 
RANTES, PRO140 and AMD3100 up to day 6, despite being able to use alternate co-
receptors (Table 2.3). Either expression levels of the alternate co-receptors on PBMC are 
lower than on the transfected cell lines, or these coreceptors simply do not function as 
HIV-1 entry receptors on primary cells (Sharron et al., 2000) (Refer to Chapter 4).  
 
The CCR5 inhibitors were also effective against the R5 isolates from subtypes A, B and 
E. One R5X4 subtype B isolate (92US077) was effectively inhibited by AMD3100 but 
not by RANTES and PRO140, suggesting that it too uses CXCR4 preferentially to enter 
PBMC. Overall, there was a good, and subtype-independent, correlation between the 
classification of an isolate as R5 or X4 by use of the co-receptor-transfected cell lines, 
and its sensitivity to CCR5- or CXCR4-specific entry inhibitors in PBMC (Trkola et al., 
2001; Trkola et al., 1998). However, the isolates classified as R5X4, because they could 
use both CCR5 and CXCR4 in co-receptor-transfected cells (Table 2.3), were sensitive 
only to the CXCR4 inhibitor AMD3100 in PBMC, and were little affected by the CCR5 
antagonists PRO140 and RANTES (Table 2.3). Hence CXCR4 is the co-receptor of 
choice for these R5X4 isolates in primary T-cells, with only a minority of the viruses 
present entering the cells via CCR5.  
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Table 2.2: Coreceptor usage by HIV-1 subtype C isolates from AIDS patients 
 
 
 
Isolate  
ID Source 
CD4  
count  Viral load 
Subtype  
env  
MT-2  
assay 
Minor  
coreceptors Biotype 
CXCR4 CCR5 
PCP1  PBMC 2 ND C NSI  -  ++++ CXCR6+++ R5 
CM1 PBMC 43 146,514 C NSI  -  ++ R5 
CM7 PBMC 79 14,089 C NSI  -  ++++ R5 
SW2 Plasma 84 157,150 C NSI  -  ++++ R5 
SW3 Plasma 53 261,880 C NSI  -  ++++ R5 
SW4 Plasma 76 1,496,620 C NSI  -  ++++ R5 
SW5 PBMC 40 1,374,235 C NSI  -  ++++ R5 
SW8 Plasma 67 1,198,880 C NSI  -  + R5 
SW9 Plasma 65 301,605 C NSI  -  ++++ R5 
SW14 PBMC 32 >5,000,000 C NSI  -  +++ R5 
SW16 PBMC 9 151,630 C NSI  -  + R5 
SW22 PBMC 67 2,749,340 C NSI  -  ++ R5 
SW23 PBMC 10 696,000 C NSI  -  ++++ R5 
SW26 PBMC 25 ND C NSI  -  ++++ R5 
SW28 Plasma 43 3,814,130 C NSI  -  ++++ R5 
SW29 PBMC 12 1,190,180 C NSI  -  ++++ R5 
SW34 PBMC 40 127,000 C NSI  -  ++++ R5 
SW35 PBMC 37 1,652,870 C NSI  -  ++++ R5 
SW36 PBMC 55 201,340 C NSI  -  ++++ R5 
SW37 PBMC 121 34,210 C NSI  -  + R5 
SW38 PBMC 37 1,777,930 C NSI  -  ++++ R5 
SW39 PBMC 94 321,070 C NSI  -  ++++ R5 
SW40 PBMC 67 856,180 C NSI  -  ++++ R5 
SW41 PBMC 60 3,162,240 C NSI  -  +++ R5 
CM9 PBMC 24 ND C SI  ++++  ++++ CCR3+++  
CXCR6+++  
BOB+++ 
R5X4 
SW7 PBMC 10 ND C SI  ++++  - X4 
SW12 Plasma 27 68,410 C SI  ++++  - X4 
SW20 PBMC 2 43,595 C SI  ++  ++++ R5X4 
SW30 PBMC 2 73,860 C SI  ++++  ++++ R5X4 
Data shown of day 12 
*scoring system (In house endpoint p24 assay) 
  - = <250 pg/ml p24 antigen,   + = 250 pg-1 ng/ml p24 antigen ++ = 1-2 ng/ml p24 antigen 
 +++ = 2-4 ng/ml p24 antigen  ++++ = >4 ng/ml p24 antigen 
U87.CD4 cells  
expressing* 
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Table 2.3 Inhibition of HIV-1 subtype C viruses by CCR5 and CXCR4 inhibitors 
 
Virus Subtype Phenotype Day
19 nM 4 nM 167 nM 33 nM 500 nM 100 nM
PCP1 C R5 CXCR6 6 97 63 98 88 34 18
CM1 C R5 6 87 49 78 59 0 8
CM7 C R5 8 94 89 97 100 3 19
SW5 C R5 4 100 75 100 100 19 6
SW23 C R5 8 100 89 98 94 0 0
SW26 C R5 8 100 91 93 87 8 0
SW29 C R5 8 98 74 98 91 13 0
SW38 C R5 8 100 34 100 96 0 0
CM9 C R5X4 CXCR6, Bob, R3 8 36 36 34 13 97 58
SW7 C X4 4 0 24 0 5 100 87
SW12 C X4 10 0 0 0 0 86 31
SW20 C R5X4 8 0 0 79 0 100 0
SW30 C R5X4 8 24 9 8 39 85 3
DJ258 A R5 8 100 82 100 98 46 0
92RW026 A R5 8 98 69 100 100 63 23
JR-FL B R5 10 99 71 100 98 0 36
92US714 B R5 4 95 60 100 100 0 0
92US077 B R5X4 6 17 48 48 41 99 76
2044 B X4 6 20 23 30 22 39 21
CM235 E R5 10 95 62 100 97 22 2
92TH001 E R5 10 100 88 99 98 60 21
* Inhibition >90% is bolded and inhibition <90% is in italics
CCR5 inhibitors* CXCXR4 inhibitor*
RANTES at: PRO140 at: AMD3100 at:
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2.3.5 Replication of NSI and SI viruses in wild type and D32/D32-CCR5 PBMC 
The subtype C isolates used above were also tested for their ability to replicate in PBMC 
deficient of CCR5 (i.e., cells from an HIV-1-negative individual was confirmed by PCR 
to have the CCR5 D32/D32 genotype). None of the R5 isolates were able to replicate in 
the CCR5 D32/D32 PBMC but all replicated well in the CCR5 +/+ PBMC, confirming 
their dependence on CCR5 to infect cells (Table 2.4). The R5X4 and X4 isolates were 
able to replicate in both the CCR5 D32/D32 and the CCR5 +/+ PBMC, although p24 
production from the CCR5 D32/D32 cells was relatively low. In particular, the replication 
of isolate SW20 was sporadic in the CCR5 D32/D32 PBMC, with only some of the 
replicate wells producing p24 antigen. This contrasts with the consistent replication of the 
same virus in the CCR5 +/+ PBMC.  
 
2.3.6 CXCR4-using subtype C viruses show alterations in V3 loop  
The V3 loop is involved in determining coreceptor usage (Hoffman et al., 2002a). Certain 
genetic changes in this region are associated with CXCR4 use, in the context of viruses 
from subtypes B and D (De Wolf et al., 1994). To determine whether CXCR4-using 
subtype C isolates also have distinctive V3 loop sequences, RNA was isolated and their 
V3 regions sequenced. Phylogenetic analysis of the nucleotide sequences of all 16 V3 
loop sequences showed that all clustered with HIV-1 subtype C (data not shown), 
confirming the HMA data. The V3 loops of all the R5 viruses were 35 amino acids in 
length and contained the GPGQ motif at the crown that is characteristic of HIV-1 subtype 
C viruses (Figure 2.1). A neutral serine residue was always present at position 11 and, in 
most cases, an amino acid with a negatively charged side chain (either D or E) at position 
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25. The net charge of the V3 loop was +3 to +5. In contrast, the V3 loops of the R5X4 
and X4 viruses varied markedly from the consensus sequence, containing substitutions, 
deletions and insertions. A common, and unusual, feature was a two-residue insertion 
between positions 13 and 14, most frequently isoleucine and glycine, which increased the 
length of the loop to 37 amino acids.  
 
Table 2.4: HIV-1 subtype C replication in PBMC from D32/D32 and wt/wt donors 
 
A tetrapeptide motif containing positively charged arginine residues was also frequently 
present in the V3 loops of the R5X4 and X4 isolates, resulting in a marked increase in the 
overall positive charge of the loops to +6 to +9. Furthermore, all the R5X4 and X4 
isolates had either a neutral or positively charged amino acid substitution or a deletion at 
Isolates D32/D32 wt/wtb
R5
   PCP1  -  ++++
   CM1  -  ++++
   CM7  -  ++++
   SW5  -  +++
   SW23  -  ++++
   SW26  -  ++++
   SW29  -  ++++
   SW38  -  ++++
R5X4
   CM9  +  ++
   SW20  +/-  +
   SW30  +  ++++
X4
   SW7  +  +++
   SW12  ++  +++
a
p24 antigen level on day 8 (kinetic p24 assay). -, <250 pg of p24 antigen/ml; +, 250 pg to 10 ng of p24 antigen/ml; 
++, 10-30 ng of p24 antigen/ml; +++,30-60 ng of p24 antigen/ml; ++++, >60 ng/ml p24 antigen/ml.
bwt, wild type.
p24 antigen level for genotype a
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position 25. There were no sequence motifs that distinguished between R5X4 and X4 
viruses. 
 
Figure 2.1: Predicted V3 amino acid sequence of 16 South African HIV-1 subtype C 
isolates (11 R5 and 5 R5X4 or X4) compared to a HIV-1 subtype C consensus sequence. 
The overall positive charge, number of amino acids and biotype of each isolate is shown 
on the right. Dashes (-) indicate concurrence and a period (.) indicates a deletion or lack 
of an insertion. Changed amino acids are indicated. Positions 11 and 25 (associated with 
changes in biological phenotype), the tip of the V3 loops and region with insertions are 
highlighted in grey. Amino acid abbreviations are shown in Appendix B. GenBank 
accession numbers are listed in Appendix D (Sequencing was performed by Jabulani 
Nhlapo and amino acid sequence analysis by myself) 
 
1 5 10 15 20 25 30 35 charge #aa biotype
C_CON C T R P N N N T R K S I R . . I G P G Q T F Y A T G D I I G D I R Q A H C +4 35 R5
SW4  -  -  -  - S  -  -  -  -  -  -  -  - . . V  -  -  -  - S  - H  -  -  - E  -  -  -  -  -  -  -  -  -  - +5 35 R5
SW5  -  -  -  -  -  -  -  -  -  -  -  -  - . .  -  -  -  -  - A  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - +4 35 R5
SW14  - I  -  -  -  -  -  - S  -  -  -  - . .  -  -  -  -  -  -  -  -  -  -  - R  -  -  -  -  -  -  -  -  -  - +5 35 R5
SW16  -  -  -  -  -  -  -  -  -  -  - V  - . .  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - +4 35 R5
SW22  -  -  -  - S  -  -  -  -  -  -  -  - . .  -  -  -  -  - A  -  -  -  - N E  -  -  -  -  -  -  -  -  -  - +4 35 R5
SW23  - A  -  -  -  -  -  -  -  -  - V  - . .  -  -  -  -  -  -  -  -  -  -  - G  -  -  -  -  -  -  -  -  -  - +5 35 R5
SW26  -  -  -  - S  -  -  -  - T  - V  - . .  -  -  -  -  -  -  - F  -  - N  - V  -  -  -  -  -  -  -  -  - +3 35 R5
SW29  -  -  -  - G  -  -  -  -  -  - V  - . .  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - N  -  -  -  -  -  - +5 35 R5
SW34  -  -  -  - N  -  -  - T T  - V  - . .  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - N  -  - A  -  -  -  +3 35 R5
SW35  - A  -  -  -  -  -  -  - T  - V  - . .  -  -  -  -  - A  -  -  -  - N  -  -  -  - K  -  -  -  -  -  -  +5 35 R5
SW38  -  -  -  - G  -  -  -  -  -  - V  - . .  -  -  -  -  - A  -  -  -  -  -  -  -  -  -  -  -  - K  - Y  - +4 35 R5
CM9  - A  -  - G  -  -  - I  - R  -  - . .  -  -  - R Y A  -  -  - K E T  -  -  -  -  -  -  -  -  -  - +6 35 R5X4
SW7  -  -  -  - G S  - K Q R I R N I R  -  -  -  - R A  - H T N  - . V  -  -  -  -  - K  - Y  - +8 36 X4
SW12  - M  -  - G  -  -  -  -  - R V  - I G  -  -  - R  -  -  -  -  - P  - G  - N K  -  -  -  -  -  -  - +8 37 X4
SW20  -  -  -  -  -  -  -  -  -  -  -  -  - T G  -  - R  -  -  -  -  - V  -  - Q  -  -  -  - V  -  -  -  -  - +6 37 R5X4
SW30  -  -  -  -  -  -  -  -  -  -  - V  - I G  -  - R  - H A  -  - T T  - K V  -  - N  - R  -  -  -  -  +9 37 R5X4
  
 
58  
2.4 Discussion  
Here we describe HIV-1 subtype C isolates from patients with late-stage AIDS that grow 
in MT-2 cells (SI viruses) and use CXCR4 for entry into cells. These isolates were fully 
sensitive to AMD3100, a CXCR4-specific entry inhibitor and were able to grow in 
PBMC devoid of CCR5. Most of these SI viruses had significant genetic changes in the 
V3 loop compared to NSI viruses isolated from the same cohort. This is a similar 
observation to those reported for viruses from subtypes B and D (De Wolf et al., 1994; 
Hoffman et al., 2002b). Hence the HIV-1 subtype C envelope glycoproteins can 
accommodate the amino acid changes needed to use CXCR4 as a coreceptor. Probably, 
the gp120 proteins from all subtypes interact with CXCR4 in a broadly similar manner.  
 
Our observations stand in contrast to previous reports, including our own, that subtype C 
infections rarely involved viruses with the SI phenotype (Abebe et al., 1999; Bjorndal et 
al., 1999; Cecilia et al., 2000; Morris et al., 2001; Ping et al., 1999; Tien et al., 1999). 
These earlier descriptions of subtype C isolates mostly involved cohorts of patients in the 
relatively early stages of HIV-1 infection, identified relatively soon after subtype C 
viruses started to spread rapidly in the geographic area under study. Now, we have 
deliberately selected for study patients with advanced AIDS since they were more likely 
to harbour SI viruses. The isolation of CXCR4-using viruses from some of our late-stage 
AIDS patients suggests that subtype C viruses may undergo a phenotypic switch during 
disease progression, as occurs during subtype B infection (Connor et al., 1997; Richman 
and Bozzette, 1994; Scarlatti et al., 1997). However because our cohort was 
observational, we cannot know whether any of the patients with SI viruses had NSI 
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viruses at an earlier stage. Prolonged, longitudinal follow-up of individuals with acute 
subtype C-infection will be needed to address this issue (See Chapter 3). Although viral 
stocks were grown in PBMC in vitro it is likely that the dominant population is 
representative of the in vivo swarm as V3 sequence analysis of cultured isolates and from 
uncultured plasma samples from 5 of these patients showed them to be identical (data not 
shown). Thus phenotypes identified in vitro are likely to reflect the dominant phenotype 
in the patients.  
 
Although only 5 of our 29 (17%) AIDS patients were infected with SI viruses, this 
represents a higher frequency than was observed in previous studies on subtype C 
infection (Abebe et al., 1999; Bjorndal et al., 1999; Cecilia et al., 2000; Morris et al., 
2001; Ping et al., 1999; Tien et al., 1999). In subtype B cohorts, from 50-90% of patients 
with late-stage AIDS have been reported to harbour SI isolates (Richman and Bozzette, 
1994; Scarlatti et al., 1997). Whether the frequency of subtype C X4 viruses will increase 
over time or will remain relatively low compared to subtype B infections remains to be 
determined. HIV-1 subtype C might be compared to subtype A/E in Thailand where SI 
viruses were identified later during the epidemic with ever increasing frequency (De 
Wolf et al., 1994; Menu et al., 1999; Sutthent et al., 2002; Sutthent et al., 2001; Utaipat 
et al., 2002). Further studies on subtype C infection may reveal the same trend. In any 
case, the assumptions that subtype C viruses use CCR5 almost exclusively are unlikely to 
be valid with more reports of SI viruses being detected (Cilliers et al., 2003; Janse Van 
Rensburg et al., 2002; Johnston et al., 2003; Pollakis et al., 2004). 
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Most of the patients in our study had TB, which is the most common opportunistic 
infection in AIDS patients in South Africa. CCR5 expression levels are affected by 
environmental factors, such as TB, among African patients, which could favor a 
relatively high frequency of R5 viruses throughout the course of disease (Clerici et al., 
2000; Fraziano et al., 1999). The transmission of R5 viruses may be particularly efficient 
in areas such as South Africa where there is a high incidence of early HIV-1 infection 
(Gouws et al., 2002), which is associated with high viral loads and R5 viruses. 
Furthermore, any individuals who harbour SI viruses early in infection may not survive 
long enough in an African health-care setting to become enrolled in a clinical cohort. 
Hence this factor might lead to under-representation of SI isolates in a cohort such as 
ours. Patients with cryptococcal meningitis were particularly likely to have CXCR4-using 
viruses, which is probably related to the association between this opportunistic infection 
and advanced HIV-1 disease.  
 
We previously showed that subtype C viruses were as sensitive as subtype B viruses to 
the CCR5 inhibitors, PRO140, RANTES and TAK-779 (Trkola et al., 2002). Here, we 
have extended our observations to a more diverse group of viruses and we have also 
tested the CXCR4 inhibitor, AMD3100. Together, these studies support the clinical 
evaluation of coreceptor-specific entry inhibitors in South Africa; the antiviral responses 
are likely to be similar to those that have been observed in studies on subtype B 
infections in North America and Europe (Hendrix et al., 2002; Reynes, 2002). Subtype C 
accounts for the vast majority of global HIV-1 infections that are spread by heterosexual 
and perinatal transmission in developing countries. The ability of coreceptor inhibitors to 
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prevent infection makes them particularly attractive as interventions in high incidence 
settings. Novel approaches could include the use of entry inhibitors as microbicides to 
prevent sexual transmission or as supplements to be added to breast-milk to block 
perinatal infection. Such interventions would however need to be effective, cheap and 
simple to administer. Our data suggest that therapeutic or preventative approaches based 
on coreceptor entry inhibitors could be useful in developing countries where subtype C 
circulates and where such interventions are most desperately needed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
62  
CHAPTER 3 
 
LONGITUDINAL ANALYSIS OF TWO HIV-1 SUBTYPE C ISOLATES 
UNDERGOING A CORECEPTOR SWITCH 
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3.1 Introduction 
 
The use of CCR5 by HIV-1 isolates is normally associated with early transmission and 
the asymptomatic phase of HIV-1 infection, while the use of CXCR4 occurs mostly later 
during the disease stage. The occurrence of a switch from a CCR5-using (R5) to CXCR4-
using (X4) or CXCR4/CCR5 (R5X4) leads to rapid depletion of CD4 cells and 
accelerated disease progression (Karlsson et al., 1994; Koot et al., 1993). Coreceptor 
switching has been shown for subtype B (Scarlatti et al., 1997). In subtype C, the 
occurrence of SI isolates have been demonstrated but there have been no longitudinal 
studies to show a switch in coreceptor use over time (Janse Van Rensburg et al., 2002, 
Cilliers et al., 2003; Johnston et al., 2003; Pollakis et al., 2004). Coreceptor switching 
has been shown to be associated with changes in sensitivity to coreceptor inhibitors or 
their natural ligands (Scarlatti et al., 1997). A switch in coreceptor use will therefore 
render CCR5 coreceptor inhibitors ineffective (Scarlatti et al., 1997). 
 
The ability to use the CXCR4 coreceptor is associated with genetic changes in the V3 
region often including an increase in the overall positive charge (Hoffman et al., 2002a). 
Changes at specific positions 11 and 25 with positively charged amino acids (i.e arginine 
(R), lysine (K) and histidine (H)) determines an X4 or R5/X4 phenotype (Milich, 
Margolin, and Swanstrom, 1993). The length of V1 and V2 regions as well as insertions 
and deletions in V3 has also been implicated in contributing to the X4 or R5X4 
phenotype (Jansson et al., 2001). The higher charge of the V3 loop is more likely to 
interact with a negatively charged CXCR4 (Hoffmann et al., 1999).  
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The aim of this study was to examine coreceptor usage of HIV-1 subtype C isolates from 
an acutely infected cohort. Two individuals were analyzed further as they were shown to 
have undergone a coreceptor switch. The next aim was to establish if these isolates 
became less sensitive to CCR5 coreceptor inhibitors over time and to determine genetic 
changes that allowed the isolates to switch coreceptor use. 
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3.2 Materials and Methods  
3.2.1 HIV viral isolates 
Ten commercial sex workers in Kwa-Zulu Natal participating in a Phase III clinical trial 
of a vaginal microbicide (N9) were followed longitudinally (Table 3.1). The women were 
HIV antibody negative at enrollment and were tested monthly for HIV-1/2 antibodies. 
When the women tested antibody positive they were enrolled and samples were collected 
longitudinally for virus isolation. HIV-1 was isolated from PBMC by co-culturing with 
normal donor PBMC. Viral loads were determined using Chiron bDNA assay (Chiron, 
San Francisco, CA). CD4 counts were determined using a FACS count (Becton 
Dickinson, San Jose, CA) (as described in Chapter 2). Two women who underwent a 
coreceptor switch were studied intensively. Du151 was followed for 20 months and six 
samples were collected including one from pre-seroconversion. Four samples over 33 
months were collected from Du179.  
 
3.2.2 Coreceptor assays 
Viruses were tested for their ability to replicate in U87.CD4 cells transfected with either 
CCR5 or CXCR4 cells as previously described in Chapter 2. Phenotypic assays were 
performed on MT-2 cell lines as described in Chapter 2. 
 
3.2.3 Inhibition assays  
The viral isolates were tested for their sensitivity to entry inhibitors to determine 
preferential coreceptor use. These assays were performed on CD8-depleted PBMC with 
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p24 antigen readout as described for the coreceptor inhibitors as well as for the fusion 
inhibitor T-20 as described in Chapter 2 and Chapter 4. 
 
3.2.4 V3 sequencing 
V3 sequencing was performed as described in Chapter 2 and Chapter 6. 
 
  
 
67  
3.3 Results 
3.3.1 Patient characteristics 
Viral isolates from ten patients with acute HIV infection were characterized (Table 3.1). 
All the isolates were subtype C and all except Du179 used CCR5 (Table 3.1). Six women 
were followed longitudinally: Du123, Du151, Du156, Du179, Du368 and Du422. Of 
these six, two isolates (Du151 and Du179) had either an SI phenotype or underwent a 
phenotypic switch and were investigated more fully. The remaining four individuals 
retained the R5 phenotype for the duration of the study (data not shown).  
 
Du151 was estimated to be infected around September 1998 and the first isolate was 
obtained approximately 1 month and 3 days post infection when no serum antibodies 
were detectable (pre-seroconversion). No CD4 count was available for this sample but 
the viral load was very high consistent with acute infection (Table 3.2). Follow-up 
samples were obtained 2.1, 8.8, 12, 18.6 and 19.9 months post infection. During this time 
the CD4 counts dropped from 367 to 66 cells/ml. Viral levels remained high throughout 
the study (>500 000 copies RNA/ml). This individual developed AIDS and died within 2 
years and was termed a rapid progressor. (Table 3.2). 
 
It was estimated that Du179 was infected from the first of August 1997 and the first 
isolate was obtained 16.1 months. In this study the first isolate studied was obtained 19.8 
months post infection. Follow-up samples were obtained 21.9, 31.2 and 33.8 months post 
infection and viral isolates were generated at these time points. The CD4 count at 19.8 
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months post infection was 435 cells/ml, but declined. The viral load remained low during 
the study period (Table 3.3). 
 
Table 3.1 Viral isolates from a cohort of acutely infected patients 
- indicates no result  
      (Adapted from Williamson et al., 2003) 
 
Table 3.2: Longitudinal isolates of Du151 with clinical and phenotypic data 
N/A not available 
 
 
 
Isolate ID
Estimated months 
after infection CD4 cell count (cells/
ml)
VL RNA 
copies/ml
Viral genotype 
(gag/pol/env) MT-2 Phenotype Biotype
Du123 3.5 841 19,331 C/-/C NSI R5
Du151-Nov 98 2.1 367 >500,000 C/C/C NSI R5
Du156 <1 404 22,122 C/C/C NSI R5
Du172 3.2 793 1,916 C/C/C NSI R5
Du174 14.1 634 9,454 C/C/C NSI R5
Du179-Nov 98 16.1 394 1,359 C/C/C SI R5X4
Du204 6.5 633 8,734 C/C/C NSI R5
Du281 4.7 594 24,689 C/C/C NSI R5
Du368 8.3 670 13,993 C/-/C NSI R5
Du422 2 409 17,118 C/C/C NSI R5
Isolate ID Sample date Estimated months after infection
CD4 cell count 
(cells/ml)
VL RNA 
copies/ml MT-2 Phenotype Biotype
Du151-Oct 98 26-Oct-98 1.1 N/A 579,480 NSI R5
Du151-Nov 98 24-Nov-98 2.1 367 569,300 NSI R5
Du151-Jun 99 15-Jun-99 8.8 239 756,660 NSI R5
Du151-Sep 99 23-Sep-99 12.0 N/A 321,040 NSI R5
Du151-Mar 00 30-Mar-00 18.6 143 >500,000 SI R5X4
Du151-May 00 11-May-00 19.9 66 1,163,800 SI R5X4
  
 
69  
Table 3.3: Longitudinal isolates of Du179 with clinical and phenotypic data 
N/A not available  
 
3.3.2 Coreceptor usage 
Du151 and Du179 isolates were grown in U87.CD4.CCR5 and U87.CD4.CXCR4 to 
determine coreceptor usage. The first four isolates of Du151 were able to replicate 
efficiently in U87.CD4.CCR5 cells but were unable to replicate in cells expressing 
CXCR4. The last two isolates, Du151-Mar 00 and Du151-May 00 were able to replicate 
in cells expressing both CCR5 and CXCR4. This demonstrates that the isolates from the 
last two time points were fully dual tropic. These data correlated with the MT-2 data used 
to determine the phenotype of the isolate. 
Du179 was able to replicate in both CCR5 and CXCR4 cells indicating that the 
virus isolate for the first three time points were dual tropic. The isolate from the last time 
point was only able to replicate in CXCR4 expressing cells demonstrating that it was an 
X4 isolate. 
 
3.3.3 Sensitivity of Du151 and Du179 to entry inhibitors  
Du151 and Du179 isolates were tested against two CCR5 (RANTES and PRO140) and 
two CXCR4 coreceptor inhibitors (AMD3100 and T-140) and the fusion inhibitor T-20 
(Figures 3.1 and 3.2). The first four isolates of Du151 were effectively inhibited 100% at 
Isolate ID Sample date Estimated months after infection
CD4 cell count 
(cells/ml)
VL RNA 
copies/ml MT-2 Phenotype Biotype
Du179-Mar 99 18-Mar-99 19.8 435 4,895 SI R5X4
Du179-May 99 20-May-99 21.9 N/A N/A SI R5X4
Du179-Feb 00 24-Feb-00 31.2 259 3,131 SI R5X4
Du179-May 00 13-May-00 33.8 231 2,228 SI X4
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the highest concentration tested, indicating that CCR5 is the major coreceptor used by 
these isolates. The last two isolates of Du151 were not inhibited by the CCR5 inhibitors, 
indicating that they were using another coreceptor to infect PBMC. The two CXCR4 
inhibitors AMD3100 and T-140 were unable to inhibit any of the R5 isolates and were 
ineffective against Du151-Mar 00 an R5X4 isolate. This might suggest that this isolate 
was able to use both CCR5 and CXCR4 with the same efficiency. However the later 
isolate (Du 151-May 00) preferentially uses CXCR4 (Table 3.4). This data indicates that 
Du151 is initially an R5 isolate but evolves from using CCR5 to a dual tropic isolate and 
to using CXCR4 preferentially on PBMC. 
 
Du179-Mar 99 was not inhibited by either RANTES or PRO140 indicating that it uses 
CXCR4 to infect PBMC. The CXCR4 inhibitors AMD3100 and T-140 were unable to 
inhibit the first two isolates, which may indicate that these isolates were fully dual tropic 
and able to use CCR5 when CXCR4 is blocked. AMD3100 was able to partially inhibit 
the last two isolates. T-140 only partially inhibited the first three isolates but was 
effective at inhibiting the last isolate Du179-May 00 (Table 3.4). This indicates that the 
last two isolates were more prone to using CXCR4 even though it is not fully inhibited by 
the CXCR4 inhibitors. 
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Table 3.4: Inhibition of Du151 and Du179 longitudinal samples. 
% Inhibition higher than 90% is bolded 
 
3.3.4 Inhibition with T-20 
No naturally occurring resistance mutations for T-20 were noted in the HR-1 sequence of 
either Du151 or Du179 (data not shown). Both Du151 and Du179 were sensitive to T-20 
(Figures 3.1 and 3.2). All Du151 isolates were inhibited 100% at 1 mg/ml except the last 
isolate, which was slightly less sensitive at 91% (Table 3.2). Du179 was inhibited more 
than 90% at 1 mg/ml T-20 except the last isolate, which was only inhibited 76% at 1 
mg/ml. Thus it appears if there was a tendency for the later isolates to become slightly 
less sensitive to T-20 (Figure 3.2). 
 
3.3.5 Analysis of V3 sequences 
The six Du151 and four Du179 isolates were sequenced in the V3 region, aligned and 
compared. The V3 region of Du151 had 35 amino acids for all 6 isolates but the overall 
charge decreased from 4.5 to 2.5 (Figure 3.3). The last two isolates Du151-Mar 00 and 
RANTES PRO140 AMD3100 T-140 T-20
150 mg/ml 25 mg/ml 500 nM 2 mg/ml 1 mg/ml
Du151-Oct 98 R5 100 100 9 3 100
Du151-Nov 98 R5 100 100 0 6 100
Du151-Jun 99 R5 99 98 15 51 100
Du151-Sep 99 R5 100 100 1 12 100
Du151-Mar 00 R5X4 41 11 3 0 100
Du151-May 00 R5X4 31 0 91 100 91
Du179-Mar 99 R5X4 29 39 24 13 99
Du179-May 99 R5X4 23 19 32 24 97
Du179-Feb 00 R5X4 4 5 77 46 93
Du179-May 00 X4 0 0 71 95 76
Isolate number Biotype
% Inhibition
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Du151-May 00 had an increased charge of 8.5 and were accompanied by a large number 
of amino acid substitutions in the V3 region (Figure 3.3). These two isolates both had an 
R5X4 biotype. Changes in the crown of V3 changed for the R5 isolates from GPGQ to 
GPGL for the two R5X4 isolates. A positive charge was noted at position 25, which is 
associated with coreceptor switching. 
 
Du179 had fewer changes in the V3 region with most changes occurring for the latter two 
isolates (Du179-Feb 00 and Du179-May 00). A change in charge from 4.5 to 6 for the 
latter isolate in the V3 region was noted which coincided with a change from dual 
tropism (R5X4) to mono-tropism (X4 isolate) in culture as well as on PBMC assays. The 
V3 region consisted of only 34 amino acids and the last isolate Du179-May 00 had only 
32 amino acids. The switch from dual tropism to monotropism (X4) was accompanied by 
a deletion next to position 25, which is normally associated with charge changes. This is 
in contrast to Du151 and other X4 isolates (Chapter 2) which either retain 35 amino acids 
or have insertions to be able to undergo a phenotypic switch. This data indicate that 
charge related changes in the V3 region are required for Du179 to be able to switch from 
a dual tropic isolate to a monotropic (X4) isolate.  
 
3.3.6 Changes in other regions of gp160 
Insertions were noted in the V5 region of Du151-Mar 00 and Du151-May 00. A change 
in the fusion peptide was seen when Du151 switched phenotype from LLGFLG to 
FLGFLG (Mia Coetzer, personal communication). No changes were seen in other regions 
for Du179. 
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Figure 3.1: Inhibition of Du151 by coreceptor and fusion inhibitors. The longitudinal 
isolates become less sensitive to the CCR5 inhibitors as a result of the coreceptor switch.  
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Figure 3.2: Inhibition of Du179 by two CCR5 inhibitors and two CXCR4 inhibitors as 
well as a fusion inhibitor. 
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              1   5   10   15   20    25   30   35  Charge #aa Biotype 
Du151-OCT 98  CTRPNNNTRKSIRIGPGQTFYATGAIIGNIREAHC    4.5    35   R5 
Du151-Nov 98  ------------------------E----------    3.5    35   R5 
Du151-Jun 99  -----------M------S-----E---D--Q---    2.5    35   R5 
Du151-Sep 99  ------------------------E---D--Q---    2.5    35   R5 
Du151-Mar OO  -----S-K-RGV-----LS-F--RK---D--Q---    8.5    35  R5X4 
Du151-May OO  -----S-K-RGV-----LA-F--RK---D--Q---    8.5    35  R5X4 
 
 
Figure 3.3: V3 amino acid sequences of Du151 longitudinal isolates. Positions 11 and 
25, which are associated with a coreceptor switch (highlighted in yellow). The number of 
amino acids (#aa) is indicated and the biotype indicates coreceptor usage. (Amino acid 
abbreviations are shown in Appendix B) (Sequences courtesy of Mia Coetzer) 
 
 
              1   5   10    15  20   25   30  34   Charge  #aa  Biotype 
Du179-Mar 99  CTRPGNNTRKSIRIGPGQAFYTNHIIGDIRQAHC    4.5     34   R5X4 
Du179-May 99  --------------------------------Y-     5      34   R5X4 
Du179-Feb 00  ------K--R------------TNT-------S-     5      34   R5X4 
Du179-May 00  ------K-IR---L---------K..------S-     6      32    X4  
 
Figure 3.4: V3 amino acid sequences of Du179 longitudinal isolates. Positions 11 and 25 
are highlighted in yellow (according to consensus sequence), which are associated with a 
coreceptor switch. The number of amino acids (#aa) is indicated and the biotype indicates 
coreceptor usage. (Sequences courtesy of Mia Coetzer) 
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3.4 Discussion 
Ten HIV-1 subtype C isolates from an acutely infected patient cohort were selected for 
this study. Longitudinal follow-up samples were obtained from 6 patients of whom two 
(Du151 and Du179) had undergone a coreceptor switch or already had an SI phenotype. 
The other four isolates continued using the CCR5 coreceptor. The occurrence of an SI 
phenotype for HIV-1 subtype C is rare with only a few reported cases (Cilliers et al., 
2003; Janse Van Rensburg et al., 2002; Johnston et al., 2003; Pollakis et al., 2004). The 
frequency of CXCR4 using isolates was low (2/10) 20% similar to what we found in our 
previous study described in Chapter 2. Longitudinal follow-up of 2 patients undergoing a 
coreceptor switch gave some clues as to the necessary changes required to engage 
CXCR4.  
 
The first isolate for Du151 was obtained pre-seroconversion and six isolates were 
generated over a period of 20 months. The coreceptor switch for Du151 was 
accompanied by changes in the V3 region with a charge change from 4.5 to 2.5, which 
increased, to 8.5. Changes were also seen in the V1 and V5 loops and in the gp41 region. 
Du151 was shown to be dually infected with two HIV-1 subtype C strains and this may 
be accountable for the coreceptor switch due to recombination (Grobler et al., 2004). 
Coreceptor inhibition data indicated that the change was gradual from an R5 isolate to a 
fully dual tropic isolate and then preferential use of CXCR4 on PBMC. Even though the 
isolate became less sensitive to CCR5 inhibitors, CXCR4 inhibitors were effective at 
inhibiting the last isolate of Du151. The gradual change in coreceptor usage is reflected 
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in the steady decline in CD4 count which was associated with the emergence of X4 
isolates. 
 
The first isolate obtained from Du179 was 19.8 months post infection and already 
possessed the ability to use both CCR5 and CXCR4 in cell lines. It too was shown to be 
dually infected (Grobler et al., 2004). Coreceptor inhibition data suggested that this 
isolate was fully dual tropic from onset and was resistant to both CCR5 and CXCR4 
coreceptor inhibitors for the initial three isolates. Even though V3 loop charges 
resembled R5 isolates it appeared as if they were able to use both CCR5 and CXCR4 
efficiently on PBMC. The later isolate became sensitive to the CXCR4 entry inhibitor 
indicating that it was evolving to use CXCR4 preferentially in PBMC. This switch in 
coreceptor use was accompanied by an increase in charge as well as a two amino acid 
deletion, which rendered the V3 loop only 32 amino acids in length.  
 
This is the first study using longitudinal samples to show a coreceptor switch in subtype 
C. The switch in coreceptor use will benefit the virus in that it provides new targets and 
possible escape from the immune system. This switch in coreceptor use will have 
implications for CCR5 coreceptor inhibitors, as they will become ineffective against 
these isolates. Dual infection has been shown to be responsible for rapid progression to 
AIDS in some patients (Gottlieb et al., 2004). Here we describe two individuals dually 
infected with different strains of HIV-1 subtype C. The one individual progressed rapidly 
to AIDS and the other did not, which may indicate differences in immune systems to 
control the virus.  
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Targeting different regions of the entry process could be used to prevent HIV-1 from 
replicating even if the virus undergoes a coreceptor switch. Most HIV-1 subtype C 
isolates use CCR5 and the occurrence of X4 isolates are very rare. Here we showed two 
isolates that did switch coreceptor usage. More longitudinal follow-up studies are 
required to determine if this phenomenon occur at a higher rate as the epidemic 
progresses. 
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CHAPTER 4 
 
USE OF ALTERNATE CORECEPTORS ON PRIMARY CELLS BY TWO HIV-1 
ISOLATES 
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4.1 Introduction.  
The two most important coreceptors for HIV-1 entry are CCR5 and CXCR4, and all 
HIV-1 isolates tested to date use one or both (Doms, 2000). A few rare isolates can also 
use other coreceptors present on coreceptor-transfected cell- lines, including CCR1, 
CCR2b, CCR3, Bob/GPR15, CXCR6 (STRL33) and CCR8 (Cilliers et al., 2003; Deng et 
al., 1997; Edinger et al., 1998; Pohlmann, Krumbiegel, and Kirchhoff, 1999; Xiao et al., 
1998). Some of these receptors such as CXCR6 and CCR8 have been shown to function 
as HIV entry coreceptors on primary cells in vitro. (Lee et al., 2000; Sharron et al., 2000; 
Zhang et al., 2000; Zhang et al., 2001). Further evidence that some isolates can use 
alternate coreceptors comes from studies where both major coreceptors are either absent 
or blocked. In this regard, the use of PBMC with a 32-base pair deletion in CCR5 
(D32/D32 CCR5) in the presence of a CXCR4 inhibitor has proven particularly useful 
(Azevedo-Pereira et al., 2003; Willey et al., 2003; Zhang et al., 2000). Identification of 
alternative HIV-1 coreceptors is hampered by the lack of suitable ligands although in 
some instances chemokines have been used to provide suggestive evidence (Willey et al., 
2003). Collectively these data demonstrate that some rare isolates can exploit alternate 
coreceptors on primary cells in vitro, although whether such receptors are used by HIV-1 
in vivo remains unclear (Sharron et al., 2000; Willey et al., 2003; Zhang and Moore, 
1999; Zhang et al., 2001).  
 
The ability of some viral isolates to use alternate coreceptors could impact on the efficacy 
of entry inhibitors and possibly also HIV pathogenesis. Hence it is relevant to identify 
and characterize HIV isolates able to use alternate coreceptors on primary cells.  
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Viral macrophage inflammatory protein-1 (vMIP-1), a promiscuous chemokine expressed 
by Human Herpes Virus 8, has been shown to bind to a range of coreceptors, including 
CCR8, GPR1, CXCR6 and to a lesser extent Bob/GPR15 (Dairaghi et al., 1999; Willey et 
al., 2003). This chemokine has been shown to prevent HIV-1 infection of some isolates 
on primary cells when the major coreceptors are absent or blocked. This suggests that 
vMIP-1 might be useful in identifying alternate coreceptors that could be used by HIV-1 
isolates (Willey et al., 2003). The aim of this study was to further investigate how two 
unusual HIV-1 isolates can use alternate coreceptors on primary cells, by using 
chemokines with defined receptor binding profiles.   
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4.2 Materials and Methods  
4.2.1 HIV-1 viral isolates: 
Two previously described isolates, CM4 (99ZACM4) and CM9 (99ZACM9) from a 
cohort of AIDS patients, were selected for further analysis (Bredell et al., 2002; Cilliers 
et al., 2003; Papathanasopoulos et al., 2002; Trkola et al., 2001). CM4 was isolated in 
1999 from a thirty-four year old male in Johannesburg, South Africa who had advanced 
HIV infection and cryptococcal meningitis. This patient had a viral load of 163,755 HIV-
1 RNA copies/ml (by bDNA assay) and CD4 count of 47 cells/ml. CM9 was described in 
Chapter 2 and was isolated in 1999 from a thirty- year old female also with cryptococcal 
meningitis and with a CD4 count of 24 cells/ml. No viral load was available for this 
patient. Viral isolates were generated from both patients as described in Chapter 2. CM4-
P1 was the first isolation reported in a previous publication (Trkola et al., 2001), which 
was later re-expanded using PHA-stimulated PBMC and IL-2 to generate high titre stocks 
for these experiments (CM4-P2). The gp160 encoding regions of both CM4-P1 and 
CM4-P2 were sequenced and shown to be more than 99% identical (Figure 4.1a). CM4 
was reported initially as an env subtype C by HMA (Bredell et al., 2002), but subsequent 
sequence analysis indicated that this virus was a complex recombinant of at least five 
different subtypes with multiple breakpoints in the env region (Papathanasopoulos et al., 
2002). CM9 was subtype C throughout the genome (Papathanasopoulos et al., 2002).  
 
4.2.2 Coreceptor assays on cell lines 
Both viruses were tested for their ability to replicate in U87.CD4 cells transfected with 
either CCR5 or CXCR4 cells as previously described in Chapter 2. In addition, U87.CD4 
cell lines expressing CCR1 and GHOST.3 cell lines expressing Bob/GPR15, CCR1, 
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CCR3 and CXCR6 were used to measure alternate coreceptor usage. These assays were 
performed as described in Chapter 2. 
 
4.2.3 D32/D32 CCR5 PBMC cell preparation 
Blood was drawn from individuals identified with the D32/D32 CCR5 mutation and 
PBMC isolated and stimulated with PHA and IL-2 as previously described in Chapter 2 
and (Willey et al., 2003). AMD3100 (1 mM) was used to inhibit entry via CXCR4. 
CM4 titrations experiments were performed using D32/D32 CCR5 PBMC 
stimulated with PHA and used at 1 X105 cells/well. CM4 was titred from 1000, 800, 600, 
400, 200, 100, 50 and 10 TCID50 and added to the cells. The experiments were 
performed in 96 well round bottom plates and cells were washed 24 hours after infection. 
The levels of p24 antigen production were measured as described in Chapter 2. The same 
protocol was followed for the normal donor PBMC assays. 
 
4.2.4 Entry inhibitor assays  
Entry inhibitor assays were performed using PHA-stimulated PBMC from wt/wt (wild-
type/wild-type) CCR5 and D32/D32 CCR5 donor cells. Cells were incubated with the 
specific inhibitor for 1 hour before adding 1,000 TCID50 (50% tissue culture infectious 
dose per ml of virus). Assays were performed on 96 well plates using RPMI 1640, 10% 
fetal calf serum and IL-2 as previously described in Chapter 2 (Willey et al., 2003). 
Inhibitors tested included the anti-CCR5 Mab PRO140 (Progenics Pharmaceuticals, New 
York), chemokines RANTES (PeproTech Inc., Rocky Hill, N.J), I309, eotaxin, vMIP-I 
(all from R&D Systems, Inc) and AMD3100 (AnorMED Inc., Langley, Canada). Viral 
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replication was measured by p24 antigen production or reverse transcriptase (RT) activity 
using an RT-enzyme-linked immunosorbent assay (CavidiTech, Uppsala, Sweden). T-20 
(American Peptide Company and Hoffmann-La Roche, Palo Alto, Ca) experiments were 
performed as described in Chapter 5. 
 
4.2.5 RNA extraction and amplification of the gp160 region 
HIV-1 viral RNA was extracted from 200 µl of culture supernatant from different cell 
lines using the MagNA Pure LC Total Nucleic Acid Isolation Kit and automated MagNA 
Pure LC Instrument (Roche Diagnostics GmbH, Mannheim, Germany). A reverse 
transcription step was performed and the cDNA was used to amplify the gp160 region 
with primers as previously described (Gao et al., 1996). PCR products were purified 
using the High Pure PCR Product Purification kit (Roche Diagnostics GmbH, Mannheim, 
Germany). Sequencing reactions were performed in a MicroAmp 96 well optical reaction 
plate using the ABI PRISM Big dye Terminator v3.0 Cycle Sequencing kit and ABI 
PRISM 3100 automated sequencer. Sequence analysis was performed using the 
Sequencher version 4.0 software (Gene Codes Corporation). The Clustal X program was 
used for alignments. 
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4.3 Results 
4.3.1 Coreceptor usage of CM4 and CM9 
Two HIV-1 isolates from patients with cryptococcal meningitis, a severe AIDS defining 
condition, were selected for this study. CM9 is an HIV-1 subtype C isolate able to use 
CCR5, CXCR4, CCR3, CXCR6 and Bob/GPR15 to replicate in transfected cell lines as 
described in Chapter 2 (Table 4.1). While the efficiency with which CM9 used the three 
minor coreceptors was considerably lower than for the two major coreceptors (i.e. CCR5 
and CXCR4), their usage was highly reproducible. CM4, a complex recombinant virus 
with subtype C-like envelope was able to use both CCR5 and Bob/GPR15 with equal 
efficiency on transfected cell lines (Table 4.1). This isolate was unable to use CXCR4, as 
judged by its inability to replicate in U87.CD4.CXCR4 or MT-2 cells. It was also unable 
to use CCR3, CXCR6 or CCR1. CCR1 was included as a negative control for both CM4 
and CM9 (Table 4.1). 
 
Both CM4 and CM9 were able to replicate in D32/D32 CCR5 PBMC efficiently although 
CM4 replicated to higher levels (84 ng/ml versus 10 ng/ml p24 in one representative 
experiment) (see also Figures 4.2 and 4.3). The growth seen for CM9 in D32/D32 CCR5 
PBMC is most likely related to the ability of this isolate to use CXCR4 (Figure 4.2). 
Since CM4 is unable to use CXCR4, growth in D32/D32 CCR5 PBMC must be due to an 
alternate coreceptor. Whether CM4 is using Bob/GPR15 to enter PBMC cannot be 
assessed at present, as no inhibitor or natural ligand to block this coreceptor is available. 
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Table 4.1: Growth of CM4 and CM9 on coreceptor transfected cell lines 
 
4.3.2 Use of CCR5 and CXCR4 inhibitors to determine coreceptor use 
To further define coreceptor specificity of CM9 and CM4, specific inhibitors were used. 
The CCR5 inhibitors included PRO140 and RANTES. AMD3100 was used to block 
CXCR4. The assays were performed on wt/wt CCR5 PHA-stimulated PBMC with a p24 
antigen read-out on day 6. CM4 was not inhibited by either PRO140 or RANTES at the 
same concentrations that were active against other HIV-1 isolates (Table 4.2) (Chapter 2), 
(Trkola et al., 2001). This isolate was also insensitive to AMD3100, consistent with its 
inability to use CXCR4. Hence, neither CCR5 nor CXCR4 inhibitors were effective 
against CM4. In contrast, CM9 was sensitive to AMD3100 (97% inhibition on day 6, 
Table 4.2). However, like CM4, CM9 was insensitive to the CCR5 inhibitors. Thus the 
major coreceptor of preference for this pleiotropic isolate is CXCR4 (Chapter 2). 
We next tested the ability of CM4 and CM9 to be inhibited by the fusion inhibitor 
T-20, which is not coreceptor-specific. Both isolates were fully sensitive to T-20 and 
were inhibited by >99% at 1 µg/ml (Table 4.2). This demonstrates that use of an alternate 
coreceptor does not radically alter the envelope-mediated fusion process. 
 
 
 
Isolate
CCR5 CXCR4 CCR1 Bob/GPR15 CCR1 CCR3 CXCR6
CM4 70 <1 <1 65 <1 <1 <1
CM9 69 48 <1 3 <1 3 8.5
Coreceptor usage (Day12 p24 ng/ml)
GHOST.3U87.CD4
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Table 4.2: Inhibition data on normal donor (wt/wt) CCR5 PBMC 
 
4.3.3 Env sequence analysis of CM4 and CM9 grown in different cell lines.   
To determine if minor quasispecies were accounting for multiple coreceptor use, CM4 
and CM9 were grown in different cell lines. The env genes were then sequenced and 
compared to those of the original infecting strain. CM4-P2 was grown in normal donor 
PBMC, D32/D32 CCR5 PBMC, and GHOST.3 cells expressing Bob/GPR15. The amino 
acid sequences of the expanded viruses were then compared to the original infecting 
stock (CM4-P1). All gp160 sequences from CM4-P2 grown in different cells were 
identical and had only 1 amino acid change in V3 region (T300N) compared to the earlier 
stock (CM4-P1) (Figure 4.1a). Hence, the major viral population of CM4 uses both 
CCR5 and Bob/GPR15 as coreceptors on transfected cell lines as well as on D32/D32 
CCR5 PBMC, suggesting that the same envelope glycoprotein configuration can use both 
CCR5 and Bob/GPR15. CM4 had a low overall charge of +3 in the V3 loop, which is 
more consistent with usage of CCR5 than of CXCR4 (Hoffman et al., 2002a). 
 
Isolate
CM4
CM9
% Inhibition
167 nM 19 nM 500 nM  1 µg/ml
PRO140                    RANTES                       AMD3100                       T-20                     
33 24 4 99
36 34 97 100
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Figure 4.1a: Full- length envelope amino acid sequence alignment of CM4 grown in 
different cell lines and PBMC. The original culture supernatant is labelled CM4-P1. The 
regrown strain is labelled CM4-P2. CM4-P2 grown in PBMC (CM4-PBMC), D32/D32 
CCR5 PBMC (CM4-D32) and GHOST.3.Bob cell line (CM4-Bob) is shown. The 
variable loops are highlighted in grey and amino acid changes shown. Dots indicate 
identical amino acids. (Sequences provided by Dr Maria Papathanasopoulos and Trudy 
Patience) 
 
A similar analysis was done using CM9 grown in cell lines expressing CCR5, 
CXCR4, CCR3, CXCR6 and Bob/GPR15, with the resulting sequences then compared to 
the original isolate grown in wt/wt PBMC. Distinct amino acid sequences changes in 
gp160 were noted between the selected populations, particularly in the V1/V2 and V3 
regions of gp120, and in the cytoplasmic tail of gp41 (Figure 4.1b). Viruses that grew in 
the CXCR6/Bonzo and CCR3 cell lines were virtually identical in sequence, and most 
similar to the viruses that grew in the CCR5 transfected cells. The sequence of the virus 
gp120 
                    *        20         *        40         *        60         *        80         *       100         *       120       
CM4-P1   : MRVRGIQRNWQQCWKWGTLILGLVIICSASDNLWVTVYYGVPVWKEAKTTLFCASDAKAYVKEEHNIWATHACVPTDPNPQEIYMENVTENFNMWKNNMVEQMHEDVISLWDQSLKPCVK : 120 
CM4-P2   : ........................................................................................................................ : 120  
CM4-PBMC : ........................................................................................................................ : 120  
CM4-D32  : ........................................................................................................................ : 120  
CM4-Bob  : ........................................................................................................................ : 120  
                                                                                                                                          
                      V1           V2                                                      
                    *       140         *       160         *       180         *       200         *       220         *       240       
CM4-P1   : LTPLCVILNCSNVNVTSNGNTSSIKEAGEIKNCSFNATTEIRNKRKKVYALFYKLDIVPLKDNSNDNSSYILINCNTSAITQACPKVTFEPIPIHYCAPAGYAILKCNNKTFNGTGPCNN : 240 
CM4-P2   : ........................................................................................................................ : 240 
CM4-PBMC : ................................. ....................................................................................... : 240 
CM4-D32  : ........................................................................................................................ : 240 
CM4-Bob  : ........................................................................................................................ : 240 
                                                                                                                                          
                                                                  V3                                                                     
                    *       260         *       280         *       300         *       320         *       340         *       360       
CM4-P1   : VSTVQCTHGIKPVVSTQLLLNGSLAEGEIIIRSENLTDNTKTIIVHLNQSVNIT CIRPTNNTRQSIRFGPGQVFFGTDVIGDIRQAHCNISKADWNKTLQGVSKKLIELFPNKKIEFKPS : 360  
CM4-P2   : ........................................Q............. ....N............................................................. : 360 
CM4-PBMC : ...................................................... ....N............................................................. : 360  
CM4-D32  : ..........................................................N............................................................. : 360  
CM4-Bob  : ...................................................... ....N............................................................. : 360  
                                                                                                                                          
                                V4          V5                    
                    *       380         *       400         *       420         *       440         *       460         *       480       
CM4-P1   : SGGDVEITTHSFNCGGEFFFCNTSGLFNSTWGKNDTNRTIGTGTNENITLPCRIKQIVNMWQRVGQAIYAPPIQGIIRCESNITGILLTRDGGNNNSSNNNNDTEIFRPG GGDMRDNWRS : 480 
CM4-P2   : .............................................................................................................. .......... : 480 
CM4-PBMC : .............................................................................................................. .......... : 480 
CM4-D32  : ............................................................................... ............................... .......... : 480 
CM4-Bob  : .............................................................................................................. .......... : 480 
                                                                                                                                          
                                         gp41                                                      
                    *       500         *       520         *       540         *       560         *       580         *       600       
CM4-P1   : ELYKYKVVQIEPLGVAPTKAKRRVVEREKRAIGFGAMFLGFLGAAGSTMGAASVTLTVQARQLLSGIVQQQNNLLRAIEAQQHMLKLTVWGIKQLQARVLAVEKYLKDQQLLGIWGCSGK : 600  
CM4-P2   : ........................................................................................................................ : 600  
CM4-PBMC : ........................................................................................................................ : 600  
CM4-D32  : ........................................................................................................................ : 600  
CM4-Bob  : ........................................................................................................................ : 600  
                                                                                                                                          
                    *       620         *       640         *       660         *       680         *       700         *       720       
CM4-P1   : LICTTTVPWNSSWSNKSLDYIWNNMTWAQWEREIDNYTDLIYNLIEESNNQQEINEKELLELDKWAGLWTWFDITNWLWYIRIFIMIVGGLIGLRIIFAVLSIINRVRQGYSPLSFQTLT : 720  
CM4-P2   : ........................................................................................................................ : 720 
CM4-PBMC : ........................................................................................................................ : 720  
CM4-D32  : ........................................................................................................................ : 720  
CM4-Bob  : ........................................................................................................................ : 720  
                                                                                                                                          
                    *       740         *       760         *       780         *       800         *       820         *       840       
CM4-P1   : HHQRESPDRPGRIEEGDGEQDRDRSIRLVSGFLALAWDDLRSLCLFSYHRLRDSILIVARILELLGHRGWEILKYLWSLLQYWSQELKNSAINLFNTLAIAVAEGTDRIIEAILRICRAI : 840  
CM4-P2   : ........................................................................................................................ : 840  
CM4-PBMC : ........................................................................................................................ : 840  
CM4-D32  : ........................................................................................................................ : 840  
CM4-Bob  : ........................................................................................................................ : 840  
                    *             
CM4-P1   : RNIPTRIRQGLEAALL : 856 
CM4-P2   : ................ : 856 
CM4-PBMC : ................ : 856 
CM4-D32  : ................ : 856 
CM4-Bob  : ................ : 856 
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grown in CXCR4-expressing cells was identical to the original PBMC sequence and most 
similar to the virus that grew out of the Bob/GPR15 cells. Three changes were noted in 
the V3 crown region between these two populations. The viruses expanded on the 
CXCR4 or Bob/GPR15 cells had a GPRY motif while those grown in CCR5, 
CXCR6/Bonzo or CCR3 expressing cells had a GPGY sequence. There was no  
difference in the overall charge (+6) or number of amino acids in the V3 region of the 
different selected populations, so no prediction about coreceptor usage could be made 
from the genotype. An insertion in the cytoplasmic tail of the gp41 region was noted for 
almost all viruses grown in coreceptor-transfected cells except for those grown in 
CXCR4 transfected cells (Figure 4.1b). This suggests that the original CM9 isolate 
comprised at least 2 distinct populations, one that uses CCR5, CXCR6 and CCR3 and a 
second that uses CXCR4 and Bob/GPR15. This mixed population may account for the 
usage of at least 2 different coreceptors by this isolate. 
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Figure 4.1b: Full length envelope amino acid sequence of CM9 grown in different cell 
lines and PBMC (CM9-PBMC). CM9 was grown in U87.CD4.CXCR4 (CM9-X4), 
GHOST.3 transfected with Bob/GPR15 (CM9-Bob), U87.CD4.CCR5 (CM9-R5) and 
GHOST.3.CXCR6 (CM9-CXCR6) and CCR3 (CM9-R3) respectively. The variable 
loops are highlighted in grey and amino acid changes shown. Dots indicate identical 
amino acids and dashes indicate amino acid insertions. (Sequences provided by Dr Maria 
Papthanasopoulos and Trudy Patience) 
 
4.3.4 Inhibition assays on D32/D32 CCR5 PBMC 
We next explored the ability of chemokines that act as natural ligands for alternate 
coreceptors to inhibit CM4 and CM9 replication in D32/D32 CCR5 PBMC. The 
chemokine vMIP-1 is a promiscuous chemokine secreted by Human Herpes Virus 8 that 
binds to CCR8, GPR1, Bob/GPR15 and CXCR6 (Dairaghi et al., 1999; Simmons et al., 
2000; Willey et al., 2003). Eotaxin is the ligand for CCR3, and I309 is specific for CCR8. 
CM9 was grown in D32/D32 CCR5 PBMC in the presence of vMIP-1, I309 and eotaxin 
gp120                      V1     
                    *        20         *        40         *        60         *        80         *       100         *       120         *       
CM9-PBMC : MRVREILRNYQQWWIWSILGFWMICNVVGNLWVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMHLENVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLECTN : 130 
CM9-X4   : .................................................................................................................................. : 130 
CM9-Bob  : .................................................................................................................................. : 130 
CM9-R5   : ..............................................................................................................................K.G. : 130 
CM9-CXCR6: ..............................................................................................................................K.G. : 130 
CM9-R3   : ..............................................................................................................................K.G. : 130 
                                                                                                                                                 
       V2                                                                                                          
                    140         *       160         *       180         *       200         *       220         *       240         *       260     
CM9-PBMC : ATFN-STTHNNATYNDTIAGEMKNCSFNVTTELRDRKKKEYALFYRLD IVPLGGNSSKGNASKYRLINCNSSTITQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVST : 259  
CM9-X4   : ....-................................................................ ............................................................. : 259  
CM9-Bob  : ....-................................................................ ............................................................. : 259  
CM9-R5   : ....N...Y.S................KT........................................ ............................................................. : 260 
CM9-CXCR6: ....N...Y.S................KT........................................ ............................................................. : 260  
CM9-R3   : ....N...Y.S................KT........................................ ............................................................. : 260  
                                                                                                                                                 
                     V3             V4   
                      *       280         *       300         *       320         *       340         *       360         *       380         *     
CM9-PBMC : QLLLNGSLAEEEIIIRSENLTDNVKTIIVHLNESVPIV CARPGNNTIKRIRIGPRYAFYAKETIIGDIRQAHCNISEEKWNKTLQQVGKKLKEHFPNKTITFAPHSGGDLEIITHSFNCRGEFFYCNTSK : 389 
CM9-X4   : ...................................... ............................................................................................ : 389 
CM9-Bob  : ...................................... ............................................................................................ : 389 
CM9-R5   : ...................................... ........R.......G.......A............................G....................T................. : 390 
CM9-CXCR6: ...................................... ........R.......G.......A............................G...................................... : 390 
CM9-R3   : ...................................... ........R.......G.......A............................G...................................... : 390 
                                                                                                                                                 
                          V5        gp41   
                    400         *       420         *       440         *       460         *       480         *       500         *       520     
CM9-PBMC : LFNRPNGTESNSNQTTESNSNRTITLQC RIRQIINMWQEVGQAMYAPPIKGNITCTSNITGLLLTRDGG EKNTTNEKEIFRPGGGDMRDNWRSELYKYKVVEIKPLGIAPTGAKRRVVEREKRAVGLLGA : 519  
CM9-X4   : ............ ......................................................... ............................................................. : 519  
CM9-Bob  : ............................ ......................................... ................................................... .......... : 519 
CM9-R5   : ............................ ......................................... ............................................................. : 520  
CM9-CXCR6: ............................ ......................................... ............................................................. : 520  
CM9-R3   : ............................ ......................................... .......T..................................................... : 520  
                                                                                                                                                 
                                                                                                                                                 
                      *       540         *       560         *       580         *       600         *       620         *       640         *     
CM9-PBMC : VFLGFLGAAGSTMGAASIALTVQTRQLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLSIERYLRDQQLLGLWGCSGKRICTTAVPWNSSWSNRSKEEIWDNMTWMQWDREISNYTDIIYNLLE : 649 
CM9-X4   : .................................................................................................................................. : 649  
CM9-Bob  : .......................................................................................................D.......................... : 649  
CM9-R5   : .................................................................................................................................. : 650  
CM9-CXCR6: .................................................................................................................................. : 650  
CM9-R3   : .................................................................................................................................. : 650  
                                                                                                                                                 
                                                                                                                                                 
                   660         *       680         *       700         *       720         *       740         *       760         *       780      
CM9-PBMC : ESQNQQEENEKELLELDSWKNLWSWFDITQWLWYIKIFIMIIGGLIGLRIIFAVLSIVNRVRQGYSPLSFQTLIPTSRGPPDRLERIEEEGGEQDKDRSVRLVSGFLPLIWDDLRSLCLFSYHRLRDFIL : 779  
CM9-X4   : .................................................................................................................................. : 779  
CM9-Bob  : ...........D...................................................................................................................... : 779  
CM9-R5   : ...........D...................................................................................................................... : 780 
CM9-CXCR6: .................................................................................................................................. : 780  
CM9-R3   : ...........D...................................................................................................................... : 780  
                                                                                                                                                 
                                                                                                      
                     *       800         *       820         *       840         *       860              
CM9-PBMC : IVVRAVELLGRR -------GWEILKYLGSLVQYWGLELKRSAISLLDTIAIAVAEGTDRIIEFIQRLGRAIYHIPRRIRQGFEVALQ : 859 
CM9-X4   : ............ -------.................................................................... : 859 
CM9-Bob  : ............RLRGLQR...T....................I.....T.......H....S.H...........I...C...P.. : 866 
CM9-R5   : ............RLRGLQR........................I.............H....S.............I.......P.. : 867 
CM9-CXCR6: ...........SSLRGLQR.................................................................... : 867 
CM9-R3   : ...........SSLRGLQR.................................................................... : 867 
  
 
91  
either singly or in combination with AMD3100. It was previously shown that CM9 could 
be inhibited by AMD3100 for up to 6 days on normal donor PBMC, consistent with its 
efficient use of CXCR4 for entry (Chapter 2). However, in this study we found that CM9 
was eventually able to replicate in the presence of AMD3100 on D32/D32 CCR5 PBMC 
when the assay was extended beyond 6 days (Figure 4.2A). When AMD3100 was 
combined with eotaxin, the natural ligand for CCR3, there was enhanced viral 
replication. vMIP-1 and I309 had no effect on CM9 replication when tested individually 
(Figure 4.2A) but when they were combined with AMD3100 inhibition was complete 
(Figure 4.2B). Since both I309 and vMIP-1 can bind to CCR8, CM9 may be using CCR8 
to infect D32/D32 CCR5 PBMC in the presence of AMD3100. 
CM4 was tested in D32/D32 CCR5 PBMC in the absence and presence of 
AMD3100, vMIP-1, I309 and CXCL16 (Figure 4.3). CXCL16 is the natural ligand for 
CXCR6. None of these inhibitors had any effect on CM4 replication except vMIP-1, 
which caused a delay. Hence, CM4 is using a coreceptor other than CCR5, CXCR4, 
CCR8 or CXCR6 to productively infect PBMC. Its identity is still unclear, but it may be 
a vMIP-1 receptor. 
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Figure 4.2: Inhibition of CM9 in D32/D32 CCR5 PBMC. (A) Growth curve of CM9 in 
the presence of AMD3100, vMIP-1, I309, eotaxin or without inhibitors. (B) CM9 in the 
presence of AMD3100 alone or in combinations with vMIP-1, I309 or eotaxin or no 
inhibitors. (Samantha Willey and Mathew Sullivan in Dr Paul Clapham’s laboratory 
performed these experiments) 
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Figure 4.3: Growth curve of CM4 in D32/D32 CCR5 PBMC in the presence of 
AMD3100, vMIP1, I309, CXCL16 or without inhibitors. (Samantha Willey and Mathew 
Sullivan in Dr Paul Clapham’s laboratory performed these experiments). 
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Figure 4.4: Titration of CM4-P2 performed on D32/D32 CCR5 PBMC and normal donor 
PBMC. CM4 was diluted starting at 1000 TCID50 down to 10 TCID50 and the levels of 
p24 were measured using an in-house p24 assay. The top figure was performed in 
D32/D32 CCR5 PBMC and the bottom experiment was performed on normal donor 
PBMC (wt/wt). 
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4.3.5 Titration of CM4 on D32/D32 CCR5 and normal donor PBMC 
Titration experiments were performed in order to establish how well CM4 infects PBMC 
with or without CCR5 and to determine the levels of infection in the absence of CCR5. 
CM4-P2 was diluted using different TCID50 concentrations starting at 1000, 800, 600, 
400, 200, 100, 50 and 10 and was grown in D32/D32 CCR5 PBMC and normal donor 
PBMC. The ability of the virus to grow in the PBMC was measured using an in-house 
p24 antigen assay and were measured on days 4, 8 and 12. CM4 was able to replicate 
very efficiently in the D32/D32 CCR5 PBMC up to 200 TCID50 and was unable to infect 
PBMC at a lower concentration (Figure 4.4). CM4-P2 was able to infect normal donor 
PBMC at 10 TCID50 albeit at low levels. This suggests that CM4-P2 requires 200 TCID50 
or higher to be able to use an alternate coreceptor. This may explain why CM4-P1, which 
had a very low titre, was unable to infect PBMC deficient of CCR5. 
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4.4 Discussion 
The identification of HIV-1 isolates able to use coreceptors other than CCR5 and CXCR4 
on primary cells is rare (Lee et al., 2000; Willey et al., 2003; Zhang et al., 2000). While 
the significance of alternate coreceptor usage is uncertain, the possibility that HIV-1 can 
expand its cellular host range through the use of alternate coreceptors remains a 
theoretical possibility. Here we report on how two isolates, CM4 and CM9, can use 
alternate coreceptors to infect primary cells. Inhibition data suggests that CCR8 and an as 
yet unknown coreceptor can mediate HIV-1 entry for these two isolates respectively. 
Such isolates would be expected to be refractory to inhibition by agents directed at CCR5 
and CXCR4.   
 
CM4, an R5 isolate able to utilize Bob/GPR15, on transfected cell lines was isolated from 
a patient with advanced HIV disease. Its insensitivity to both CCR5 and CXCR4 
inhibitors suggested that it could use an alternate coreceptor to infect PBMC. This 
receptor is apparently also present on D32/D32 CCR5 PBMC and can support high levels 
of replication. Whether CM4 is able to use Bob/GPR15 on primary cells remains to be 
determined. Bob/GPR15 is an orphan G-protein coupled receptor whose mRNA is widely 
expressed in the colon, spleen, PHA stimulated PBMC, purified T-cells and to a lesser 
extent in unstimulated PBMC (Deng et al., 1997). Until a natural ligand to Bob/GPR15 is 
identified it will remain difficult to prove that CM4 is using this receptor to enter primary 
cells. In a previous study a different batch of CM4 (CM4-P1) was inhibited by RANTES, 
PRO140 and TAK779 suggesting that entry was CCR5-dependent (Trkola et al., 2001). 
For the experiments reported here, CM4 had been expanded in PHA-stimulated PBMC to 
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generate a high titre stock (CM4-P2). The entry of this virus preparation was found to be 
independent of CCR5, as reflected by its ability to grow in D32/D32 CCR5 PBMC. 
Experiments directly comparing the properties of the original (CM4-P1) and expanded 
viral stock (CM4-P2) confirmed these findings (data not shown). The envelope sequences 
of CM4-P1 and CM4-P2 showed they were more than 99% identical (Figure 4.1a). It is 
unlikely that the single amino acid change T300N between CM4-P1 and CM-4P2 is 
responsible for the altered coreceptor phenotype. It is more likely that the ability of CM4-
P2 to grow in D32/D32 CCR5 PBMC is related to the viral titre, with the ability to use 
alternate coreceptors only being revealed when the viral titre is high (Figure 4.3). 
Nevertheless we cannot formally rule out that the ability of CM4 to replicate in D32/D32 
CCR5 PBMC, presumably by alternate coreceptor-use, was acquired or selected for 
during in vitro passage. 
 
CM9 was also isolated from a patient with advanced HIV infection and it too is a 
pleiotropic isolate that has a preference for CXCR4-usage (Chapter 2). Other studies have 
shown that CXCR4 is the coreceptor of preference for most dual- or pleiotropic isolates 
(Yi et al., 1999). CM9 was previously shown to use alternate coreceptors, CCR3, CXCR6 
and Bob/GPR15 albeit less efficiently than CXCR4 (Cilliers et al., 2003). In this study 
we show that in addition to using these five coreceptors, CM9 can also use CCR8. This 
was confirmed using NP2.CD4.CCR8 transfected cells, which supported CM9 replication 
(data not shown). However, the use of CCR8 appears to be less efficient than CXCR4. 
Thus during the first 6 days, replication in PBMC was fully inhibited by AMD3100, 
suggesting a dominant role of CXCR4. However, replication at later time points was 
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inhibited by both vMIP-1 and I309, a CCR8-specific inhibitor, in the presence of 
AMD3100. Thus it appears that growth in the presence of AMD3100 after 6 days is due 
to the ability of this isolate to use CCR8. This later use of CCR8 may be related to 
expression levels of this receptor on PBMC, which may vary in culture, or the utilization 
of CCR8 by different populations in the CM9 stock, or less efficient usage of CCR8 
compared to CXCR4. CCR8 is expressed at high level in the thymus and has the ability 
to facilitate HIV-1 entry into thymocytes (Lee et al., 2000). This receptor has been 
reported to be used by a handful of simian immunodeficiency virus (SIV), HIV-1 and 
HIV-2 isolates and is one of the more commonly used alternate coreceptors (Horuk et al., 
1998; Rucker et al., 1997). However, most of the above studies were performed only on 
cell lines, raising questions as to the significance of the findings for understanding 
replication in primary cells. Our finding that CM9 uses CCR8 on primary cells suggests 
that CCR8 may indeed prove to be a significant HIV-1 coreceptor for some isolates, a 
factor that may need to be taken into consideration in clinical studies of CCR5 and 
CXCR4 inhibitors. Chemokines that target CCR8, such as I309 may need to be 
considered for drug development.   
 
Analysis of envelope sequences from viruses grown in PBMC and cell lines revealed that 
the same viral population of CM4 was able to use CCR5, Bob/GPR15 and a coreceptor 
on CCR5 deficient PBMC. In contrast, distinct viral populations may account for some of 
the promiscuous coreceptor activity of CM9. Two distinct viral populations could be 
discerned in gp160 from CM9. The population able to use CCR5, CXCR6 or CCR3 had 
three amino acid changes in the V3 region and 4 amino acid changes in V2 compared to 
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the population able to utilize CXCR4 or Bob/GPR15. However the population able to 
utilize Bob/GPR15 also had an insertion in the gp41 similar to that found in the CCR5, 
CXCR6 and CCR3 using virus. This suggests that the Bob/GPR15 utilizing envelope is 
distinct from all the other populations; it even may be a recombinant between different 
populations. Further studies on this virus may provide clues as to the genetic 
determinants of both major and alternate coreceptor usage. However the CCR8-using 
virus is likely to be a subpopulation different than the one that uses CXCR4, as the usage 
of the latter coreceptor was effectively inhibited up to day 6 in a PBMC culture. Hence, 
the sequence analysis performed on CM9 grown in the different cell lines may not used 
to conclusively indicate which viral population accounts for use of the CCR8 receptor on 
D32/D32 CCR5 PBMC. 
 
Whether it is significant that both the CM4 and the CM9 isolates were derived from 
patients with cryptococcal meningitis still remains unclear. Cryptococcal meningitis is a 
severe AIDS condition that arises after the immune system has deteriorated and it is 
associated with high levels of viral replication in blood and cerebrospinal fluid (Morris et 
al., 1998). It is possible that when CD4 target cells are limited HIV-1 isolates exploit 
other receptors to maintain high levels of replication. Alternatively, cryptococcal 
meningitis could up-regulate other chemokine receptors or allow access of HIV-1 to other 
cell populations, such as in the central nervous system that may promote use of alternate 
coreceptors. This data may also point to the need for the use of a combination of entry 
inhibitors that target different stages in the entry cycle, such as the CD4-binding site or 
the fusion process. T-20 was able to efficiently inhibit both CM4 and CM9 strains 
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suggesting that it is not influenced by alternate coreceptor usage. Thus T-20 may be a 
useful adjunct to coreceptor inhibitors (Tremblay et al., 2000, Tremblay et al., 2002). 
Collectively these data suggest that alternate coreceptors need to be considered when 
developing entry inhibitors and that such isolates pose a potential threat to the clinical use 
of inhibitors targeting only CCR5 and CXCR4. 
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CHAPTER 5 
 
SENSITIVITY OF HIV-1 SUBTYPE C ISOLATES TO THE ENTRY INHIBITOR 
T-20 
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5.1 Introduction 
T-20 is the first in a new class of anti-retroviral drugs termed entry inhibitors licensed for 
use in humans and is known by the name T-20 or Fuzeon. In Phase III human clinical 
trials this drug has been shown to be effective for patients in deep salvage therapy 
including those with viruses resistant to reverse transcriptase and protease inhibitors 
(Lalezari et al., 2003b). Coreceptor interactions have also been reported to play a role in 
T-20 efficiency with CCR5-using isolates requiring higher concentrations of T-20 to 
inhibit replication compared to CXCR4-using viruses. (Derdeyn et al., 2000; Derdeyn et 
al., 2001; Reeves et al., 2002). Resistance to T-20 is associated with changes in the HR-1 
region, particularly the GIV motif (Hanna et al., 2002; Kilby et al., 2002; Villahermosa et 
al., 2003; Wei et al., 2002). This motif is highly conserved among HIV-1 isolates, which 
has led to the assumption that all subtypes are naturally susceptible to T-20 (Hanna et al., 
2002; Villahermosa et al., 2003; Xu et al., 2002). However, there have been almost no 
comprehensive phenotypic assessments of the sensitivities of non-B subtypes to T-20 to 
validate this assumption.  
 
Subtype C viruses show significant genetic differences from subtype B in the HR-2 
region used to design T-20, with 12 of the 36 amino acids in the consensus C sequence 
being different (Hanna et al., 2002). In addition subtype C viruses show differences in 
coreceptor preference with reported but infrequent use of CXCR4 (Cilliers et al., 2003; 
Janse Van Rensburg et al., 2002; Johnston et al., 2003). We therefore aimed to determine 
whether T-20 would be effective in vitro against subtype C viruses able to use both 
  
 
103  
CCR5 and/or CXCR4 as well as viruses from patients with resistance to other anti-
retroviral drugs.  
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5.2 Materials and methods  
5.2.1 Viral isolates 
The primary isolates used in the study were derived from South African patients infected 
with HIV-1 subtype C viruses. This included 4 isolates from acutely infected sex workers 
(Williamson et al., 2003), 11 isolates from adult patients with AIDS (Chapter 2) and 3 
isolates from pediatric AIDS patients (Appendix A). In addition viruses were isolated 
from 5 patients failing anti-retroviral therapies. These were DR10 (currently or 
previously treated with d4T, 3TC, EFV, AZT, ddI); DR19 (AZT, ddI, EFV); DR28 
(AZT, 3TC, EFV, ddI, d4T); DR62 (3TC, d4T) and DR100 (d4T, 3TC, RTV). Clinical 
data for these isolates are described in Appendix A. Sequence analysis revealed the 
presence of drug resistance mutations in the pol gene (see list of mutations at bottom of 
Table 5.2). Primary virus stocks were generated as described in Chapter 2. Of these 23 
subtype C isolates, 15 used the CCR5 coreceptor, 3 used CXCR4 and 5 used both CCR5 
and CXCR4 (Chapter 2 and Chapter 3). Six HIV-1 subtype B R5 isolates from acutely 
infected South African patients were included for comparison.   
 
5.2.2 Nucleic acid amplification and sequencing 
Full- length gp160 was amplified from viral RNA in a nested RT-PCR using the first 
round outer primers env A and env N and second round inner primers env B and env M as 
described previously (Gao et al., 1996). Primers specific for the gp41 region were used to 
sequence the PCR products in both directions. The sequencing reactions were 
electrophoresed and analyzed on an ABI3100 sequencer (Applied Biosystems, CA). 
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Sequence data was edited and assembled and neighbor-joining trees were constructed 
from the nucleotide sequences as described previously (Papathanasopoulos et al., 2002).   
 
5.2.3 T-20 phenotypic sensitivity assays 
Experiments were performed using peripheral blood mononuclear cells (PBMC) with a 
p24 antigen read-out. Five-fold dilutions of T-20 (American Peptide Company, Inc, 
Sunnyvale, California) were pre- incubated with each virus (1,000 TCID50) in 100 ml 
RPMI 1640 plus 10% FCS and IL-2 for 1 hr. Following this, 105 CD8-depleted activated 
PBMC (Chapter 2) in 100 ml was added to give a final concentration of 1, 0.2, 0.04 and 
0.008 mg/ml T-20. Levels of p24 antigen in supernatants were measured on days 4, 6, 8 
and 10 by chemiluminescence ELISA as described (Trkola et al., 2001) (Chapter 2). 
Experiments were done in duplicate and repeated twice with different batches of PBMC. 
Data are shown as the percentage inhibition by T-20 relative to viral cultures without T-
20 (virus control). The mean 50% inhibitory concentration (IC50) and IC90 values were 
calculated for each virus.  
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5.3 Results 
We investigated the amino acid similarity between T-20 and the corresponding region in 
the gp41 sequences of the isolates used in this study. Phylogenetic analysis of the gp41 
gene confirmed the subtype designation of all subtype C and B isolates used in this study 
(Figure 5.1). Analysis of the predicted amino acid sequences of the T-20 region in HR-2 
showed that between 10 and 16 of the 36 amino acids were different (Table 5.1). These 
changes were present for almost all subtype C isolates at certain positions in the HR-2 
region. The median number of changes for the South African subtype C viruses was 12 
(33%) which is the same as the consensus subtype C. Collectively more than half the loci 
(19 of 36) could tolerate variation. However 17 loci were 100% conserved suggesting 
functionally relevant domains in this region. The 6 South African subtype B sequences 
showed the lowest level of variation, with only 2 to 6 amino acid differences (6-17% 
difference) as expected, given that T-20 is derived from a sub type B isolate. These data 
are shown graphically in Figure 5.2  
 
This high level of genetic diversity prompted us to investigate the efficacy of T-20 to 
inhibit HIV-1 subtype C virus replication in vitro. Table 5.2 shows that all 23 subtype C 
isolates were inhibited >90% at 1 mg/ml T-20. The IC50 values ranged from 0.008-0.324 
mg/ml with 7 isolates having IC50 values at the lowest concentration tested (0.008 mg/ml). 
Of these, 4 used CXCR4 and 3 used CCR5. There were, however, no significant 
differences in IC50 or IC90 values between the CCR5 and CXCR4-using viruses (Figure 
5.3 A and B). There were no apparent differences in the sensitivity of viruses from adult  
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Figure 5.1: Phylogenetic analysis of gp41 sequences of isolates used in this study. All 23 
subtype C isolates clustered significantly with C references and the two subtype B 
isolates clustered with the subtype B references. 
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Table 5.1: Amino acid sequences in the HR-2 region of gp41 subtype C isolates aligned to T-20 
 
T-20 sequence Y T S L I H S L I E E S Q N Q Q E K N E Q E L L E L D K W A S L W N W F # aa changes
Consensus C sequence  .  . G T  . Y R  . L  . D  .  .  .  .  .  .  .  .  . K D  .  . A  .  . S  . N N  .  .  .  .  . 12 (33%)
Subtype C-acute
Du123a  .  . G T  . Y K  . L  .  .  .  .  .  .  .  .  .  .  . K D  .  . A  .  . S  . K N  .  . S  .  . 12 (33%)
Du151a  .  . G T  . Y R  . L  . D  .  .  .  .  .  .  .  .  . K D  .  . A  .  . S  . K N  .  .  .  .  . 12 (33%)
Du174 F  . D I  . Y N  . L  . V  .  .  .  .  .  . E  .  . K D  .  . A  . N  .  . Q N  .  . G  .  . 15 (42%)
Du422a  .  . N T  . F R  . L  . D  .  .  .  .  .  .  .  .  . K D  .  . A  .  . S  . K N  .  .  .  .  . 12 (33%)
Subtype C-AIDS
PCP1  .  . G E  . Y R  . L  .  .  .  .  .  .  .  .  .  .  . K D  .  . A  .  . S  . N N  .  .  .  .  . 11 (31%)
SW5  .  . N T  . Y R  . L  .  .  .  . T  .  .  . N  .  . K D  .  . A  .  . S  . K N  .  .  .  .  . 13 (36%)
SW26  . S N T  . Y K  . L  . D  .  . I  .  .  . Q  .  . K D  .  . A  .  . S  . K N  .  . S  .  . 16 (44%)
SW29  .  . N I  . Y R  . L  . D  .  .  .  .  .  . N  .  . K D  .  . A  .  .  .  . N N  .  .  .  .  . 12 (33%)
SW38  .  . D T  . Y R  . L  .  .  .  . T  .  .  .  .  .  . K D  .  . A  .  .  .  . N N  .  .  .  .  . 11 (31%)
CM1  .  . D T  . Y R  . L  . A  .  .  .  .  .  .  .  .  .  . D  .  . A  .  .  .  . N N  .  .  .  .  . 10 (28%)
CM7  .  . N T  . Y R  . L  . E  .  . T  .  .  .  .   .  . K D  .  . A  .  . S  . K N  .  .  .  .  . 13 (36%)
CM9  .  . D I  . Y N  . L  .  .  .  .  .  .  .  . E  .  . K  .  .  .  .  .  . S  . K N  .  . S  .  . 11 (31%)
SW20  .  . N T  . Y R  . L  . D  .  .  .  .  .  .  .  .  . K D  .  . A  .  .  .  . N N  .  .  .  .  . 11 (31%)
SW30  .  . E T  . Y R  . L  .  .  .  .  .  .  .  . R  .  .  . D  .  . A  .  . S  . N N  .  . S  .  . 12 (33%)
SW7  .  . D T  . Y R  . L  . V  .  .  .  .  .  .  .  .  . K D  .  . A  .  .  .  . N  .  .  . S  .  . 12 (33%)
Subtype C-pediatric AIDS
RP1  .  . E T  . Y R  . L  . D  .  .  .  .  .  . Q  .  . K D  .  . A  .  . R  . N N  .  . S  .  . 14 (39%)
TM1b  .  . N T  . Y R  . L  . D  .  . S  .  .  . E  .  . K D  .  . A  .  . S  . N S  .  .  .  .  . 14 (39%)
TM9  .  . N T  . Y R  . L  .  .  .  .  .  .  .  . D  .  . K D  .  . A  .  . S  . K N  .  .  .  .  . 12 (33%)
Subtype C-drug resistant
DR10  .  . D T  . Y R  . L  .  .  .  . T  .  .  .  .  .  . K D  .  .  .  .  .  .  . D  .  .  .  .  .  . 10 (28%)
DR19  .  . G  .  . Y N  . L  . V  .  .  .  .  .  . Q  .  . K D  .  . A  . N N  . Q  .  .  .  .  .  . 13 (36%)
DR28  .  . D E  . Y R M L  . D  .  . I  .  .  .  .  .  . K D  .  . A  .  . R  . N N  .  .  .  .  . 14 (39%)
DR62  .  . G I  . Y Q  . L  .  .  .  . I  .  .  . Q  .  . K D  .  . A  .  .  .  . Q N  .  . S  .  . 13 (36%)
DR100  .  . D I  . Y T  . L  . D  .  . S  .  .  .  .  .  .  . D  .  . A  .  .  .  . N  .  .  .  .  .  . 10 (28%)
Subtype B-acute
SM1  .  . G  .  . Y  .  . L  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 3 (8%)
SM2  .  . G V  . Y N  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . N  .  . T  .  . 6 (17%)
DS3  .  .  .  .  . Y  .  .  .  .  .  .  .  .  .  .  . H  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 2 (6%)
DS8  .  . K E  . Y K  .  .  . I  .  .  .  .  .  .  .  .  . L  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 6 (17%)
DS9  .  . G  .  . Y T  . L  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 4 (11%)
DS12  .  . G I  . Y  .  .  . Q  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 4 (11%)
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Figure 5.2: Variation in the HR-2 region of HIV-1 subtype C and B compared to T-20. 
The mean percentage amino acid changes at a certain position containing the total 
number of isolates with a change at that position. This was compared to the T-20 peptide 
in the HR-2 region comparing subtype C with subtype B isolates. 
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Table 5.2: Inhibition of HIV-1 subtype C viruses by T-20 and analysis of baseline resistance patterns 
 
Biotype Day
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
1 mg/ml 200 ng/ml IC90 IC50 A R Q L L S G I V Q Q Q S N L L R
Subtype C-acute
Du123a R5 8 100 98 0.088 0.010 . . . . . . . . . . . . . . . . .
Du151a R5 8 100 100 0.078 0.014 . . . . . . . . . . . . . . . . .
Du174 R5 6 100 100 0.073 0.014 . . . . . . . . . . . . . . . . .
Du422a R5 8 100 93 0.207 0.035 . . . . . . . . . . . . . . . . .
Subtype C-AIDS
PCP1 R5, CXCR6 6 93 87 0.294 0.017 . . . . . . . . . . . . . . . . .
SW5 R5 8 100 100 0.132 0.009 . . . . . . . . . . . . . . . . .
SW26 R5 6 98 98 0.073 0.008 . . . . . . . . . . . . . . . . .
SW29 R5 6 99 90 0.312 0.046 . . . . . . . . . . . . N . . . .
SW38 R5 6 100 100 0.173 0.063 . . . . . . . . . . . . . . . . K
CM1 R5 6 98 94 0.191 0.090 . . . . . . . . . . . . . . . . .
CM7 R5 6 92 90 0.249 0.123  .  .  .  .  .  .  .  .  .  .  .  . N  .  .  .  .
CM9 R5X4, CXCR6, Bob, R3 6 100 93 0.260 0.059 T . . . . . . . . . . . . . . . .
SW20 R5X4 8 96 96 0.093 0.008 . . . . . . . . . . . . . . . . .
SW30 R5X4 6 100 94 0.093 0.008 . . L . . . . . . . . . . . . . .
SW7 X4 4 98 92 0.468 0.031 . . . . . . . V . . . . . . . . .
Subtype C-pediatric AIDS
RP1 R5X4 6 90 53 0.910 0.276 . . . . . . . . . . . . . . . . .
TM1b R5X4 6 100 100 0.073 0.008  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
TM9 X4 8 99 95 0.008 0.008 . . . . . . . . . . . . . . . . .
Subtype C-drug resistant**
DR10 R5 10 100 89 0.378 0.094 . . . . . . . . . . . . N . . . .
DR19 R5 10 99 99 0.027 0.008  . . . . . . . . . . . .  . . . . .
DR28 X4 6 100 89 0.399 0.070 T . . . . . . . . . . .  . . . . .
DR62 R5 10 100 100 0.022 0.008  . . . . . . . . . . . .  . . . . .
DR100 R5 10 99 57 0.559 0.324  .  .  .  .  .  .  .  .  .  .  .  . N  .  .  .  .
Subtype B-acute
SM1 R5 6 93 62 0.966 0.079 . . L . . . . . . . . . N . . . .
SM2 R5 6 93 69 0.952 0.150 . . L . . . . . . . . . N . . . .
DS3 R5 6 95 70 0.766 0.156  .  .  .  .  .  .  .  .  .  .  .  . N  .  .  . M
DS8 R5X4 6 100 100 0.148 0.026  .  .  .  .  .  .  .  .  .  .  .  . N  .  .  .  .
DS9 R5 6 98 62 0.481 0.252  .  . L  .  .  .  .  .  .  .  .  . N  .  .  .  .
DS12 R5X4 6 84 31 >1 0.430  .  .  .  .  .  .  .  .  .  .  .  . N  .  .  .  .
* Inhibition >90% is bolded and inhibition <90% is in italics
T-20 at*: 
**Isolates have the following resistance mutations in reverse transcriptase: DR10 (M41L, D67N, T69D, M184I, Y188L, G190A, L210W, T215Y); DR19 (D67N, T69_SS, V106M, G190A, L210W, T215Y); DR28 (K103N, 
M184V, T215Y, M230L); DR62 (D67N, K70R, M184V, K219Q); DR100 (M184V, G333E). Protease mutations found in DR100 (M46I, I54V, V82A) 
Region associated with T-20 resistanceVirus T-20 (mg/ml)
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and pediatric patients collected at different stages of disease progression (Figure 5.3A 
and B). Inhibition was not affected by the presence of drug resistance mutations in the pol 
gene, as all 5 isolates from patients failing anti-retroviral therapies were fully sensitive to 
T-20 (Figure 5.3C).  
 
The mean IC90 for subtype C was 0.2243 mg/ml compared to 0.7188 mg/ml for subtype B.  
The IC50 for subtype C was 0.0578 mg/ml and 0.1822 mg/ml (Figure 5.4). The differences 
in IC90 and IC50 values between subtype C and B isolates were analyzed and found to be 
not significant according to the Wilcoxon signed rank test (Figure 5.4), although there 
were fewer subtype B isolates compared to subtype C isolates. The 2 viruses that used 
alternate coreceptors (PCP1 and CM9) were also effectively inhibited by T-20. The 6 
subtype B isolates had the highest IC90 values ranging from (0.148 to >1 mg/ml) 
compared to the subtype C isolates (range 0.008-0.910 mg/ml). Thus despite the 33% 
difference in the consensus sequences of HR-2 between subtypes B and C, T-20 appears 
to be highly effective against both subtypes. 
 
Genetic changes spanning amino acids 36-45 of HR-1 have been shown to confer 
resistance to T-20 (Kilby et al., 2002; Poveda et al., 2002; Rimsky, Shugars, and 
Matthews, 1998; Wei et al., 2002). The most important mutations are G36D/S and 
V38M/A (bolded in Table 5.2) but changes at position 37, 39, 40, 42 and 43 have also 
been found in patients failing T-20 therapy (Kilby et al., 2002; Poveda et al., 2002). 
Analysis of this region among the isolates used in this study showed no evidence for  
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(A) 
(B) 
(C) 
 
Figure 5.3: Sensitivity of HIV-1 subtype C isolates to T-20. The graphs show percentage 
inhibition plotted against the concentration of T-20 in µg/ml. The IC90 and IC50’s are 
shown with a dotted line. (A) AIDS R5 viruses are compared to (B) AIDS X4 and R5X4 
isolates. Isolates resistant to reverse transcriptase and protease inhibitors are shown to be 
fully sensitive to T-20 (C). 
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mutations associated with T-20 resistance except for 1 isolate (SW7) that had the I37V 
mutation (Table 5.2). This mutation was previously seen among patients failing T-20 
(Roman et al., 2003; Wei et al., 2002) but in the case of SW7 this is likely to be a 
naturally occurring polymorphism as this isolate was fully sensitive to T-20. Other 
polymorphisms in this region also had little to no impact. 
 
 
Figure 5.4: Comparison of IC90 and IC50 values between subtype C and B isolates. 
Differences between HIV-1 subtypes B and C were found to be not significant 
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5.4 Discussion 
These data show that HIV-1 subtype C isolates are highly sensitive to T-20 in vitro and 
do not harbour naturally occurring polymorphisms that might confer resistance to T-20. 
This includes isolates from patients failing other anti- retroviral therapies who had 
resistance mutations in the pol gene. All isolates were sensitive at 1 mg/ml, which is the 
physiological concentration at which T-20 is effective (Kilby et al., 1998). This suggests 
that T-20 would be highly effective in HIV-1 subtype C infected patients including those 
failing other anti-retroviral regimens.   
 
Sequence analysis revealed that the HR-1 region was considerably more conserved than 
HR-2, which also showed a high degree of variation between subtypes. While the precise 
interaction between HR-1 and HR-2 and the mechanism whereby T-20 inhibits the 
formation of the 6-helical bundle remains unclear, these interactions can nevertheless 
accommodate significant genetic changes. This may favour the broad applicability of T-
20 as an antiviral agent as it is likely to function against very diverse HIV strains. 
However, there does appear to be a limit to the degree of variation as T-20 is not effective 
against HIV-2 isolates, which shows 22 amino acid differences in the T-20 region (Wild 
et al., 1994). The large amount of variation may also facilitate multiple pathways to 
developing T-20 resistance including changes at distal sites, as has been seen among 
some patients failing therapy. This includes changes in HR-2 as well as other regions of 
envelope (Derdeyn et al., 2000; Derdeyn et al., 2001; Reeves et al., 2002). The 
conservation of the GIV motif in the majority of HIV-1 isolates suggests that T-20 binds 
to the same region in HR-1 of all HIV-1 subtypes.    
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There is some debate regarding the efficacy of T-20 against isolates using different 
coreceptors with some studies showing that CCR5-using isolates were more resistant to 
T-20 (Derdeyn et al., 2000; Derdeyn et al., 2001; Reeves et al., 2002). However other 
studies have shown no differences in sensitivity based on coreceptor usage (Greenberg et 
al., 2001). While some of the CXCR4-using viruses in this study were more sensitive to 
T-20 compared to R5 isolates there was no significant differences between these two  
groups. The IC50 values for our subtype C isolates appeared to be lower than published 
IC50 values for subtype B isolates (Derdeyn et al., 2000; Derdeyn et al., 2001; Reeves et 
al., 2002; Wild et al., 1994). However the majority of these studies used cell lines or 
fusion assays and in some cases cloned envelopes and is therefore not directly 
comparable to ours, which used primary PBMC and primary viruses. Further comparative 
studies with larger numbers of subtype B isolates are needed to determine whether 
subtype C isolates are indeed more sensitive to T-20. 
 
HIV-1 subtype C is the most rapidly expanding viral subtype worldwide and it is 
therefore important to ensure that new agents function effectively against these viruses. 
Our data suggest that therapeutic or preventative agents based on T-20 would be effective 
in countries where subtype C predominates. While T-20 is unlikely to be widely used in 
developing countries because of the complexities of administration and cost, its 
development may have particular significance for such countries where the burden of 
infection resides and where new strategies are needed. Given that entry inhibitors block 
viral infection at the cell surface, they may serve as potent preventative agents for use as 
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microbicides or to prevent mother-to-child transmission. Thus further studies on the 
sensitivities of subtype C isolates to new entry inhibitors, particularly those with different 
phenotypic and genotypic properties are warranted.  
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CHAPTER 6 
 
IN VITRO GENERATION OF HIV-1 SUBTYPE C ISOLATES RESISTANT TO 
T-20 
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6.1 Introduction 
Treatment of HIV-1 infection has focused mostly on antiretroviral therapies targeting the 
two major viral enzymes, reverse transcriptase and protease. While these therapies have 
proven highly effective in the treatment of HIV infection they have shown limitations due 
to intolerability and resis tance (Carpenter et al., 2000; Bucher, Young, and Battegay, 
2004). T-20 represents a new treatment option for patients and is the first entry inhibitor 
to have received Food and Drug Administration approval (Kilby et al., 1998; Lalezari et 
al., 2003b).  T-20 has shown efficacy in human trials and proven to be safe and well 
tolerated in treatment-experienced patients (Lalezari et al., 2003a; Kilby et al., 2002). . 
 
T-20 is a peptide consisting of 36 amino acids that mimics a corresponding area in the 
second heptad repeat region (HR-2) in the gp41 envelope glycoprotein of an HIV-1 
subtype B isolate (Wild et al., 1994). The T-20 peptide binds to the first heptad repeat 
region (HR-1), thereby preventing the binding of HR-1 to HR-2 and fusion of the host 
and virus cell membranes (Wild et al., 1994; Chan et al., 1997). Genetic analyses of 
published sequences in Genbank have shown very little variation in the HR-1 region. 
This led to the assumption that T-20 will be effective against most genetic subtypes 
(Hanna et al., 2002; Villahermosa et al., 2003; Xu et al., 2002), which was confirmed for 
subtype C isolates (Cilliers et al., 2004). The high level of genetic variation seen in HR-2, 
the region from which T-20 was derived, among different genetic subtypes appears not to 
compromise the efficacy of T-20, most likely due to the low variation in the HR-1 region 
to which T-20 binds (Hanna et al., 2002). 
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Both in vitro and in vivo studies have shown that resistance to T-20 is associated with 
changes in the GIV motif at positions 36-38 in the HR-1 region (Kilby et al., 2002; Wei 
et al., 2002) particularly with changes at G36D/S and V38M/A (Lalezari et al., 2003b; 
Rimsky, Shugars, and Matthews, 1998). Less frequent resistance mutations include 
G36E, G36V, I37T and to a lesser extent I37V (Rimsky, Shugars, and Matthews, 1998; 
Roman et al., 2003; Lu et al., 2004). Resistance-associated amino acid substitutions 
outside this region have also been reported including Q39H, Q40H, N/S42T and N43D 
(Roman et al., 2003; Sista et al., 2004). Changes in the HR-2 region (Q110Q/E, E119E/Q 
and R122R/K) have been described in a patient participating in a clinical study (Poveda 
et al., 2002). Regions in gp120 have also been implicated in influencing sensitivity to T-
20 with changes found in some X4 viruses exposed to T-20 (Reeves et al., 2002; Reeves 
et al., 2004). 
 
Although resistance to T-20 among subtype B HIV-1 isolates has been well 
characterized, there is at present little information about T-20 resistance among non-B 
viruses. It is known that T-20 is effective against subtype C viruses, and that background 
genotypic resistance to T-20 is low (Chapter 5). The majority of new infections 
worldwide are now caused by subtype C viruses, therefore alternative treatment options 
and characterization of resistance to novel drugs among these viruses is of importance. 
This study therefore aimed to investigate resistance to T-20 among isolates of HIV-1 
subtype C.   
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6.2 Materials and Methods  
6.2.1 Generating T-20 resistant isolates 
Eleven HIV-1 subtype C isolates, previously shown to be sensitive to T-20 (Chapter 5), 
were cultured in the presence of increasing concentrations of T-20 to select for resistant 
viruses. Peripheral blood mononuclear cells (PBMC) were CD8 depleted using 
RosetteSep CD8 depletion cocktail (StemCell Technologies, Vancouver, Canada) (as 
described in Chapter 2) and plated at a concentration of 2x106 cells/ml in 24 well plates. 
The cultures were maintained in RPMI 1640 containing glutamine, 10% fetal calf serum 
(FCS) and IL-2 (Chapter 2, Chapter 5). Virus was added at 1000 TCID50 and incubated 
for an hour before the addition of 0.005 mg/ml T-20. Cultures were monitored for viral 
replication every second day using a p24 antigen assay as previously described (Cilliers 
et al., 2003; Trkola et al., 2001). Cultures with low (<1 ng/ml) p24 antigen were re-fed 
using the same concentration of T-20. Cultures with more than 1 ng/ml p24 antigen were 
cultured with an increased concentration of T-20. Once cultures reached more than 50 
ng/ml p24 antigen they were maintained with between 5 and 10 mg/ml T-20. The cultures 
were fed weekly with fresh CD8 depleted PHA stimulated donor PBMC. Two sets of 
resistance experiments were performed, the first (S1) used T-20 obtained from American 
Peptide Company, Inc, Sunnyvale, California and the second experiment was performed 
with T-20 obtained from Roche, Palo Alto. The second experiment (S2) was set up using 
day 29 culture supernatants from S1 starting with 5 µg/ml of T-20, increased later to 10 
mg/ml. This was to eliminate any virus that might be sensitive to T-20 and to obtain pure 
cultures of T-20 resistant viruses. Once isolates grew in a concentration of 10 mg/ml they 
were considered to be resistant to T-20. 
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6.2.2 Phenotypic sensitivity assay 
The level of phenotypic resistance to T-20 was determined using PBMC with a p24 
antigen read-out. Resistant viruses (S2 day 29, 1000 TCID50) were incubated with five-
fold dilutions of T-20, starting at 25 µg/ml, for 1 hour before the addition of 105 
cells/well CD8 depleted PBMC in 96 well plates. The levels of p24 antigen were 
determined on days 4, 6, 8 and 10. IC90 and IC50 values were determined as previously 
described (Chapter 2, Chapter 5) (Trkola et al., 2001). 
 
6.2.3 Sequencing of gp41   
RNA was extracted from 200 ml of culture supernatant using the MagNA Pure LC 
Isolation station (Roche Applied Science, Penzberg, Germany) and the Total Nucleic  
Acid isolation kit (Roche Applied Science) as described by the manufacturer. The nucleic 
acid was resuspended in a final volume of 50 ml. Reverse transcription was performed 
using Expand High Fidelity Reverse Transcriptase (Roche Applied Science). The 
reaction was primed using the gp41RO primer (5’-GGCAAGTGCTAAGAATCCGT-3’). 
Amplification was performed using the Expand High Fidelity PCR system (Roche 
Applied Science) in a nested PCR. First round amplification was performed using 
gp41FO (5’-GCCAGTGGTATCAACTCAAC-3’) and gp41RO. Amplification was 
performed as follows: 94°C for 5 min, 25 cycles of 94°C for 30 secs, 55°C for 30 secs 
and 72°C for 1 min. Primers used for the second round reaction were gp41FI (5’-
GAAGGACAACTGGAGAAGTG-3’) and gp41RI (5’-GCTCTCCACCTTCTTCTTCG-
3’). Cycling conditions were identical to those used in the first round. Amplified samples 
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were electrophoresed on a 1% agarose gel and yielded a product of approximately 700 
bp. PCR product was purified using the High Pure PCR purification system (Roche 
Applied Science). Sequencing was performed in both directions with the ABI Big Dye 
terminator system, as described by the manufacturer, using gp41FI and gp41RI. 
Sequences were joined using the Sequencher 4.1.4 program (GeneCodes, Ann Arbor, 
MI). Multiple alignments were performed using Clustal X. Phylogenetic analysis of 
parental, S1 and S2 nucleic acid sequences was performed with Mega version 2.1. A 
neighbor-joining tree was constructed with distances calculated using Kimura's two-
parameter method. Bootstrap values are the result of 1000 resamplings and are given as 
percentages. 
 
6.2.4 Sequencing of V3 
The V3 region was amplified using primers BF (5'-TAACACAAGCCTGTCCAAAGG-
3') and BR (5'-AATTCTAGGTCCCCTCCTGA-3'). RNA was reverse transcribed with 
AMV Reverse Transcriptase (Roche Molecular Biochemicals) and amplified with Super-
Therm Polymerase (Southern Cross Biotechnologies); the PCR product was cleaned with 
a High Pure PCR Product Purification kit (Roche Applied Science). Sequencing was 
performed in both directions with the BF and BR primers as described in Chapter 3. 
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6.3 Results 
6.3.1 Generation of T-20 resistant isolates 
Eleven HIV-1 subtype C isolates, previously shown to be sensitive to T-20 (Cilliers et al., 
2004), were included in this study. Eight isolates were from adult patients with advanced 
HIV disease (Cilliers et al., 2003), two were from acutely infected adult patients 
(Du151a, Du422a) (Williamson et al., 2003) and one was from a pediatric patient with 
rapid disease progression (RP1). Seven isolates were R5, two were R5X4 and two were 
X4 viruses. Two isolates were able to utilize minor coreceptors: CM9 (CXCR6, CCR3, 
Bob) and PCP1 (CXCR6) (Chapter 2). One of the X4 isolates from a drug-treated patient 
(DR28) had existing reverse transcriptase drug resistance mutations K103N, M184V, 
T215Y and M230L (Chapter 5). All other isolates were from drug naïve patients. The 
subtype B isolates consisted of three R5 and one R5X4 virus from patients with acute 
infection (SM1 and SM2) and patients with AIDS (DS3 and DS12). 
 
Isolates were grown in the presence of increasing concentrations of T-20 (from 0.005 
mg/ml up to 10 mg/ml) and virus growth was monitored using a p24 antigen assay for 36 
days (S1). Most isolates showed only low-level replication during the first 2 weeks of 
culture when T-20 concentrations ranged from 0.05 to 1 mg/ml, but by day 18 all isolates 
replicated at varying but detectable levels. Two isolates (Du422a and SW38) showed 
higher levels of replication producing more than 100 ng/ml p24 antigen within 11-15 
days at 1 mg/ml T-20. By day 29 viral replication for all isolates at 10 mg/ml was high 
(>25 ng/ml p24 antigen), stable and unaffected by the addition of fresh T-20. Virus 
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populations from day 29 cultures (S1) were sequenced to determine the resistance 
profiles in gp41. 
 
In order to enrich for T-20 resistant virus the S1 day 29 cultures were used to infect a 
fresh batch of PBMC at a starting concentration of 5 mg/ml T-20 (S2). These cultures 
were continuously cultured in the presence of 10 mg/ml T-20 from day 4 onwards until 
day 29. Three isolates (SW38, SW7 and RP1) were able to grow from outset of culture 
although most isolates had a lag phase before virus replication was noted. However, by 
day 29 all isolates replicated to high levels (>25 ng/ml p24 antigen) in 10 mg/ml of T-20. 
These viruses were sequenced on day 29 (S2) to determine if new resistance mutations 
had developed and how these compared to the subtype B isolates and previously reported 
mutations. 
 
6.3.2 Changes in HR-1 associated with T-20 resistance 
The gp41 region of virus cultures from T-20 naïve parental viruses, S1 and S2 was 
sequenced and the HR-1 region analysed to determine if genotypic resistance to T-20 
developed. Parental viruses were all genotypically sensitive to T-20 and, with the 
exception of SW7 (GVV), all had the GIV motif (Chapter 5). The cultures from the first 
passage (S1) had changes mostly in the GIV motif with more changes at position 36 
(7/11) followed by position 38 (3/11) (Table 6.1). Some changes were also noted outside 
the GIV motif at positions 42, 43, 45 and 50 in the HR-1 region. No resistance mutations 
were noted for the subtype B isolates in S1 even though they were able to replicate in the 
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presence of 10 mg/ml T-20. Further analysis on day 36 revealed resistance mutations not 
evident at day 29 (data not shown). 
 
Cultures in S1 contained mixed populations with both T-20 sensitive and resistant viruses 
present at day 29 (as observed in sequencing chromatograms and indicated in Table 6.1). 
To obtain pure resistant cultures a second experiment (S2) was set up using 5 mg/ml T-20 
to exclude T-20 sensitive viruses. The cultures were sequenced in the gp41 region on day 
29. Sequence data confirmed that viruses genotypically resistant to T-20 were present 
largely as pure populations in S2 cultures. Phylogenetic analysis of parental, S1 and S2 
sequences was performed to eliminate the possibility of contamination during virus 
culture. All sequences from the same isolate clustered together with high bootstrap 
support, and consensus sequences supported subtype designations of isolates (Figure 6.1). 
Mutations were noted in the GIV motif of 9/11 subtype C isolates and 3/4 subtype B 
isolates (Table 6.2). Some isolates also had mutations outside the GIV motif at positions 
S42D (SW29), N43K/S (Du422a, RP1, DS12), L45R (SW5), R46M (DS3) and A50T/V 
(Du151a, CM7 and RP1). For three viruses (Du422a, RP1 and DS12) high–level 
resistance was conferred by mutations in these regions as all had wild-type GIV 
sequences at S2. In some cases, resistant virus in S2 contained the major resistance 
mutations observed for that virus in S1 eg. SW29. However, interestingly, in some cases 
the predominant resistant population observed in S1 was not the same population present 
in S2, with new mutations emerging (eg. CM9). This observation reflects the dynamic 
nature of T-20 resistance mutations reported in vivo (Baldwin et al., 2004) and may be 
due to differences in fitness (presumably determined by virus entry) in a system where T-
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20 concentrations are increased gradually as in S1, as opposed to S2 where virus was 
exposed to immediate and high (5 mg/ml) levels of T-20. Most of the resistance mutations 
observed occurred at the same positions as previously reported for subtype B isolates, 
further demonstrating the importance of the GIV motif in resistance to T-20. 
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Table 6.1: Changes in the HR-1 region of subtype B and C isolates exposed to increasing concentrations of T-20 for 29 days (S1). 
Biotype
SubtypeC
Consensus G I V Q Q Q S N L L R A I E A Q Q
Du151a R5 . . . . . . . . . . . . . . A/T . .
Du422a R5 G/D . M/V . . . . . . . . . . . . . .
SW5 R5 . . . . . . . . . L/R . . . . . . .
CM7 R5 . . . . . . N . . L/M . . . . A/T . .
SW29 R5 G/S . . . . . N/D . . . . . . . . . .
SW38 R5 G/S/D . . . . . . . . . K . . . T . H
PCP1 R5/X6 G/E . . . . . . . . . . . . . . . .
RP1 R5/X4 G/D . . . . . . N/K . . . . . . A/V . .
CM9 R5/X4/X6/R3/Bob G/D . V/M . . . . . . . . . . . . . .
SW7 X4 . V V/A . . . . . . L/M . . . . . . .
DR28 X4 G/S/D . . . . . . . . . . . . . . . .
Subtype B
Consensus G I V Q Q Q N N L L R A I E A Q Q
SM1 R5 . . . . . . . . . . . . . . . . .
SM2 R5 . . . . . . . . . . . . . . . . .
DS3 R5 . . . . . . . . . . . . . . . . .
DS12 R5/X4 . . . . . . . . . . . . . . . . .
HR-1 amino acid sequences
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6.3.3 Changes in the HR-2 region  
The HR-2 region of resistant subtype C and B isolates was sequenced and analyzed to 
investigate compensatory changes, which may arise as a result of T-20 exposure. These 
changes, compared with parental and S1 viruses, were noted only for the second 
experiment (S2). Four of the 11 subtype C viruses had changes in the HR-2 region with 
one isolate containing three changes in the region corresponding to the T-20 peptide: 
SW38 had D129N, D148E and K152S mutations, Du123 a D137E mutation, CM9 an 
E151K mutation and RP1 a K147Q mutation (Table 6.3). Changes in the HR-2 were also 
noted for three of the four subtype B isolates. SM1 had a G129N mutation, SM2 a V130F 
mutation and DS12 a G129D mutation. 
 
6.3.4 Analysis of V3 amino acid sequences 
The V3 region of X4 viruses has previously been noted to undergo changes when T-20 
interacts with the gp120 region (Yuan et al., 2004). V3 sequencing was therefore 
performed on all resistant isolates to determine if changes in the V3 region might arise 
from exposure to T-20. Two of the 11 subtype C isolates had changes in the V3 region: 
Du151a had a Threonine (T) to Isoleucine (I) change at position 2 and SW38 had a 
Lysine (K) to Glutamine (Q) at position 32 (Table 6.3). These changes were close to the 
stem of the V3 region, which has been implicated in T-20-related changes within gp120 
(Yuan et al., 2004). For SW38 this change resulted in a decreased charge in the V3 loop 
from +4 to +3. 
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6.3.5 Determination of T-20 IC90 and IC50 for resistant isolates. 
The IC90 and IC50 values were determined for the T-20 resistant isolates (S2 day 29) to 
establish if there was any correlation between the degree of phenotypic resistance and the 
type or number of resistance mutations. The IC50 values had a wide range from 9.52 
µg/ml to more than 25 µg/ml, equivalent to a 7 to 234-fold increase in resistance to T-20 
compared with T-20-naïve parental viruses (data not shown). The IC90 values ranged 
from 14.1 µg/ml to more than 25 µg/ml. Three isolates had IC50 values higher than 25 
µg/ml T-20: SW7 (V38A), PCP1 (G36E and V38A) and RP1 (N43K and A50V). The 
subtype B T-20 resistant isolates had an IC50 between 17.12 µg/ml and 22.31 µg/ml, 
equivalent to an 8 to 30-fold increase in resistance to T-20 compared with parental 
viruses (data not shown). One subtype B isolate (DS3) did not replicate sufficiently to 
obtain an IC50 value. No clear association was noted between the resistance profile and 
the inhibitory concentration of T-20. 
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Table 6.2: The IC50 and IC90 values with corresponding resistance sequences for subtype C and B isolates from S2 day 29. 
 
 
 
 
Biotype
IC50 IC90 
SubtypeC
Consensus G I V Q Q Q S N L L R A I E A Q Q
Du151a R5 9.52 14.08 S/G . . . . . . . . . . . . . T . .
Du422a R5 15.24 23.55 . . . . . . . K . . . . . . . . .
SW5 R5 24.99 >25 . . L . . . . . . R . . . . . . .
CM7 R5 15.75 23.87 S . . . . . N . . . . . . . T . .
SW29 R5 19.79 >25 S . . . . . D . . . . . . . . . .
SW38 R5 19.89 >25 . . A . . . . . . . K . . . T . H
PCP1 R5/X6 >25 >25 G/E . A/V . . . . . . . . . . . . . .
RP1 R5/X4 >25 >25 . . . . . . . K . . . . . . V . .
CM9 R5/X4/X6/R3/Bob 22.62 >25 . . E . . . . . . . . . . . . . .
SW7 X4 >25 >25 . V A . . . . . . . . . . . . . .
DR28 X4 16.69 23.7 . T . . . . . . . . . . . . . . .
Subtype B
Consensus G I V Q Q Q N N L L R A I E A Q Q
SM1 R5 17.21 24.91 . . M/E/K . . . . . . . . . . . . . .
SM2 R5 22.31 >25 D . . . . . . . . . . . . . . . .
DS3 R5 NR NR S . . . . . . . . . M . . . . . .
DS12 R5/X4 17.12 >25 . . . . . . . N/K/S . . . . . . . . .
NR = no replication
Inhibitory concentration (ug/ml) HR-1 amino acid sequence 
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Table 6.3: Summary of T-20-associated changes in the HR-2 and V3 regions S2 viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HR-2 V3
Subtype C
SW38 D129N K32Q*
D148E
K152S
Du123 D137E -
CM9 E151K -
RP1 K147Q -
Du151 - T2I*
Subtype B
SM1 G129N -
SM2 V130F -
DS12 G129D -
* V3 numbering: position 1 corresponds to residue 294 in NL4.3 gp120
 - indicates no change compared with parental virus
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Figure 6.1: Phylogenetic analysis of nucleic acid sequences from parental, S1 (day 29) 
and S2 (day 29) sequences (Mega version 2.1). Consensus sequences for subtype B and 
subtype C are included. Bootstrap values exceeding 75% are shown. This data indicates 
that no contamination by another virus or different strains were responsible for the 
appropriate T-20 resistance mutations (Courtesy of Dr Penny Moore). 
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6.4 Discussion 
The development of resistance appears to be an inevitable result of exposure to T-20, 
regardless of the subtype of HIV-1. Here we describe the development of in vitro 
resistance to T-20 among subtype C isolates from patients at different stages of disease 
including one with pre-existing reverse transcriptase mutations. Mutations occurred 
predominantly in the HR-1 region, mostly at the G36 and V38 positions, which have 
previously been shown to be associated with resistance to T-20 in subtype B viruses 
(Rimsky, Shugars, and Matthews, 1998). Occurrence of T-20 associated resistance 
mutations at the same positions as subtype B emphasizes the likelihood that the 
mechanism of action for T-20 remains the same for HIV subtype C isolates. 
 
Analysis of amino acid changes in the HR-1 region of isolates selected to replicate in 10 
µg/ml T-20 (S2) revealed mutations associated with T-20 resistance in all subtype C and 
B isolates. Most of these changes occurred in the GIV motif with some isolates having 
additional changes outside this region. However, in many cases these mutations were not 
those observed in the earlier selection (S1). The reasons for this are not clear but indicate 
a dynamic interplay between populations of mutant viruses under T-20 selection in vitro. 
A number of isolates that had changes at the G36 motif at S1 reverted to the wild-type 
glycine in S2. The relative reduction in the number of G36 mutants in S2 may simply be 
a result of exposure of a mixed population of viruses (selected gradually in S1) to 
immediate high levels of T-20. This inability of G36 mutants to persist at S2 suggests that 
for some viruses, mutations at this residue may not confer the highest level of T-20 
resistance. Alternatively, perhaps the fitness of these variants was sufficiently 
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compromised to restrict their infection of fresh PBMC in the presence of high 
concentrations of T-20, resulting in the infection of PBMC in S2 with sub-populations of 
T-20-resistant viruses with increased fitness compared with G36 variants. The three 
isolates (Du422a, RP1 and DS12) that showed high level resistance in the absence of 
mutations in the GIV motif all had the N42K/S mutation suggesting that this mutation 
may cause high level resistance on its own. Further support for this comes from the 
observation that for 2 of these isolates a mutation at G36D was lost between S1 and S2 
suggesting that N42K has increased fitness compared to G36D.  Thus, mutations in GIV 
as well as those outside GIV can confer high- level resistance to T-20 for HIV-1 subtype 
C and B isolates. 
 
T-20-associated mutations in HR-1 have been reported to result in reduced affinity for 
HR-2 (and concomitant reduction in fusion activity). Mutations within HR-2 have been 
shown to result in a hyperfusinogenic Env which compensated for the initial reduc tion in 
fusogenicity associated with T-20 resistance (Baldwin et al., 2004). In this study, 
compensatory changes in the HR-2 region were noted in four HIV-1 subtype C isolates. 
These changes occurred in the region corresponding to that from which T-20 was derived 
and were spread evenly across this region. Interestingly, three of the four HIV subtype B 
isolates had changes in the HR-2 and these were mostly in the beginning of the T-20 
region, although not at the SNY motif implicated as a compensatory mutation in a T-20-
resistant and -dependent virus (Baldwin et al., 2004). Whether the changes observed in 
HR-2 among T-20 resistant subtype C isolates have any significance for development of 
T-20 resistance among subtype C isolates still needs to be determined. 
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Changes outside the gp41 have previously been shown to influence the efficiency with 
which T-20 binds to the HR-1 region (Reeves et al., 2002; Reeves et al., 2004). The 
position next to the ß21-bridging sheet of gp120 has been shown to influence coreceptor 
binding and thus impact on how well T-20 interacts with the gp41 region (Reeves et al., 
2002; Reeves et al., 2004). Coreceptor usage has also been implicated in sensitivity to T-
20, with X4 variants shown to be more susceptible than R5 isolates (Derdeyn et al., 2000; 
Derdeyn et al., 2001). In this study no difference was noted in T-20 related mutations 
between R5 and X4 isolates suggesting that the mechanism of resistance is independent 
of coreceptor usage. When T-20 resistant viruses were retested in U87.CD4.CCR5 and 
CXCR4 cells the cell tropism remained unaffected compared with parental viruses (data 
not shown). T-20 has been shown to interact with gp120 of subtype B X4 viruses and the 
V3 loop has been reported to undergo changes close to the cysteine bonds at the stem of 
the loop in the presence of T-20 (Yuan et al., 2004). In this study we noted changes 
within the V3 region of two subtype C isolates. The significance of these changes still 
needs to be determined, particularly as both were R5 isolates. We cannot exclude the 
possibility that the changes were simply culture artifacts or selection of minor 
populations either in culture or during sequencing. 
 
Selection of resistance was most pronounced for one isolate in both S1 and S2. This 
isolate, SW38, had one change in the HR-1, three changes in the HR-2 as well as a 
change in the V3 region. SW38 has three polymorphisms in the HR-1 region to which T-
20 binds, which may contribute to the rapid development of resistance to T-20 in S1 and 
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S2. This may indicate the possible role of compensatory changes at different positions in 
the envelope region to accommodate primary drug resistance mutations that allow the 
virus to replicate in the presence of T-20, despite possible reduced fitness compared with 
parental viruses (Lu et al., 2004). To fully understand the mechanism of T-20 resistance 
future work will need to examine the role of regions other than gp41 to investigate what 
influence these regions have on T-20 resistance and how the gp160 compensates for 
potentially deleterious T-20-associated mutations. 
 
In a previous study we showed that T-20 is effective against HIV-1 subtype C isolates in 
vitro suggesting that it would prove useful in the treatment of individuals infected with 
these viruses (Chapter 5). Here we demonstrate in vitro development of resistance to T-
20 among subtype C isolates. Virus resistance developed rapidly with continued exposure 
to T-20, and was genotypically comparable to resistance among subtype B HIV-1 
isolates, suggesting a common mechanism of action of the drug in both subtypes. These 
data may prove useful in the management of resistance in T-20 treated patients infected 
with subtype C viruses. 
 
  
 
137  
CHAPTER 7 
CONCLUSION 
While considerable progress has been made in the last eight years in understanding how 
HIV interacts with human cells, one of the major advances has been the discovery of 
HIV-1 coreceptors and how they function. The major coreceptors are CCR5 and CXCR4 
of which CCR5 is used more frequently. CXCR4 is used less frequently and at later 
stages. The significance of coreceptor switching and expanded coreceptor use and how 
this impacts on HIV pathogenesis remains unclear. The rarity of coreceptor switching 
among HIV-1 subtype C infected persons indicates that it is not a pre-requisite to 
developing AIDS. In the few reported cases the use of CXCR4 in HIV-1 subtype C was 
accompanied by changes mostly in the V3 region with increased positive charges as well 
as insertions or deletions similar to subtype B. Since HIV-1 subtype C accounts for most 
infections worldwide it is important to understand what allows this subtype to undergo a 
coreceptor switch albeit at a very low frequency.  
 
The development of a new class of compounds that can block HIV-1 infection has 
opened up numerous possibilities for viral control, including their use as microbicides to 
prevent sexual transmission and in infants to prevent transmission via breast-milk. In 
general these inhibitors have been well tolerated and effective in limited clinical testing, 
and their ability to block multiple steps in the entry process makes this an attractive 
approach. There is limited data available on the effectiveness of these compounds on 
HIV-1 subtype C. Due to genotypic and phenotypic differences between HIV-1 subtype 
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B and C studies need to be performed to assess the effectiveness of new and existing 
inhibitors on HIV-1 subtype C. 
 
Figure 7.1: A summary of the mean percentage inhibition for the three classes of entry 
inhibitors for HIV-1 subtype C. The number of isolates tested is shown on top of each 
bar. The results for the anti-CD4 inhibitor are not discussed in this thesis. The R5 isolates 
are shown in blue. The X4 or R5X4 isolates are shown in red. 
 
Figure 7.1 represents a summary of data presented in this thesis and additional data 
(courtesy of Elin Gray). PRO542 is a recombinant tetravalent antibody coupled to the 
CD4 molecule that binds gp120 (Allaway et al., 1995), inhibited subtype C viruses in a 
coreceptor independent manner (E. Gray unpublished data). R5 viruses were inhibited 
effectively by the CCR5 coreceptor inhibitors and the X4 and R5X4 isolates were 
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inhibited by the CXCR4 inhibitors. The fusion inhibitor was highly effective against all 
isolates tested irrespective of coreceptor use. All three stages of entry for subtype C are 
therefore susceptible to entry inhibitors. 
 
A potential obstacle to using coreceptor inhibitors is the emergence of isolates able to use 
coreceptors other than CCR5 or CXCR4. Although the use of alternate coreceptors is a 
rare event and whether these receptors are used in vivo is unknown. Nevertheless such 
isolates may pose a threat to the successful use of coreceptor inhibitors as clinical tools 
(Zhang and Moore, 1999). Two HIV-1 isolates in this study were shown to use alternate 
coreceptors on primary cells. However, they may be blocked by other agents that can 
bind to these coreceptors. In one case this was CCR8 for which an inhibitor is available 
although in the second case the receptor used was unknown. Few HIV-1 isolates are 
tested for alternate coreceptor use and their occurrence may be more common than 
current data suggests. Future studies may need to consider blocking alternate coreceptors 
should their use be more prevalent than currently described. 
 
Collectively these data suggest that the mechanism used by HIV to enter cells will be the 
same for subtype C as for subtype B and that the same prevention strategies should be 
successful for HIV-1 subtype C infected populations. However, HIV due to its genetic 
variability has already shown evidence that it can circumvent some of these new 
inhibitors irrespective of clade either by using another coreceptor or by having genetic 
differences in regions that entry inhibitors target (Moore et al., 2004). Thus it cannot be 
assumed that all entry inhibitors will be effective on HIV-1 subtype C and in vitro testing 
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is required to verify this for new agents. The synergistic use of entry inhibitors will be 
advisable to circumvent coreceptor switching either to CXCR4 or an alternate coreceptor. 
Combinations of entry inhibitors will also minimize drug resistance to a specific entry 
inhibitor targeting different phases of the entry process. The development of this new 
class of compounds and their ability to be used in combination with highly active anti-
retroviral therapy expands the opportunities to target multiple points in the viral 
replication cycle and increases the possibilities for controlling HIV.  
 
7.1 USEFUL OUTCOMES 
These data has provided useful information on the susceptibility of HIV-1 subtype C 
isolates to entry inhibitors as well as resistance profiles for T-20, which is more or less 
similar to subtype B. Such data are needed prior to the clinical use of these drugs in South 
Africa. The information obtained may be more broadly applicable to other regions of the 
world where subtype C circulates. Furthermore the pattern of genetic mutations in the 
subtype C envelope gene associated with resistance to entry inhibitors will be useful for 
future application of entry inhibitors. This is important, given that the envelope gene of 
HIV shows considerable genetic variation and that resistance patterns may differ between 
subtypes for some inhibitors. Collectively the data obtained here will give an indication 
as to the potential efficacy of these novel drugs in HIV-1 subtype C infected patients and 
to their potential use as preventative agents, which are desperately needed in countries 
where HIV-1 subtype C circulates. 
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APPENDIX A 
 
Patient information from whom viral isolates were derived 
________________________________________________________________________ 
Sample ID Ethnicity      Age      Sex      CD4     VL          SI/NSI  Clinical Status  
________________________________________________________________________ 
Acutely infected patients 
Du123a N/A  N/A F 841 19,331  NSI acute 
Du151a N/A  N/A F 367 >500,000 NSI acute 
Du174  N/A  N/A F N/A 11,628  NSI acute 
Du422a N/A  N/A F 397 67,982  NSI acute 
 
Pediatric AIDS 
RP1  Black  N/A N/A 7 178,830 SI N/A 
TM1b  Black  8.4 M N/A 190,990 SI severe (C) 
TM9  Black  8 M 11 296,865 SI severe (C) 
 
Drug resistant  
DR10  Black  40 M 43 14,194  NSI Candida 
                                                                                                                        Oesophagus 
 
DR19  Black  6 M 439 15,200  NSI N/A 
DR28  Black  9 M 173 269,000 SI N/A 
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________________________________________________________________________ 
Sample ID Ethnicity      Age      Sex CD4   VL          SI/NSI  Clinical Status  
________________________________________________________________________ 
DR62  Black  6 F 1231 57,100  NSI      N/A 
DR100  Black  2 M 716 489,000 NSI      N/A 
 
Subtype B  
SM1   Caucasian N/A M N/A N/A  NSI      Acute 
SM2  Caucasian N/A M N/A N/A  NSI      Acute 
DS3  Caucasian 39 M 59 N/A  NSI      AIDS 
DS8  Caucasian 34 M 99 N/A  SI      AIDS 
DS9  Caucasian 39 M 4 N/A  NSI      AIDS 
DS12  Caucasian 26 M 51 N/A  SI      AIDS 
 
N/A= not available 
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APPENDIX B 
Amino acid abbreviations  
 
Amino acid    Abbreviation 
Alanine    A 
Arginine    R 
Asparagine    N 
Aspartic acid    D 
Cysteine    C 
Glutamine    Q 
Glutamic acid     E 
Glycine    G 
Histidine    H 
Isoleucine    I 
Leucine    L 
Lysine     K 
Methionine    M 
Phenylalanine    F 
Proline      P 
Serine      S 
Threonine    T 
Tryptophan    W 
Tyrosine    Y 
Valine     V 
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APPENDIX C 
Buffers and solutions for p24 assay 
10x NaHCO3: 
Weigh 42g NaHCO3 and add 500ml double distilled water (ddH20) and set pH at 8.5. 
 
10x TBS to make up 5 litres:  
Weigh 421g NaCl and 51g Tris-Trizma base. Add 5 liters of double distilled water 
(ddH2O). Set pH at 7.5 using HCl to adjust. 
 
1x TBS for 20 liters:  
Use 2 liters 10x TBS and add 18 liters of distilled water. 
 
10x PBS for 10 liters:  
Weigh 800g of NaCl, 20g KCl, 144g NA2HPO4, 24g KH2PO4  
Add 8 liters of distilled water and adjust pH to 7.4 with HCl and adjust to 10 liters 
 
10x TROPIX Wash buffer: 
ELISA-Light Kit. For 1- liter use 100ml of 10x concentrate and add 900ml double 
distilled water. 
 
10x TROPIX Wash buffer 
To make up 1 liter weigh out 24.3g of TRIS base add 10ml of MgCl2 (1M). Adjust to 1 
liter using distilled water and set pH at 9.8. 
 
 
 
 
 
 
  
 
189  
APPENDIX D 
 
GenBank accession numbers for the V3 sequences are  
 
AY170657 (SW4),   AY170658 (SW5),   AY170659 (SW14),   
AY170660 (SW16),   AY170661 (SW22),   AY170662 (SW23),   
AY170663 (SW26),   AY170664 (SW29),   AY170665 (SW34),   
AY170666 (SW35),   AY170667 (SW38),   AF411967 (CM9),   
AF411966 (SW7),   AY230878 (SW12),   AY230879 (SW20),   
AY230880 (SW30). 
 
GenBank accession numbers for gp41 sequences 
AY504998 (99ZADu174)  AY505011 (99ZASM2)     
AY504999 (99ZASW5)  AF411967 (99ZACM9)     
AY505000 (99ZASW26)  AF411966 (99ZASW7)     
AY505001 (99ZASW29)  AF544007 (ZADu123)     
AY505002 (99ZASW38)  AY043173 (ZADu151)     
AY505003 (98ZACM1)  AY043175 (ZADu422)     
AY505004 (99ZACM7)  AY529667 (00ZAPCP1)     
AY505005 (02ZADR10)  AY529669 (99ZASW20)     
AY505006 (02ZADR19)  AY529673 (99ZASW30)     
AY505007 (02ZADR28)  AY529673 (01ZARP1)     
AY505008 (02ZADR62)  AY529677 (99ZATM1b)     
  
 
190  
AY505009 (03ZADR100)  AY529679 (99ZATM9)     
AY505010 (99ZASM1)   
 
Full genome sequences 
 
AF411964 (99ZACM4) 
AF411966 (99ZASW7) 
AF411967 (99ZACM9) 
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APPENDIX E 
 
Ethical clearance 
 
Ethical clearance was obtained from the University of Witwatersrand Committee for 
Research on Human Subjects (Medical) protocol number M040911 
 
 
 
 
 
 
 
 
 
